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Abstract 
 
 
Cancer has currently a major impact in the worldwide health, with breast and colon 
carcinomas presenting the second and third highest incidence rates, respectively. Despite 
the important advances in understanding the mechanism of carcinogenesis, disease 
progression, and development of new and more effective therapies, advanced cancer is still 
generally an incurable disease. The currently used treatments have improved both the 
survival and cure rates of patients; however there are some serious drawbacks, mostly 
concerning high toxicity and serious side-effects, which may cause even the death of a 
small percentage of patients. Furthermore, many patients suffer from tumors that are 
resistant to the conventional treatments, thus not taking profit from any therapeutic benefit. 
The resistance seen in the aggressive forms of the disease remains to be the biggest 
challenge of current treatments. More than half of the treated patients suffer from a disease 
relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, 
and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) 
within the tumors. These cells retain the capacity of repopulating the tumor after the 
treatment, while being insensitive to conventional anticancer therapies, antimitotic agents 
or radiation. It is still not entirely clear if CSC originate from the epithelial stem cells which 
are essential to maintain proliferative homeostasis or result by accumulation of mutations 
from differentiated cells. However it is known that only a few number of CSC are necessary 
and sufficient for tumor regeneration. In this scenario, new cancer therapies under 
development should fulfil two conditions: (i) reduce the toxicity displayed in current therapies 
and most importantly, (ii) specifically target and eliminate CSC to overcome drug resistance 
and tumor recurrence. 
Both criteria could be accomplished using innovative targeted nanomedicines for drug 
and/or gene delivery, which is widely expected to bring promise and create novel 
therapeutics in advanced cancer therapy. Nanoparticles have shown, in both preclinical and 
clinical practice, to improve the therapeutic window of the therapeutic agents by specifically 
delivering higher concentrations to the tumor lesions, while reducing the systemic toxicity. 
This behavior explains the increased interest of research groups and pharmaceutical 
companies in nanomedicine-based systems to treat cancer, resulting in an increase in the 
approved and clinically tested products in the last decades. 
The advances observed in molecular biology and biotechnology have been contributing for 
the identification and understanding of the complex biological pathways associated with 
cancer development, and consequently for the emergence of gene therapy as a promising 
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therapeutic alternative in diseases with a strong genetic component. New biomarkers and 
therapeutic targets have been identified. AKT2 is one of the three Protein (serine/threonine) 
Kinase B (PKB or AKT) isoforms that is amplified in solid tumors. This oncogene is 
increased in response to apoptosis and its activation is also associated with 
phosphoinositide 3-kinase (PI3K) related effects as well as TWIST-promoted metastatic 
process by enhancing cell migration and invasion. Activation of TWIST/AKT2 signaling 
pathway is involved in E-cadherin silencing in the population of CSC, conferring them high 
tumorigenic potential. Thus, a therapeutic RNAi-mediated strategy using AKT2 as a 
downstream target represents an enormous step forward CSC eradication and anti-cancer 
therapy. 
The effects of AKT2 silencing in different breast and colon cancer cells, expressing and 
non-expressing TWIST are discussed in the present work. The obtained results 
demonstrated that the AKT2 inhibition is effective in terms of reducing cells migration, 
invasion, and transformation via different mechanisms and do not depend on the presence 
of TWIST within the tumor. We were able to observe that for cell lines expressing TWIST, 
AKT2 acts via Epithelial-Mesenchymal Transition (EMT) reversion, while for cells not 
expressing TWIST, AKT2 acts via mTOR pathway promoting the reduction of stemness 
markers and alteration in the expression of apoptotic genes such as the Bcl-2 and p53. In 
summary, the aim of this work was to silence the AKT2 expression using an small interfering 
RNA (siRNA) against the AKT2 (siAKT2) in different cancer cells lines in order to prove that, 
not only in bulk cancer cells but also in the sub-population of CSC, the AKT2 knockdown is 
able to impair their increased tumorigenic ability, reverting their mesenchymal phenotype, 
reducing cell invasion, inhibiting colony formation or inducing apoptosis. Due to the effect 
of AKT2 in both bulk cells and CSC, the therapy with siAKT2 could be used as two different 
strategies: i) to revert the EMT and maintain the tumors in its primary stage for easier 
chirurgical removal, and ii) prevent the tumor recurrence through the inhibition of CSC 
tumorigenic and metastatic potential. 
Despite the enormous outbreak of gene therapy in the last years, its clinical use is still 
limited mainly due to genetic material-associated delivery difficulties, such as fast 
degradation, insufficient transfection efficiency or dose limiting vectors toxicity. In order to 
overcome these problems, we pursued the development and validation of a nanocarrier 
composed by Pluronic® F127 micelles associated with polyethylenimine (PEI)-based 
polyplexes to deliver a siAKT2. The proposed system for the delivery of siAKT2 seems to 
gather the requirements for an efficient and safe transport of siRNA in terms of their 
physicochemical characteristics, internalization capacity, biological efficacy and toxicity 
profile. These results make us believe that this new formulation will constitute a 
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technological platform for the development of systems to encapsulate different siRNAs, as 
well as other types of genetic material. We are putting efforts in the improvement of these 
formulation in order to achieve a potential gene or multifunctional delivery system, 
approaching the so increasingly required personalized and combined therapies and 
bringing new hope into the field of cancer therapy.  
 
 
 
Keywords: Breast and Colon Cancer, AKT2, TWIST, Epithelial-Mesenchymal Transition, 
mTOR pathway, Cancer Stem Cells, Gene Delivery, siRNA, Nanoparticles, Polymeric 
Micelles. 
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Resumo 
 
 
As doenças oncológicas possuem um enorme impacto na saúde das populações a nível 
mundial, apresentando o cancro da mama e o do cólon a segunda e terceira maior taxa de 
incidência, respetivamente. Apesar dos importantes avanços observados nos últimos anos 
na compreensão dos mecanismos de carcinogénese e progressão da doença, bem como 
no desenvolvimento de terapias mais eficazes, o cancro em estadios mais avançados é 
ainda geralmente uma doença incurável. Os tratamentos usados atualmente têm vindo a 
melhorar as taxas de sobrevivência e de cura dos doentes, contudo existem ainda algumas 
dificuldades especialmente relativas à elevada toxicidade e aos efeitos secundários 
severos, responsáveis até pela morte de uma pequena percentagem dos doentes. 
Adicionalmente, muitos doentes apresentam tumores que são resistentes aos tratamentos 
convencionais, não alcançando assim nenhum benefício terapêutico. A resistência à 
terapêutica observada nas formas mais agressivas da doença continua a ser o maior 
desafio dos tratamentos atuais. Mais de metade dos doentes tratados com terapias 
convencionais sofrem de uma recidiva da doença, na sua maioria com metástases 
distantes. A manutenção do cancro, a resistência à terapia e o potencial metastático da 
doença parece ser sustentado pela presença de células estaminais cancerígenas (CEC) 
no microambiente do tumor. Estas células retêm a capacidade de repopular o tumor após 
o tratamento e são insensíveis aos tratamentos convencionais com compostos 
antimitóticos ou à radiação. 
Ainda não está absolutamente esclarecido se as CEC são originadas a partir das células 
estaminais epiteliais, essenciais à manutenção da proliferação homeostática, ou se 
resultam da acumulação de mutações de células diferenciadas. No entanto, estudos 
demonstram que apenas um pequeno número de CEC é suficiente para provocar a 
regeneração do tumor. Perante este cenário, as novas terapêuticas para o cancro em 
desenvolvimento devem satisfazer duas condições: 1) reduzir a toxicidade causada pelas 
terapias atuais e, mais importante ainda, 2) atingir e eliminar especificamente as CEC de 
forma a evitar a resistência à terapêutica e a recorrência do tumor. Ambas as condições 
podem ser alcançadas usando terapêuticas inovadoras baseadas em nanomedicina 
direcionada para a veiculação de fármacos e/ou material genético, nas quais se deposita 
uma nova esperança no campo da terapia contra o cancro avançado. As nanopartículas 
têm demonstrado, tanto na prática clínica como na pré-clínica, serem capazes de melhorar 
a janela terapêutica de um determinado fármaco ao permitir a entrega de maiores 
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concentrações do mesmo às lesões tumorais, reduzindo ao mesmo tempo a sua toxicidade 
sistémica. Este comportamento explica o interesse crescente que se tem verificado por 
parte de diversos grupos de investigação e indústrias farmacêuticas na nanomedicina para 
o tratamento do cancro. Consequentemente, nos últimos anos, tem-se verificado também 
um aumento na aprovação e entrada no mercado, bem como a aplicação clínica de 
produtos baseados em nanopartículas. 
Os avanços na biologia molecular e biotecnologia têm contribuído para a identificação e 
compreensão das complexas vias biológicas associadas ao desenvolvimento do cancro e, 
consequentemente têm contribuído para o crescimento da terapia génica como uma 
alternativa terapêutica promissora para o tratamento de doenças com um forte componente 
genético. Novos biomarcadores e agentes terapêuticos têm sido identificados nos últimos 
anos. 
O AKT2 é uma das três isoformas da proteína quinase B (PKB ou AKT) que está 
amplificada em tumores sólidos. Este oncogene está aumentado em resposta à apoptose 
e a sua ativação está também associada com os efeitos da fosfoinositídeo 3-quinase (PI3K) 
e com o processo metastático promovido pelo TWIST, nomeadamente o aumento da 
migração e invasão celular. A activação da via biológica TWIST/AKT2 está envolvida no 
silenciamento da E-caderina na população de CEC, o que lhes confere um elevado 
potencial tumorogénico. Desta forma, uma estratégia terapêutica baseada na tecnologia 
de RNA de interferência, usando a AKT2 como alvo, surge como uma alternativa 
importante na terapia oncológica e, mais importante, na erradicação das CEC. Os efeitos 
do silenciamento do AKT2 em diferentes linhas celulares de cancro da mama e do cólon, 
com e sem expressão de TWIST, são discutidos no presente trabalho. Os resultados 
obtidos demonstram que a inibição do AKT2 é eficaz na redução da migração, invasão e 
transformação celular via diferentes mecanismos e que não depende da presença de 
TWIST no tumor. Foi possível observar que para as linhas celulares que expressam 
TWIST, o AKT2 atua via redução da transição epitelial-mesenquimal (EMT), enquanto que 
em células que não expressam TWIST, o AKT2 atua pela via do mTOR promovendo a 
redução de marcadores de malignidade e alteração de genes apoptóticos como o Bcl-2 e 
o p53. Em resumo, o objetivo deste trabalho consiste no silenciamento da expressão do 
AKT2 usando pequenos fragmentos de RNA de interferência (siRNA) contra o AKT2 
(siAKT2) com o objetivo de provar que, não apenas em linhas de cancro parentais mas 
também nas sub-populações de CEC, o silenciamento do AKT2 é capaz de comprometer 
as suas características tumorigénicas através da reversão do seu fenótipo mesenquimal, 
redução da invasão celular, inibição da formação de colónias ou indução da apoptose. 
Devido ao efeito observado do AKT2 nas células de cancro parentais e também nas CEC, 
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a terapia com siAKT2 poderia ser usada em duas possíveis estratégias: 1) para reverter o 
EMT e manter os tumores no seu estadio inicial, e como tal mais facilmente removíveis 
cirurgicamente, e ii) prevenir a recorrência do tumor através da inibição do potencial 
tumorigénico e metastático das CEC. 
Apesar da enorme eclosão da terapia génica nos últimos anos, o seu uso clínico é ainda 
bastante limitado, maioritariamente devido às dificuldades relacionadas com a veiculação 
do material genético tais como a rápida degradação dos oligonucleótidos, a insuficiente 
eficiência de transfeção ou a toxicidade associada aos vetores usualmente utilizados. Com 
o objetivo de ultrapassar esses problemas, este trabalho teve como segundo objetivo o 
desenvolvimento e validação de uma formulação para a veiculação de siAKT2, consistindo 
em micelas de Pluronic® F127 associadas com poliplexos de polietilenoimina (PEI). O 
nanosistema proposto parece preencher os requisitos necessários a um transportador de 
siRNA seguro e eficiente em termos das suas características físico-químicas, capacidade 
de sofrer internalização pelas células, eficácia biológica, e perfil de toxicidade. Estes 
resultados promissores fazem-nos acreditar que esta nova formulação pode servir como 
uma plataforma tecnológica ao desenvolvimento de sistemas para encapsular diferentes 
siRNAs, bem como outros tipos de material genético. Reunimos esforços no sentido de 
melhorar esta formulação com o objetivo de alcançar um sistema de veiculação genético 
e/ou multifuncional promissor. Desta forma, será possível alcançar mais facilmente a 
desejada terapia combinada e personalizada e com o objetivo final de trazer uma nova 
esperança no campo da terapia contra o cancro. 
 
 
 
Palavras-chave: Cancro da Mama e Colon, AKT2, TWIST, Transição Epitelial-
Mesenquimal, via do mTOR, Células Estaminais Cancerígenas, Veiculação de Genes, 
siRNA, Nanopartículas, Micelas Poliméricas. 
 
 
 
 
 
 
 
 
 
 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xiv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xv 
Table of Contents 
 
 
 
Acknowledgements ......................................................................................................... v 
Abstract ......................................................................................................................... vii 
Resumo ........................................................................................................................... xi 
List of Figures .............................................................................................................. xxi 
List of Tables .............................................................................................................. xxiv 
Abbreviations .............................................................................................................. xxv 
Aims and Organization of the Thesis ........................................................................ xxxi 
 
CHAPTER 1 .................................................................................................................... 1 
State of Art – Epithelial-Mesenchymal Transition as the Motor for Stemness: AKT2 
Emerges as a Potential Therapeutic Target .................................................................. 1 
1.1. Cancer Facts ..................................................................................................... 3 
1.1.1. Cancer Scenario .......................................................................................... 4 
1.1.2. Cancer Treatment ........................................................................................ 5 
1.2. The Cancer Stem Cells Theory ......................................................................... 6 
1.2.1. Cancer Stem Cell Models ............................................................................. 6 
1.2.2. Cancer Stem Cell Properties ........................................................................ 9 
1.2.3. Targeting CSC ............................................................................................. 9 
1.3. Epithelial-Mesenchymal Transition (EMT) ..................................................... 12 
1.3.1. Adhesion-related Proteins: E-cadherin ....................................................... 13 
1.3.2. Tumor-associated Proteins in EMT Activation ............................................ 16 
1.3.2.1. The influence of tumor microenvironment .................................................. 16 
1.3.2.2. Players at the cell membrane level ............................................................. 18 
1.3.2.3. Intracellular transcriptional regulation of EMT ............................................. 19 
1.4. The Importance of TWIST-based Signaling Pathways in the EMT Program 19 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xvi 
1.4.1. TWIST Mechanism of Action: AKT2 and PI3K as the Leading Players ....... 21 
1.5. RNA Interference Regulation of EMT.............................................................. 24 
1.5.1. miRNA and Cancer ..................................................................................... 27 
1.5.2. siRNA-mediated Silencing of AKT Isoforms ................................................ 27 
1.6. Conclusions ..................................................................................................... 29 
1.7. References ....................................................................................................... 30 
 
CHAPTER 2 .................................................................................................................. 41 
State of Art – Nanotechnology for Gene Delivery ....................................................... 41 
2.1. The Problematic Choice of a Vector for Gene Therapy ................................. 43 
2.2. Non-viral Gene Delivery Systems ................................................................... 45 
2.2.1. Polymer-based Delivery Systems (Polyplexes) ........................................... 49 
2.2.1.1. Cationic polymers ....................................................................................... 49 
2.2.1.2. Amphiphilic polymers .................................................................................. 51 
2.2.1.3. Characteristics of amphiphilic copolymers and copolymer-based 
structures .................................................................................................................. 53 
a) Self-assembly ............................................................................................. 53 
b) Surface hydrophilicity and functionalization ................................................. 55 
c) Stimuli-responsive properties ...................................................................... 55 
2.2.1.4. Amphiphilic polymers-based gene delivery systems ................................... 56 
2.2.1.5. Pluronic® and its role as biological response modifier ................................. 57 
2.2.1.6. Polymer-based non-viral vectors on the way to clinical trials ....................... 58 
2.2.2. Lipid-based Delivery Systems (Lipoplexes) ................................................. 60 
2.2.2.1. Cationic lipoplexes ...................................................................................... 61 
2.2.2.2. Anionic and neutral lipids ............................................................................ 62 
2.2.3. Lipid Nanoparticles ..................................................................................... 62 
2.2.4. Combination of Polymers and Lipids: does it meet the ideal system? ......... 65 
2.3. Conclusions ..................................................................................................... 68 
2.4. References ....................................................................................................... 69 
Table of Contents 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xvii 
CHAPTER 3 .................................................................................................................. 89 
Formulation Studies and Efficacy Assessment of Different siRNA Delivery Systems
 ........................................................................................................................................ 89 
3.1. Introduction ..................................................................................................... 91 
3.2. Materials and Methods .................................................................................... 92 
3.2.1. Materials .................................................................................................... 92 
3.2.2. Polyplexes Preparation .............................................................................. 93 
3.2.3. PEI- and CS-based Micelles Preparation ................................................... 94 
3.2.4. Association Efficiency (AE) ........................................................................ 94 
3.2.5. Particles Physicochemical Properties Characterization .............................. 95 
3.2.6. Serum Stability ........................................................................................... 95 
3.2.7. Cell lines Culture Conditions ...................................................................... 95 
3.2.8. GFP Reporter Gene Silencing Assay ......................................................... 95 
3.2.9. In vitro Cytotoxicity Assay .......................................................................... 96 
3.2.10. Conjugation of F127 with 5-DTAF .............................................................. 96 
3.2.11. Internalization Assays ................................................................................ 97 
3.2.12. Statistical Analysis ..................................................................................... 98 
3.3. Results ............................................................................................................. 98 
3.3.1. CS-based Polyplexes ................................................................................. 98 
3.3.2. Pluronic®-based Micelles Containing CS-polyplexes ................................ 102 
3.3.3. PEI-based Systems .................................................................................. 103 
3.4. Discussion ..................................................................................................... 107 
3.5. Conclusions .................................................................................................. 110 
3.6. References ..................................................................................................... 111 
 
CHAPTER 4 ................................................................................................................ 117 
AKT2-related Biological Pathway Characterization and Validation in Breast and Colon 
Cancer Stem Cells ....................................................................................................... 117 
4.1. Introduction ................................................................................................... 119 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xviii 
4.2. Materials and Methods .................................................................................. 120 
4.2.1. Materials ................................................................................................... 120 
4.2.2. Cell Lines and Culture Conditions ............................................................. 120 
4.2.3. Fluorescence-Activated Cell Sorting (FACS) ............................................ 121 
4.2.4. Cell Transfection ....................................................................................... 121 
4.2.5. RNA Extraction and Quantitative RT-PCR (qRT-PCR).............................. 122 
4.2.6. Protein Extraction and Western Blotting (WB) ........................................... 123 
4.2.7. Proliferation Assay .................................................................................... 123 
4.2.8. Wound Healing Migration Assay ............................................................... 123 
4.2.9. Cell Transformation Assay (Anchorage-independent Growth Assay) ........ 124 
4.2.10. Invasion Assay ......................................................................................... 124 
4.2.11. Statistical Analysis .................................................................................... 124 
4.3. Results............................................................................................................ 125 
4.3.1. AKT2 Silencing Impairs Proliferation and Migration of Cancer Cells ......... 125 
4.3.2. AKT2 Inhibits Anchorage-independent Growth and Invasion of CSC ........ 125 
4.3.3. AKT2 Inhibition is Achieved via Diverse Signaling Pathways .................... 129 
4.4. Discussion ..................................................................................................... 134 
4.5. Conclusions ................................................................................................... 136 
4.6. References ..................................................................................................... 136 
 
CHAPTER 5 ................................................................................................................ 141 
Functional Validation of Amphiphilic-based Polymeric Micelles for siRNA Delivery 
and Cancer Stem Cells Genes Inhibition ................................................................... 141 
5.1. Introduction .................................................................................................... 143 
5.2. Material and Methods .................................................................................... 143 
5.2.1. Materials ................................................................................................... 143 
5.2.2. Polyplexes PEI-siRNA Production............................................................. 144 
5.2.3. Production of Micelles ............................................................................... 145 
5.2.4. Micelles Physicochemical Characterization ............................................... 145 
Table of Contents 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xix 
5.2.5. Cell Lines and Culture Conditions ............................................................ 145 
5.2.6. Cell Transfection with the PM ................................................................... 146 
5.2.7. Serum Stability Assay .............................................................................. 146 
5.2.8. Assessment of Micelles Toxicity ............................................................... 147 
5.2.9. Fluorescence-Activated Cell Sorting (FACS) ............................................ 147 
5.2.10. Micelles Internalization ............................................................................. 147 
a) Confocal microscopy (qualitative analysis) ............................................... 147 
b) Flow cytometry (quantitative analysis) ...................................................... 148 
5.2.11. Green Fluorescent Protein Silencing Efficacy ........................................... 148 
5.2.12. RNA Extraction and Quantitative RT-PCR (qRT-PCR) ............................. 149 
5.2.13. Cell Transformation Assay (Anchorage-independent Growth Assay) ....... 149 
5.2.14. Invasion Assay ......................................................................................... 149 
5.2.15. In vivo Maximum Tolerated Dose (MTD) Determination ........................... 150 
5.2.16. Statistical Analysis ................................................................................... 150 
5.3. Results ........................................................................................................... 150 
5.3.1. PM are Technologically Favorable for siRNA Delivery ............................. 150 
5.3.2. Complete PM Internalization Occurs After 4 hours of Incubation .............. 152 
5.3.3. PM do not Present in vitro or in vivo Toxicity ............................................ 155 
5.3.4. PM-siGFP Efficiently Silence the GFP Reporter Gene Expression ........... 157 
5.3.5. PM-siAKT2 Reduce the Metastatic Potential of CSC ................................ 157 
5.4. Discussion ..................................................................................................... 160 
5.5. Conclusions .................................................................................................. 162 
5.6. References ..................................................................................................... 163 
 
CHAPTER 6 ................................................................................................................ 167 
General Conclusions and Future Perspectives......................................................... 167 
 
 
 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Figures 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxi 
List of Figures 
 
 
CHAPTER 1 
Figure 1.1. The complexity of cancer .......................................................................... 3 
Figure 1. 2. Cancer statistics ...................................................................................... 4 
Figure 1. 3. CSC therapy resistance accordingly the different models ........................ 7 
Figure 1. 4. Schematic representation of the EMT process as well as some of the most 
representative affected proteins ............................................................................... 12 
Figure 1. 5. Schematic representation of E-cadherin ................................................ 14 
Figure 1. 6. Schematic representation of the most important biological pathways 
involved in cancer and EMT activation ..................................................................... 17 
Figure 1. 7. Schematic representation of PI3K/AKT2 mechanism of action .............. 21 
Figure 1. 8. RNA interference mechanism ................................................................ 26 
 
CHAPTER 2 
Figure 2. 1. In vitro barriers for non-viral vectors based gene delivery ...................... 45 
Figure 2. 2. Different types of nanotechnology-based systems for gene delivery ...... 46 
Figure 2. 3. Advantages and limitations in nucleic acid nanosystems delivery .......... 47 
Figure 2. 4. Schematic representation of the mechanisms of nanoDDS for CSC 
targeting. .................................................................................................................. 48 
Figure 2. 5. Diagram of an amphiphilic polymers-based micelle ............................... 52 
Figure 2. 6. The main features of amphiphilic copolymers and their based 
structures ................................................................................................................. 52 
Figure 2. 7. Schematic representation of a SNALP and its main components .......... 63 
Figure 2. 8. Schematic representation of a type of lipopolyplex and its main 
components. ............................................................................................................ 66 
 
CHAPTER 3 
Figure 3. 1. General structure of Pluronic® and PEI polymers .................................. 92 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xxii 
Figure 3. 2. Reaction schematic for the conjugation of F127 with 5-DTAF via 
nucleophilic aromatic substitution by an addition-elimination mechanism .................. 97 
Figure 3. 3. Polyplexes association efficiency ........................................................... 99 
Figure 3. 4. In vitro cytotoxicity of CS-siRNA polyplexes at different N/P ration in MDA-
MB-231 cells ............................................................................................................. 99 
Figure 3. 5. Polyplexes CS-siRNA silencing efficacy 72 hours after transfection in RXO-
C colon cancer cells expressing GFP...................................................................... 101 
Figure 3. 6. Polyplexes physicochemical characterization using CL213 CS ............ 101 
Figure 3. 7. Comparative cytotoxicity and IC50 values of Pluronic® F127 and F108 in 
MDA-MB-231 cells .................................................................................................. 103 
Figure 3. 8. CS-siRNA-Pluronic® micelles silencing efficacy 72 hours after transfection 
with the siGFP and siC in RXO-C colon cancer cells .............................................. 103 
Figure 3. 9. PEI-siRNA polyplexes and PEI-siRNA-Pluronic® micelles (obtained by 
DM) silencing efficacy in GFP expressing RXO-C cells ........................................... 104 
Figure 3. 10. PEI-siRNA-Pluronic® internalization behavior .................................... 105 
Figure 3. 11. Physicochemical characterization of PEI-siRNA-Pluronic® micelles .. 106 
Figure 3. 12. Serum stability of PEI-siRNA-Pluronic® formulation ........................... 107 
Figure 3. 13. Diagram resuming the different developed tested formulations for gene 
therapy and the main results. .................................................................................. 108 
  
CHAPTER 4 
Figure 4. 1. Effect of AKT2 silencing in breast and colon cancer cell lines .............. 126 
Figure 4. 2. siAKT2 transfection reduces cells transformation ability of MDA-MB-231, 
HCT8 and MCF7 CSC and non-CSC ...................................................................... 127 
Figure 4. 3. Effects of siAKT2 in cells invasive capability of MDA-MB-231, HCT8 and 
MCF7 CSC and non-CSC ....................................................................................... 128 
Figure 4. 4. Effects of siAKT2 in cells transformation ability and invasive capability of 
MDA-MB-468 and SKBR3 ....................................................................................... 129 
Figure 4. 5. Cell lines phenotypes based in the EMT/stemness markers ................. 130 
Figure 4. 6. Impact of AKT2 silencing in key regulators of EMT reversion and mTOR-
dependent signaling pathways. Expression levels of different genes were quantified by 
List of Figures 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxiii 
qPCR in different cell lines after the treatment with siAKT2 and siC. Results are 
expressed as mean±SD (n≥3). ............................................................................... 131 
Figure 4. 7. Effects of AKT2 silencing in different signaling pathways. A) Efects of AKT2 
silencing in the mTOR pathway for TWIST+ cells. B) Efffects of AKT2 silencing in the 
EMT reversion for TWIST- cells. Results are expressed as mean±SD (n≥3). ......... 132 
Figure 4. 8. Summary of AKT2 silencing effects in cancer development in the different 
cell lines, accordingly their phenotype and TWIST expression level. ...................... 133 
 
CHAPTER 5 
Figure 5. 1. Schematic representation of micelles production ................................. 144 
Figure 5. 2. Micelles physicochemical characterization .......................................... 151 
Figure 5. 3. FACS quantification of micelles uptake by MDA-MB-231 and MCF7 
ALDH1A1 tdTomato+ versus tdTomato- ................................................................. 153 
Figure 5. 4. PM internalization visualization throught confocal microscopy ............. 154 
Figure 5. 5. In vitro cytotoxicity of PM and its isolated components ........................ 154 
Figure 5. 6. Serum stability assay PM-siRNA ......................................................... 155 
Figure 5. 7. PM toxicity in vivo ................................................................................ 156 
Figure 5. 8. GFP reporter assay for PM-siGFP biological efficacy assessment ...... 158 
Figure 5. 9. PM-siAKT2 effects in MDA-MB-231 and MCF7 cells ........................... 159 
 
CHAPTER 6 
Figure 6. 1. Schematic representation of an amphiphilic polymer based multifunctional 
nanoparticle for gene and drug delivery combination. ............................................. 173 
 
 
 
 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xxiv 
 
List of Tables 
 
 
CHAPTER 1 
Table 1. 1. Drugs in clinical development targeting CSC* ............................................... 11 
Table 1. 2. Different types of EMT and their main functions. ........................................... 13 
Table 1. 3. Main characteristics and differences between miRNA, siRNA, and shRNA. .. 25 
 
CHAPTER 2 
Table 2. 1. Examples of self-assembled particles under clinical trials evaluation. ........... 54 
Table 2. 2. Examples of polymeric nanoparticles for gene delivery at different stages of 
development. .................................................................................................................. 59 
Table 2. 3. Examples of lipidic nanoparticles for gene delivery at different stages of 
development. .................................................................................................................. 65 
 
CHAPTER 3 
Table 3. 1. Poly(ethylene glycol) and polypropylene oxide units, molecular weight and 
critical micelle concentration values of the different Pluronic® used ................................. 92 
Table 3. 2. Summary of the different tested conditions regarding the CS-based polyplexes.
 ..................................................................................................................................... 100 
Table 3. 3. Summary of the different tested conditions regarding the branched PEI-based 
systems ........................................................................................................................ 104 
Table 3. 4. Physicochemical characterization of different Pluronic®-based micelles ...... 102 
 
CHAPTER 4 
Table 4. 1. List of the cell lines used in this study and their main phenotype ................. 121 
Table 4. 2. List of the primers used in the study and their sequences ........................... 122 
Table 4. 3. List of primary antibodies used in the study and their specifications. ........... 123 
 
CHAPTER 5 
Table 5. 1. Transfection conditions accordingly the different experiments ..................... 146 
 
Abbreviations 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxv 
Abbreviations 
 
 
 
3’UTR Untranslated region 
5-DTAF 5-8[4,6-dichlorotriazin-2-yl]amino)fluorescein hydrocloride 
ABC ATP-binding cassette 
AE Association efficiency 
AGO2 Argonaute 2 
AKT Protein (serine/threorine) kinase B (PKB) 
ALDH1A1 Aldehyde dehydrogenase 1 
Alox5 Arachidone 5-lipoxigenase 
ATCC American type cell colection 
ATP Adenosine triphosphate 
BAD Bcl2-associated death promoter 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
Bcl-xL B-cell lymphoma extra large 
BCRP Breast cancer resistance protein 
BH3 Bcl-2 Homology 3 domain 
bHLH basic helix-loop-helix 
BLMH Bleomycin hydrolase 
CAMs Cell adhesion molecules 
CD Cyclodextrin  
CHEMS Cholesteryl hemisuccinate 
CMC Critical miccelar concentration 
CML Chronic myeloid leukemia 
CMT Critical micellar temperature 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CryoSEM Cyro-scanning electron microscopy 
CS Chitosan 
CSC Cancer stem cells 
CTAB Cetyltrimethylammonium bromide 
CTLA4 CytotoxicT-lymphocyte antigen 4 
CXCR4 C-X-C chemokine receptor type 4 
DAPI 4’,6-diamidino-2-phenylindole 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xxvi 
DC Denditric cells 
DD Degree of deacetylation 
DDS Drug delivery system 
DLL Delta-like ligand 
DLS Dynamic light scattering  
DM Dissolution method 
DMEM Dulbecco’s modified Eagle medium 
DMRIE 2,3-di(tetradecoxy)proply-2hydroxyethyl)-dimethylazanium 
bromide 
DMSO dimethyl sulfoxide 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine 
DOPG 1,2-Dioleoyl-sn-glycero-3-phosphoglycerol 
DOSPA 2,3dioleyloxy-N-[2(sperminecarboxamido ethyl]-N,N-dimethyl-
1-propanaminium trifluoroacetate 
DOSPER 1,3-dioleoyloxy-2-. (6-carboxyspermyl)-propyl amide 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
DOTMA 1,2-di-O-octadecenyl-3-trimethylammonium propane 
DSPC 1,2-distearoyl-sn-glycero-3phosphocholine 
dsRNA Double-stranded RNA 
DTA Diphteria toxin 
ECM Extracellular matrix 
EGFR Epidermal grownth factor recptor 
EMT Epithelial-mesenchymal transition 
EO Ethylene oxide 
EPR Enhanced permeability and retention effect 
ERK Extracellular signal–regulated kinases 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDA Food and drug administration 
FGFR Fibroblast growth factor receptors 
FH Thin-film hydration 
FR Folate Receptor 
GADPH Glyceraldehyde 3-phosphate dehydrogenase 
GFP Green fluorescent protein 
GFP-siRNA siRNA against GFP 
Abbreviations 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxvii 
GSK3 Glycogen synthase kinase 3 beta 
HER2 Hormone Estrogen Receptor 2 
HES Hydroxyethyl starch 
HIF-2α Hypoxia-inducible factor 2 alpha 
HLB Hydrophilic lipophilic balances 
HPMA N-(2-hydroxypropyl)methacrylamide 
IC50 Inhibitory concentration 50 
IFN-y Interferon Y 
IGF-1 Insulin-like growth factor 1 
IGFR Insulin-like growth factor receptor 
IL-3 Interleukin-3 
IL-6 Interleukin-6 
ILK Integrin-linked kinase 
LinOS N4-linoneolyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane 
Lipoplexes Lipid-based Delivery Systems 
LPP Lipoplexes 
MAPK Mitogen-activated protein kinase  
Md Mean diameter 
MDM2 Mouse double minute 2 homolog 
MDR Multidrug resistance 
MDT Maximum tolerated dose 
MEK Methyl ethyl ketone 
MET Mesenchymal-epithelial transition 
miRNA MicroRNA 
MRD Minimal residual disease 
MRP Multidrug resistance-associated proteins 
MTD Maximum tolerated dosis 
mTOR Mechanistic target of rapamycin 
m-TORC1/2 Mammalian target of rapamycin complex 1 and 2 
MTT 3-(4,5-dimethythiazol-2-yl)-2,5 diphenyl tetrazolium bromide 
MW Molecular weight 
N/P ratio Nitrogen/Phosphate ratio 
NF-kB Nuclear factor kappa B 
Nio-AU Gold niosomes 
NK Natural killer 
OCT4 Octamer-binding transcription factor 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xxviii 
OGN Phosphate groups 
PAEs Poly(b-amino ester)s 
PAMAM Polyamidoamine 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PCL Poly(-caprolactone) 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
Pdi Poydispersity index 
PDK1 Phosphoinositide-dependent protein kinase 1 
PDMAEMA Poly(2-(N,N-dimethylamino)ethyl methacrylate) 
PE Phosphoethanolamine 
PEG/PEO Polyethylene glycol/ Polyethyleneoxide 
PEI Polyethylenimine 
PCL Polycaprolactone  
PFA Paraforlmaldehyde 
PGE2 Prostaglandin E2 
P-gp P-glycoprotein 
PH Pleckstrin homology domain 
PHML-b-PLLA-b-PHML Poly(hydroxyletheyl methacrylate-L-lysine)-b-poly)L-lactide)—
poly(hydroxyletheyl methacrylate-L-lysine 
PI3K Phosphoinositide 3-kinase 
PILP Pegylated immuno-lipopolyplexes 
PKB Protein kinase B  
PLA Poly(d,l-lactide) 
PLAS PEGylated lipoplex-entrapped alginate scaffold 
PLGA Poly(d,l-lactide-co-glycolide) 
PLK1 Polo-like kinase 
PLL Poly(L-lysine) 
PM Polymeric micelles 
PO Propylene oxide 
Poliplexes Polymer-based Delivery Systems 
Poll II Polymerase II 
PPEEA Poly(2-aminoethyl ethylene phosphate) 
PPO Polypropylene oxice 
PTEN Phosphatase and tensin homolog 
PTX Paclitaxel 
Abbreviations 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxix 
qRT-PCR Quantitative real time polymerase chain reaction 
RFP Red Fluorescent Protein 
RISC RNA-induced silencing complex 
RRM2 Ribonucleoside-diphosphate reductase subunit M2 
RTK Receptor tirosine kinase  
SCID Severe combined immunodeficiency 
SD Mean±standard desviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser Serine 
shRNA Short hairpin RNA 
SLN Solid lipid nanoparticules 
SLUG Zinc finger protein SNAIL2 
SNAIL Zinc finger protein SNAIL1 
SNALP  Stable nucleic acid lipid particles  
SPARC Secreted protein acidic and rich in cysteine 
STAT3 Signal transducer and actibvator of transcription 3 
SV40 Simian vacuolating virus 40 
TBE Tris/Borate/EDTA 
TEM Transmission electron microscopy 
Tf Human transferrin 
TfR Transferrin receptors 
TGF- Tumor growth factor beta  
TGFR Tumor growth factor beta receptor 
Thr Threonine  
TNF Tumor necrosis factor 
TORC2 Target of rapamycin complex 2 
TQ Thymoquinone 
UV Ultra violet 
VEGF Vascular endothelial growth factor 
WB Western Blotting 
WNT Wingless-related integration site 
ZEB Zinc finger E-box-binding homeobox 
ZP Zeta potencial 
 
AKT2 siRNA-Nanoparticulate System as a New Tool To Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
_______ 
     xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Organization of the Thesis 
 _______________________________________________________________________________  
_______ 
                                                                                                                                                          xxxi 
Aims and Organization of the Thesis 
 
The high complexity of cancer diseases and their still unknown and incontrollable pattern, 
has made prioritary the study and a better understanding of the wide range of biological 
pathways involved in their development and progress. Worstly, the heterogeneity of cancer 
cell populations within the tumor difficults the complete remission of the disease, being the 
cancer recurrence one of the major challenges for the current therapies. The small 
subpopulation of CSC within a certain tumor have been reported as the responsible for the 
so feared tumor recurrence and resistance to therapy. 
 
This work could be divided in two main research areas and general objectives: 
i) Molecular biology of cancer: study and identification of AKT2 as a good target 
for cancer therapy; 
ii) Pharmaceutical technology and development: design and characterization of a 
Nanotechnology-based system for delivery of a siRNA against the AKT2. 
 
Based on the previous, the specific objectives of this work are the follows: 
 
1) Due to its recognized role as a putative oncogene, we aim to understand and 
characterize the biological pathway of AKT2 and assess the effects of AKT2 
silencing in different breast and colon cancer cell lines in terms of cell migration, 
proliferation, and gene expression pattern; 
2) Isolate the subpopulations of CSC from breast and colon cancer cells and assess 
the effects of AKT2 silencing specifically in this subpolation in terms of cell invasion, 
cell anchorage-independent growth, and gene expression pattern; 
3) Understand the downstreams effectors of AKT2 for each cell line (TWIST or mTOR); 
4) Design a nanoparticle-based system able to complex siRNA and silence the gene 
of interest using classic reporter gene assays; 
5) Characterize the new nanosystem in terms of their physicochemical features and 
stability, in vitro and in vivo toxicity, and cellular internalization; 
6) Assess the biological effects of nanoparticles complexing siRNA against the AKT2 
in subpopulations of both breast CSC and non-CSC in terms of invasion and cell 
anchorage-independent growth abilities. 
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The present thesis is organized in six chapters. In the first two chapters are presented the 
main theoretical concepts and the state of art for each of research areas: 
Chapter 1 – State of Art – Epithelial-Mesenchymal Transition as the Motor for 
Stemness: AKT2 Emerges as a Potential Therapeutic Target 
Chapter 2 – State of Art – Nanotechnology for Gene Delivery 
After the introductory section is presented the research work developed and the main 
results obtained:   
Chapter 3 (Formulation Studies and Efficacy Assessment of Different siRNA 
Delivery Systems) describes the way paved through the design and development of a 
nanoparticulate system based in polymeric micelles (PM) for siRNA delivery until reach the 
final selected formulation presented in Chapter 5; 
Chapter 4 (AKT2-related Biological Pathway Characterization and Validation in 
Breast and Colon Cancer Stem Cells) presents the study and characterization of the 
biological pathway and the role of AKT2 in the development and progression of cancer both 
in breast and colon CSC and non-CSC; 
Chapter 5 (Functional Validation of Amphiphilic-based Polymeric Micelles for siRNA 
Delivery and Cancer Stem Cells Genes Inhibition) presents the results obtained with the 
chosen PM for the delivery of siAKT2.  
In the final chapter (Chapter 6) are presented the Main Conclusions and Future 
Perspectives of the work.  
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CHAPTER 1 
 
 
 
State of Art – Epithelial-Mesenchymal Transition as the 
Motor for Stemness: AKT2 Emerges as a Potential 
Therapeutic Target 
 
 
The information presented in this chapter was partially published in the following 
publications: 
 
1) P Gener, D Rafael, Y Fernández, J Sayos, D Arango, I Abasolo, M Videira, S 
Schwartz Jr., Cancer Stem Cells and Personalized Cancer Nanomedicine. 
Nanomedicine (Lond), 11(3):307-20, 2016. 
 
2) D Rafael, S Doktorovová, H Florindo, P Gener, I Abasolo, S Schwartz Jr., M Videira, 
EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer 
Metastatic Behaviour Modulation, Current Gene Therapy, 15(3) 2015. 
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1.1. Cancer Facts 
 
According to World Health Organization (WHO), cancer is a generic term used to describe 
a large and heterogeneous group of diseases that can affect any part of the body. A key 
feature is the genesis of abnormal cells that rapidly grow beyond their normal boundaries 
invading adjacent parts of the body and spreading to other organs (metastasis) (Figure 
1.1). Metastization is of major impact in the malignancy of the disease and clinical outcome 
(1). Due to its high diversity, complexity, and unpredictable and uncontrollable character, 
cancer has become one of the most feared diseases by humans in the last decades. With 
the arise of molecular biology and biotechnology, tremendous advances have been 
observed in the last decades in the oncology field leading to the identification of biological 
pathways involved in cell growth and dissemination, as well as disease players and 
therapeutic targets/agents (Figure 1.1). 
 
 
Figure 1.1. The complexity of cancer. The figure represents different phases of the disease 
evolution and the problematic of cancer mutations that increase exponentially along with the tumor 
development originating a highly heterogeneous compartment. Circles point out the main cancer 
hallmarks as well as the associated most common therapeutic strategies. BH3: Bcl-2 homology 3 
domain; CTLA4: cytotoxic T-lymphocyte antigen 4; EGFR: epidermal growth factor receptor; PARP: 
poly (ADP-ribose) polymerase; VEGF: Vascular endothelial growth factor. 
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1.1.1. Cancer Scenario 
 
The progresses referred before enables researchers and pharmaceutical industry with the 
information necessary to develop a variety of drugs to treat the different types of cancer, 
resulting in an important decrease of the cancer related deaths (superior to 20% since 
1990s) and an increase in the patient’s overall survival (2, 3). The incidence and mortality 
rates of this disease are superior in developed countries and are expected to increase in 
the next years, with an estimated 9 million cancer deaths in 2015 and 11.4 million in 2030 
(3). Just in the USA, 1.7 million new cancer cases and 0.6 million cancer deaths are 
projected to occur in 2017 (4). Nowadays, the seven most common types of cancers 
worldwide are lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach 
cancer, liver cancer, and cervical cancer (Figure 1.2) (5). Cancers typically associated with 
infections such as the cervical cancer, stomach cancer, liver cancer and Kaposi's sarcoma 
are declining in the developing countries as infections become better controlled with the 
programs implemented by WHO. On the contrary, lung, breast, prostate, and colorectal 
cancers present a faster rate of incidence, being the world cancer incidence predicted to 
rise 75% by 2030, mainly associated with the increasing bad lifestyle practices, population 
growth and aging (3, 5). 
 
 
Figure 1. 2. Cancer statistics. Estimated incidence (A) and mortality (B) worldwide of the most 
common types of cancer in both sexes. Estimated age-standardized rates of incident cases (C) and 
deaths (D) in both sexes for all cancers excluding non-melanoma skin cancer. Data Source: 
GLOBOCAN 2012. Map Production IARC (2016) (5).   
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In the last years, due to the growing incidence of the disease, the global market share of 
medicines to treat cancer has been growing. In 2014 oncology remained as the largest 
therapeutic area worldwide regarding the market share, presenting an increase of 8% 
compared to 2013 and counting for more than 10% of the total year sales (6). As a 
consequence of the expected growth in the prevalence and incidence of oncological 
diseases in the upcoming years, it is also predicted an increase in the prescription of 
anticancer drugs, with an escalation of their global market share up to almost 15% in 2020 
(6). This disease profile entails high costs to the health care systems related to the patients’ 
cancer treatment and care. For example, only in USA, cancer care is projected to cost 
around 174 billion US dollars in 2020 (7). This scenario boosts researchers, health care 
agencies, and pharmaceutical companies to pursuit the urgent need for the development of 
new and more cost-effective treatments.   
 
1.1.2. Cancer Treatment  
 
Despite the enormous efforts employed at different fields of science and medicine, the real 
cure and eradication of cancer remains a desire far to be achieved and stands as a huge 
challenge to researchers around the world. 
Major challenges surrounding the administration of current anticancer treatments are their 
systemic toxicity, associated with serious side-effects owing this drugs lack of specificity, 
and the therapeutic resistance that cancer cells often acquire during treatment. Indeed, 
because of the use of chemotherapeutics at an early stage of the disease that renders tumor 
resistance, treatment options for late metastatic disease are often reduced (8). The ability 
of cancer cells to activate alternative molecular pathways allowing them to escape from the 
common drug therapeutic mechanism of action is one of the major mechanisms involved in 
the development of drug resistance (9, 10). Further, drug resistance also occurs through 
the increased expression of ATP-dependent drug efflux transporters on the surface of 
cancer cells (11). This causes a significant decrease of intracellular drug accumulation, 
which results into severe limitation of drug’s efficacy (12). Besides, cells with different 
phenotypes and proliferative abilities co-exist within a tumor, generating tumor 
heterogeneity and contributing to specific selection of resistant clones and disappointing 
therapeutic responses, in particular when a single drug treatment is applied. 
Special interest has been paid to the use of biopharmaceuticals and gene therapy as 
therapeutic strategies to treat cancer owing to its capacity to target the specific antigen or 
signaling pathway involved in cancer progression (13). Among the different types of gene 
therapy, the silencing of particular genes through the RNA interference (RNAi) therapy has 
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been intensively investigated as a encouraging strategy in the field of oncology, given the 
possibility of targeting oncogenes involved in proliferation, survival, angiogenesis, 
metastasis, apoptosis suppression or drug-resistance (14).   
Nowadays, more than 800 medicines and vaccines to treat cancer are under development 
and clinical assessment (2), with more than 73% of the medicines in the pipeline being 
studied based on biomarkers, presenting potential for personalized treatment (15). Some 
of the medicines under development are based on biopharmaceuticals, namely monoclonal 
antibodies, vaccines, cell or gene therapy. In 2013, the majority of biopharmaceuticals 
under development are intended to treat cancer and related diseases (more than 300), 
being the monoclonal antibodies the most studied ones with 170 medicines (16). Also, 
seventeen products under development/clinical trials were based on gene therapy such as 
ALN-VSP from Alnylam Pharmaceuticals (Phase I), B7-2/GM-CSF from NuVax 
Therapeutics (Phase I), BC-819 from BioCancell Therapeutics (Phase II), CALAA-01 from 
Calando Pharmaceuticals (Phase I), EGEN-001 from EGEN (Phase II) or GliAtak™ from 
Advantagene (Phase II) (16). 
Unfortunately, even though important clinical breakthroughs in the fight against cancer have 
been achieved by using combined protocols such as conventional chemotherapy with 
hormonal therapy or therapeutic antibodies, recurrence and metastasis are still observed. 
Thus, the development of treatments able to reduce the formation of metastasis and to 
avoid or at least reduce the recurrence of the disease is required.  
 
1.2. The Cancer Stem Cells Theory 
 
As referred previously, despite progresses in cancer management, advanced cancers have 
still low clinical response rates and high recurrence and mortality rates. Regarding this, a 
main issue that should be considered is the fact that cancer cells within a tumor are not 
equal in terms of characteristics and tumorigenic potential.  
 
1.2.1. Cancer Stem Cell Models 
 
Before the 1990s, cancer initiation and progression was explained by a clonal cancer model. 
It was considered that all tumor cells have similar characteristics and equal tumor formation 
capacity and that tumors expansion depended on clonal selection advantages (17-20). The 
first evidence regarding the existence of cancer stem cells (CSC) was obtained in acute 
myeloid leukemia (21). Subsequently, CSC were identified also in other hematopoietic 
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cancers and in many solid tumors (breast, brain, colon, prostate, lung, head & neck, among 
others) (22-24). It was also shown that the small CSC sub-population has the ability to 
generate and maintain the tumor progression (20-22, 25). Based on these observations, a 
new hierarchical model describing cancer propagation was postulated (21); CSC can self-
renew their own population and have long-term propagating capacity contrariwise to normal 
cells whose division finish by clonal exhaustion (Figure 1.3A) (26, 27).  
 
 
Figure 1. 3. CSC therapy resistance accordingly the different models. (A) CSC are more 
resistant than tumor bulk cells to most conventional therapeutic interventions. Therefore, after 
treatment, CSC remain in the tumors or in circulation inducing a rapid recurrence. (B) As for the 
hierarchic model, CSC specific therapy results in loss of proliferative capacity and decline of the 
malignancy with tumor regression. (C) Considering the novel dynamic model, the non-CSC can 
acquire CSC-features through signals from the environment and the stromal cells, thus even with 
specific CSC eradication a rapid restoration of CSC features occurs, with a subsequent recurrence 
when therapy is discontinued. (D) The best strategy to tumor remission should target not only the 
CSC but also the bulk tumor cells as well as the interconversion capacity between them. Stromal 
cells represent myofibroblasts, endothelial cells, mesenchymal stem cells, or infiltrating immune 
cells. CSC: cancer stem cells. 
 
In summary, CSC have been considered the major critical player in tumor malignancy and 
recurrence, thus strong efforts have been recently done to specifically target CSC 
subpopulation in order to improve therapy efficacy and avoid recurring tumors. However, 
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recent data suggest that targeting exclusively the CSC sub-populations may not be 
sufficient because acquisition of stemeness phenotype by other cells within tumors seems 
to be a bidirectional dynamic process (Figure 1.3B) (26, 27). Because the hierarchical 
model of cancer cannot explain the dynamic behavior of CSC, a new interconversion cancer 
model has been very recently postulated (Figure 1.3C) (26-28). According to the model, 
the amount of CSC within a tumor or cancer cell line seems to be inconstant and finely 
tuned, to maintain a specific equilibrium between CSC and non-CSC populations. In one 
hand, CSC can differentiate to non-CSC which in turn can de-differentiate and revert into 
cells with CSC properties, like resistance and self-renewal capacity with typical stemness 
gene expression signature. This cell de-differentiation process was first predicted by Marcov 
mathematical model (28) and recently confirmed experimentally in various CSC models (28-
30). In melanoma, a subpopulation of slow-cycling cells that express histone demethylase 
JARD1B was identified. As expected from CSC, during propagation of purified JARD1B 
positive cells appeared a JARD1B negative, non-CSC population. Conversely, a single 
JARD1B negative cell originates a heterogeneous progeny including JARD1B positive cells, 
suggesting a bidirectional dynamic of the CSC phenotype (31). Similarly, normal somatic 
basal-like mammary epithelial cells are able to spontaneously de-differentiate into stem-like 
cells (32). Further, regeneration of stem-like cells is observed as well in vivo after sorting, 
suggesting that stable equilibrium of CSC/non-CSC cells within a tumor occurs due to cell-
state interconversion (28). These findings reinforce the hypothesis of the existence of a 
controlled balance between CSC and non-CSC populations. It seems that cancer cells 
might survive to stress conditions by entering de-differentiation as survival mechanism. 
Several external factors and paracrine communications as well as cell-to-cell interactions 
are involved in the regulation of this process. As an example, it has been shown that 
apoptotic cells excrete prostaglandin E2 (PGE2) which promotes proliferation of 
neighbouring CSC after chemotherapy, whereas PGE2-neutralizing antibodies abrogate 
CSC repopulation after treatment (33). Similarly, the matrix cellular protein SPARC 
(secreted protein acidic and rich in cysteine, also known as osteonectin or BM-40) secreted 
by non-CSC is able to modulates the metastatic capacity of CSC in prostate cancer models 
(34), and Interleukin-6 (IL-6) secreted by non-CSC is reported to induce formation of breast 
CSC in association with octamer-binding transcription factor 4 (OCT4) expression (35). 
Furthermore, OCT4 overexpression is induced via IL-6-JAK1-STAT3 signaling pathway in 
low attachment conditions as well as in vivo to maintain dynamic equilibrium (36). 
Therefore, the dynamic phenotype of CSC represents an important challenge for targeted 
cancer therapies, as tumor cell populations are continuously evolving and therapeutic 
eradication of existing CSC populations might be followed by their regeneration from non-
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CSC. Regarding this, the major goal is to find a way that allows to targeting the CSC but 
also stopping the interconversion between CSC and non-CSC (Figure 1.3D). 
 
1.2.2. Cancer Stem Cell Properties 
 
Even though the intratumoral amount of CSC as well as the expression of stemness 
markers among this sub-population differs, depending mostly on tumor types, the essential 
stemness properties of CSC like self-renewal, tumor initiation capacity and long-term 
repopulation potential are common features independently of tumor type. Owing their ability 
to survive in non-attachment conditions showing capacity to grow as tridimensional 
tumorspheres, CSC have increased capacity to initiate tumor growth in vivo, migrate and 
intravasate the blood stream generating distant metastasis at specific sites. CSC are 
substantially insensitive to most conventional anticancer therapies, antimitotic agents, 
and/or radiation (37). Such aggressive behavior results from a particular CSC phenotype 
as well as their characteristic gene expression and epigenetic modifications. In particular, 
CSC have a potent machinery of anti-apoptotic proteins and a efficient activation of the DNA 
damage sensor and repair machinery for maintenance of genome integrity (9, 37). 
Moreover, CSC overexpress a great number of detoxifying enzymes (aldehyde 
dehydrogenase 1 (ALDH1A1), bleomycin hydrolase (BLMH)), drug efflux transporters (P-
glycoprotein (P-gp)), breast cancer resistance protein (BCRP), and the multidrug 
resistance-associated proteins (MRP) at the cell membrane, which pump-out 
chemotherapeutic drugs from the intracellular space (10, 38). In addition, induction of 
quiescence in stress conditions and higher stability under hypoxic conditions provide CSC 
with further protection against anticancer therapies (10). Accordingly, the percentage of 
CSC within a tumor often increases after treatment (33, 37, 39, 40). This often leads to 
cancer recurrence and metastatic growth since only few CSC are necessary and sufficient 
for tumor regeneration in vivo (41). For all these reasons, if cancer has to be eradicated, 
new therapies should specifically target the CSC fraction.  
 
1.2.3. Targeting CSC 
 
In agreement with the interconversion cancer model, traditional cancer treatments appear 
to be effective at reducing tumor mass but often fail to produce desired long-term outcomes, 
and remission of metastatic disease is common. Moreover, current treatments often render 
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the tumor resistant at the time of remission, possibly due to their inability to eliminate CSC 
(8, 37). 
Therapeutic targeting of CSC may have the potential to remove residual disease and 
become an important component of any given cancer treatment. Currently, there are 
multiple anti-CSC agents in pre-clinical and clinical trials (Table 1.1) (42). The likelihood of 
their clinical success will depend on many aspects, including safety, specificity, 
pharmacokinetics etc., but also on their ability to effectively target CSC. In fact, most drugs 
specifically designed to target CSC are based on the effective inhibition of crucial CSC 
signaling pathways as example: i) cell survival and proliferation pathways; including PI3K-
AKT, JAK/STAT, and NF-kB signaling, and ii) signaling linked to the stemness properties of 
CSC like self-renewal and pluripotency (Notch pathway, WNT pathway and Hedgehog 
signaling). Of note, one of the risks associated to drugs targeting commonly shared cellular 
pathways is the difficulty to distinguish normal cells and/or stem cells from CSC. High 
throughput screening methodologies are reliable approaches to reveal new therapeutic 
targets that effectively eliminate CSC without compromise the normal somatic stem cells. 
One of the hopeful targets identified by high throughput screening is Arachidone 5-
lipoxigenase (Alox5). Alox5 was found over-expressed in chronic myeloid leukemia CSC 
but not in normal hematopoietic stem cells (43). It was shown that the absence of Alox5 due 
to genetic modification or its inhibition with a specific inhibitor, Zileuton, impaired the 
induction of leukemia in the BCR-ABL inducible cancer model of chronic myeloid leukemia 
(CML) (43). The inhibition of Alox5 leads to an upregulation of the tumor suppressor gene 
Msr1 and consequently, to the inhibition of PI3K-AKT and β-catenin pathways (44). 
Currently, the use of Zileuton in combination with Imatinib is in phase I clinical trials for first 
line therapy in acute myeloid leukemia. Of note, Imatinib alone does not cure CML because 
it is not able to kill leukemia stem cells (45) . Another example of a successful high through 
screening is the chemical screen method for agents with CSC-specific toxicity. As a result, 
salinomycin was identified as a drug showing selective toxicity for CSC (46). 
Previous results from preclinical trials in human xenograft mice models and clinical pilot 
studies reveal that salinomycin is able to effectively eliminate CSC and to induce partial 
clinical regression of heavily pre-treated and therapy-resistant cancers, particularly in 
combination with novel tumor-targeted drugs (47). However, a very important drawback for 
the potential clinical application of Salinomycin is its marked neural and muscular toxicity 
(48). In this context, incorporation of cytotoxic drugs within different particulate nanocarrier 
systems, i.e. liposomes and polymeric particles, is a useful approach to modify the 
biodistribution of drugs and target tumors. Nanomedicines can in fact address not only the 
biodistribution profile of CSC-targeting drugs but also reduce their overall toxicity and 
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enhance their therapeutic efficacy by promoting higher local drug exposure and improving 
their transport properties across biological membranes (49). 
 
Table 1. 1. Drugs under clinical development with therapeutic activity against CSC* 
Therapeutic 
Target 
Drug Cancer Type Clinical phase Trial reference 
PI3K, 
mTORC1/2 
VS-5584 Solid tumors I NCT01991938 
AKT 
MK2206 Breast cancer II NCT01277757 
GSK2141795 Breast cancer II NCT01964924 
AZD5363 Breast cancer I/II NCT01625286 
STAT3 OPB-31121 Solid tumors I NCT00955812 
NF-κB 
Parthenolid 
analog 
Leukemia II/III ISRTN40571019 
Multiple 
kinases 
BBI503 Solid tumors I/II NCT01781455 
STAT3, β-
catenine, 
Nanog 
BBI608 
Gastric cancer III NCT02178956 
Esophageal 
cancer 
III NCT02178956 
Colon cancer III NCT01830621 
BBI503+ BBI608 Solid tumors I NCT02432326 
WNT pathway 
Vantictumab Solid tumors I NCT0 1345201 
Ipafricept 
Pancreatic 
cancer 
I NCT02050178 
Notch 2,3 
(receptor) 
Tarextumab 
Pancreatic 
cancer 
II NCT01647828 
Lung cancer II NCT01859741 
DLL (Notch 
ligand) 
Demcizumab 
Ovarian cancer II NCT01952249 
Pancreatic 
cancer 
II NCT02289898 
Lung cancer II NCT02259582 
Hedgehog GDC-449 Solid tumors II NCT00739661 
ABC 
transporters 
MS-209 Ovarian cancer II NCT00739661 
Tariquidar 
Ovarian cancer II NCT00069160 
Cervical cancer II NCT00069160 
Lung cancer II NCT00069160 
Kidney cancer II NCT00069160 
Chemokine 
receptors 1,2 
Reparixin Breast cancer II NCT01861054 
IL-3 receptor SL-401 Leukemia I/II NCT02268253 
Alox5 Zileuton Leukemia I NCT02047149 
 
*Details including dosage of the chemical agents under trial, duration of the trial, inclusion and 
exclusion criteria for recruiting patients, contact and locations where the trial is being conducted, and 
the current status of the trial can be obtained by searching the ‘Trial reference’ in the US National 
Institutes of Health Registry (www.clinicaltrials.gov) and EU Clinical Trials Register 
(www.clinicaltrialsregister.eu). ABC: ATP-binding cassette; AKT: protein (serine/threonine) kinase B 
(PKB); Alox5: arachidone 5-lipoxigenase; DLL: delta-like ligand; IL-3: interleukin-3; mTORC1/2: 
mammalian target of rapamycin complex 1 and 2; NF-κB: nuclear factor kappa B; PI3K: 
phosphoinositide 3-kinase; STAT3: signal transducer and activator of transcription 3; WNT: wingless-
related integration site. 
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Figure 1. 4. Schematic representation of the EMT process as well as some of the most 
representative affected proteins. EMT: epithelial-mesenchymal transition. 
 
1.3. Epithelial-Mesenchymal Transition (EMT) 
 
As referred previously, tumor invasion and subsequent metastization are the major causes 
of morbidity and mortality in patients with cancer (50). Most of malignant tumors are 
carcinomas originated from various epithelial tissues. EMT is the biological process that 
triggers the evolution from a well-differentiated adenocarcinoma to an invasive epithelial 
carcinoma (Figure 1.4) (51). It is defined as a phenomenon during which cells lose their 
characteristic epithelial traits: columnar or polygonal shape, apico-basolateral polarization, 
organization in cell layers with strong cell-cell adhesion and limited migratory potential. 
During this event, cells acquire mesenchymal features such as, spindle-shaped 
morphology, anterior-posterior polarization, focal cell-cell contacts and strong migratory 
potential, becoming able to detach from their original site, penetrate the bloodstream, and 
subsequently create metastasis at different sites. These morphological and functional 
changes, demands several intracellular molecular alterations such as the loss of epithelial 
markers including E-cadherin, certain cytokeratins, occludin, and claudin, while 
mesenchymal markers, namely N-cadherin, vimentin and fibronectin are upregulated (52, 
53). 
EMT is an essential process for appropriate embryonic development. In adults, EMT occurs 
during wound healing, tissue regeneration, organ fibrosis, and cancer progression (8). 
Based on the biological context in which EMT occur, this mechanism can be classified into 
three different subtypes presented in Table 1.2 (53). During cancer progression, the genetic 
and epigenetic changes that mainly affect oncogenes and tumor suppressor genes of 
epithelial carcinoma cells seem to be responsible for the activation of an EMT program (54, 
55). Thus, preventing epithelial carcinoma cells to undergo such transition in order to keep 
the tumor in its primary stage and, therefore, treatable should be a future goal of therapeutic 
intervention. 
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Table 1. 2. Different types of EMT and their main functions. 
EMT: epithelial-mesenchymal transition. 
 
Additionally, the necessity of EMT inhibition in epithelial carcinoma cells is also related with 
the multidrug resistance (MDR), frequently observed in cells that have undergone EMT. In 
fact, it was demonstrated that therapeutic strategies intended to modulate EMT pathways 
have led both to a decrease in invasive potential and to an increase in drug sensitivity (56, 
57). 
As a transient mechanism, the EMT is reverted when the circulating metastatic cells 
extravasate through blood or lymphatic compartment to fix and form the distant tumors, 
being this inverse process called Mesenchymal-Epithelial Transition (MET) (53, 57). 
Despite remaining a not completely characterized process, the most important step of MET 
consists in E-cadherin re-expression and cancer cells re-epithelization, being the metastatic 
lesions and the primary tumors morphologically similar (58, 59). Taking this in consideration, 
Wang G, et al. (2011) raise the hypothesis that E-cadherin may act as a tumor suppressor 
gene at the primary tumor site but may be considered oncogenic at distant metastatic sites 
(60).  
 
1.3.1. Adhesion-related Proteins: E-cadherin 
 
Metastatic events require molecular changes that enable the cells to leave the original tumor 
site. This process involves the disruption of the cell-cell adherent junction complex through 
E-cadherin downregulation. Also, the upregulation of matrix metalloproteinases and 
basement membrane degradation enzymes are responsible for improving invasion into the 
surrounding tissues (61). 
E-cadherin is a central component of cell-cell adherent junctions (Figure 1.5). Adhesion 
occurs when E-cadherin bind to other E-cadherin molecules on adjacent cells, forming a 
homotype adhesion. This mechanism is required for the formation of epithelia in the embryo 
Type of EMT Involved in Function 
EMT 1 
Embryogenesis 
Organ development 
Generation of cells with mesenchymal phenotype 
with potential for the development of new tissues 
EMT 2 
Tissue regeneration 
Organ fibrosis 
Generation of fibroblasts for tissue reconstruction 
following a trauma or inflammatory injury 
EMT 3 Tumor metastasis 
Acquisition of mesenchymal characteristics by 
epithelial carcinoma cells and loss of cell adhesion 
molecules. Acquisition of capacity to detach from 
original site and enter the bloodstream. 
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and for the maintenance of the epithelial homeostasis in adults. It is a 120 kDa glycoprotein 
with a large extracellular domain comprising five cadherin-motif subdomains, a single 
transmembrane domain and a short conserved cytoplasmic domain interacting with several 
proteins collectively termed catenins. As calcium is essential to mediate adhesive function 
of E-cadherin, its extracellular portion contains several calcium-binding sites. For 
intracellular adhesion, cytoplasmic portion of E-cadherin bind tightly to β-catenin, a 
cytoplasmic protein that is non-covalently linked to α-catenin, which in turn binds to the actin 
cytoskeleton, either directly or indirectly via actin-binding proteins as alpha-actinin and 
vinculin (62, 63).  
 
 
Figure 1. 5. Schematic representation of E-cadherin. E-cadherin being part of the cell-cell 
adherent junctions, is a crucial player in the cell adhesion and in the maintenance of the epithelial 
phenotype. 
 
The maximum homotypic activity of E-cadherin results from it linkage to cytoskeleton. 
Therefore, the reduction of E-cadherin expression promotes a sequence of signaling events 
and major cytoskeletal reorganization.  This reduction of E-cadherin expression in human 
tumors may be caused by several mechanisms such as i) proteolytic cleavage of the 
extracellular domain; ii) somatic mutations; iii) homozygous chromosomal deletions; iv) 
extracellular glycosylation that suppresses hemophilic adhesion; and v) silencing of the 
CDH1 promoter by DNA hypermethylation or through transcriptional repression (50, 64, 65). 
E-cadherin gene, CDH-1, located on chromosome 16q221, is a member of a large family of 
genes coding for calcium-dependent cell adhesion molecules (CAMs). It is a conserved 
gene, which, apart from its role in normal cells, can play a major role in malignant cell 
transformation and tumor progression (62, 64). 
The downregulation of E-cadherin expression, and the consequent dysfunction in cell-cell 
adhesion, is a major hallmark of the EMT process and is the main molecular alteration 
correlated with the invasive and metastatic process in multiple types of cancer, being then 
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considered a critical tumor suppressor protein (52, 66). Thus, many studies have focused 
on understanding the interaction between loss of E-cadherin expression and the evolution 
to an invasive epithelial carcinoma (62, 67). 
In fact, many experiments in cancer cell cultures or in vivo tumor models have shown that 
the promotion of E-cadherin expression can revert the ability of several types of carcinomas 
to invade and metastasize and that, on the contrary, the abrogation of E-cadherin-mediated 
cell adhesion in noninvasive tumor cells activates their invasiveness and metastatic powers. 
These studies underline the importance of E-cadherin in the inhibition of tumor invasion and 
metastasis (58, 68). 
E-cadherin loss promotes metastasis not only by enabling cellular disaggregation, but also 
by inducing multiple downstream transcriptional pathways and a wide range of functional 
changes in human breast epithelial cells. Onder T, et al. (2008) used two different methods 
to inhibit E-cadherin function: a) a short hairpin RNA (shRNA)-mediated knockdown of E-
cadherin that lead to a reduction of over 90% in the protein levels, and b) the production of 
a truncated form of E-cadherin lacking the protein ectodomain but preserving the 
cytoplasmatic tail. They observed that the presence of truncated proteins do not result in 
EMT, once the maintenance of the cytoplasmatic tail of E-cadherin avoid the EMT induction. 
On the other hand, the significant decrease in E-cadherin expression triggers the EMT 
process and the acquisition of metastatic ability (66). 
Downregulation of E-cadherin is accompanied by upregulation of N-cadherin and its 
placement on cellular membrane. A “cadherin switching” i.e., reduction of E-cadherin 
leading to an increased N-cadherin expression (EN-switch), is one of the most important 
changes involved in the EMT pathways. Both isoforms are used as determinant marker 
proteins to define the epithelial or mesenchymal state of a cell. Additional support for the 
relation between tumor malignancy and the ‘‘cadherin switch’’ comes from clinical studies 
performed by Gravdal K, et al. (2007) (69). The study concluded that the occurrence of EN-
switch is a more reliable parameter in evaluation of patient prognosis than presence of E-
cadherin or N-cadherin separately. The study stressed out the importance of a dependent 
relationship between the patient prognosis and EN-switch. They also conclude that a 
‘‘cadherin switch’’ had a prognostic effect on time to both biochemical failure and clinical 
recurrence in multivariate survival analyses, stronger than for each protein separately (69). 
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1.3.2. Tumor-associated Proteins in EMT Activation 
1.3.2.1. The influence of tumor microenvironment 
 
The existence of an extracellular matrix in the highly unorganized tumor epithelium brings 
together cells and secreted proteins to this environment. The SPARC is one of those 
proteins that belong to the matrix cellular family and appears to be closely related with the 
E-cadherin expression. It is a nonstructural component of extracellular matrix (ECM) that 
regulates interactions with several ECM components, modulating the activity of several 
cytokines and growth factors, promoting alterations in cells adhesion and proliferation 
capacities (70). Structurally, the SPARC-related proteins subfamily presents three main 
components: i) an acidic N-terminal domain with low calcium-binding affinity, ii) a disulfide-
bonded, copper-binding follistatin domain, with homology to the TGF-β inhibitors and iii) 
extracellular C-terminal domain with calcium-binding affinity (70). Robert G, et al. (2006) 
reported for the first time the interaction between SPARC and E-cadherin, showing that the 
overexpression of SPARC in normal human melanocytes give them a fibroblast-like 
morphology related with the E-cadherin downregulation via the induction of Snail, an E-
cadherin transcriptional repressor (71). Conversely, SPARC depletion reduced the levels of 
Snail promoting the E-cadherin upregulation (71).  
The relationship between E-cadherin and SPARC can be understood based on the recently 
described mechanism of integrin-linked kinase (ILK) stimulation. Due to their localization, 
integrin receptors seem to be the link between SPARC (extracellulary located at points of 
integrin-ECM interaction) and ILK (located at the plasma membrane). Subsequently, the 
phosphorylation of several effector proteins by the ILK, including AKT and integrins-β1/β3, 
modifies cell behavior in terms of adhesion, invasion and metastization ability (72-74). 
Nevertheless, SPARC tumorigenicity seems to be dependent on the cell type and the tumor 
environment. In fact, its overexpression is associated with metastization and invasiveness 
in melanoma, glioma, breast, prostate and colorectal carcinomas, while in the case of 
ovarian carcinoma, neuroblastoma and pancreatic adenocarcinoma its expression is 
inversely related with the tumor development (70, 71, 75).  
Still at the extracellular level, the early observations also suggested that tumor cells bearing 
a mesenchymal phenotype massively secrete active TGF-β, which triggers EMT and 
enhances angiogenesis in the tumor microenvironment. In early tumor development, TGF-
β has an inhibitory effect on tumor growth, acting as a tumor suppressor. Conversely, at 
later stages, it acts as an immunosuppressive cytokine, favoring tumor evasion, by 
converting CD4+T cells in immunosuppressive T regulatory cells and inhibiting the effector 
T cells functions  (76). Tumor cells autocrine TGF-β production aims to circumvent tumor 
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microenvironment immunity system, mainly by suppressing dendritic cells development, 
maturation and function (65, 77, 78).  
The cellular responses to TGF-β begin through the activation of the membrane receptor 
kinases complex and occur via activation of members of Smad family. Smad 2, 3 and 4 
form a complex that translocate to the nucleus and bind to transcriptions factors, triggering 
the repression of epithelial genes and the concomitant activation of mesenchymal genes. 
Snail expression, for instance, is activated when Smad3 binds to Snail promoter. 
Consequently, E-cadherin expression is suppressed and vimentin and fibronectin 
expression enhanced. Silencing Snail expression reverses this process and restores E-
cadherin levels (77, 79). 
 
 
Figure 1. 6. Schematic representation of the most important biological pathways involved in 
cancer and EMT activation. AKT: protein (serine/threonine) kinase B (PKB); BAD: Bcl2-associated 
death promoter; Bcl2: B-cell lymphoma 2; ECM: extracellular matrix;  EMT: epithelial-mesenchymal 
transition; GSKβ3: glycogen synthase kinase 3 beta; IGFR: insulin-like growth factor receptor; MAPK: 
mitogen-activated protein kinase; MDM2: mouse double minute 2 homolog; mTOR: mechanistic 
target of rapamycin; NF-κβ: nuclear factor kappa B; PI3K: phosphoinositide 3-kinase; RTK: receptor 
tirosine kinase; SLUG: zinc finger protein SNAIL2; SNAIL: zinc finger protein SNAIL1; TGFβR: tumor 
growth factor beta receptor; ZEB: zinc finger E-box-binding homeobox. 
 
TGF-β induced EMT is dependent on several other pathways, such as the MAPK/ERK 
pathway and also requires the activation of transcription factors such as nuclear factor 
kappa B (Nf-κB) (65). RAS, upstream of the MAPK/ERK pathway is active in many tumors 
via stimulation by receptor tyrosine kinases (RTKs) or by oncogenic mutations. Ras-MAPK 
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pathway induces the expression of important EMT-related transcription factors, such as 
Snail and Slug. Besides MAPK pathway, Ras also activates other important downstream 
pathways such as the Phosphatidyl-inositol-3’-kinase (PI3K) signaling pathway, explained 
later on in this chapter (65, 78, 80). The Nf-κB factor has been associated with 
tumorigenesis due to its anti-apoptotic effect in several cancer cells. Nf-κB activation, 
commonly observed in metastatic breast cancer cells, occurs in response to inflammatory 
cytokines and growth factors. It has shown to be a fundamental regulator of EMT and 
metastasis in a model of breast cancer progression, once Nf-κB hyperactivation seems to 
be related with the increased expression of TWIST in these cells (65, 78, 81). 
The referred pathways involved in EMT regulation are summarized and schematized in 
Figure 1.6. 
 
1.3.2.2. Players at the cell membrane level 
 
Apart from extracellular signals, the EMT mechanisms also require important players in the 
cell membrane. Early observations suggested that the integrin’s family is implicated in cell 
adhesion mechanisms. These heterodimeric transmembrane proteins containing one α- 
and one β- subunit are involved in the crosstalk between the tumor cell and ECM, with many 
implications in crucial cellular processes such as cell proliferation, differentiation, migration, 
invasion and apoptosis. During the EMT, changes in the ECM microenvironment or 
alterations in intracellular signals that affect the expression of integrin-associated proteins 
might cause alterations in integrin activity. Consequently, changes in the overall adhesive 
and migrative status of the cells are expected to occur. Studies on integrin-β1 and its 
correlation with histological grading of cancer metastasis have insinuated integrin-β1 as a 
potential therapeutic target in metastatic cancer (50). However, the study of Parvani JG, et 
al. (2013) demonstrated that the specific downregulation of integrin-β1 failed to affect the 
growth and dissemination of breast cancer due to the compensatory upregulation of 
integrin-β3, which drives EMT through the oncogenic TGF-β signaling pathway. Therefore, 
these findings highlight the importance of targeting both β1 and β3 integrins to more 
efficiently eradicate breast cancer metastatic disease (82). 
The well-known relation between integrins and TGF-β in the stimulation of EMT and 
metastasis renders integrin-β1 to be an important player in several key signaling 
cytoplasmic transduction pathways (83). 
Additionally, several reports linked the integrin-β1 induced signals with the AKT isoforms 
activation explained below. As an example, Arboleda MJ, et al. (2003), demonstrated that 
AKT2 causes the upregulation of integrin-β1, increasing human breast and ovarian cancer 
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cells invasion and metastization (84). More recently, Virtakoivu R, et al. (2012) 
demonstrated in vitro that in prostate cancer cells, both AKT1 and AKT2 are inhibitors of 
integrin-β1. In this model their downregulation promotes the activation of cell surface 
integrin-β1, enhancing migration and invasion (85). Taken together, these results indicate 
that AKT may have a major role in the regulation of cell motility and invasiveness, being 
therefore a possible prognostic factor to identify the patient metastization stage. However, 
other EMT players present similar behavior, stressing out that the effect of integrins 
activation is both cell-type and differentiation-stage dependent (85-87). 
 
1.3.2.3. Intracellular transcriptional regulation of EMT 
 
E-cadherin downregulation, crucial to the initiation of an EMT process, requires genes 
downregulation followed by the activation of mesenchymal oncogenes expression. 
Identification of these genes could lead to development of new tumor markers and new 
strategies for targeted therapy.  
The transcriptional regulation of EMT essentially involves three families of transcription 
factors, the Snail, ZEB and bHLH families (50, 58, 65). The zinc-finger transcription factors 
Snail, Slug, ZEB1 (δEF1), ZEB2 (SIP1) and E47, a member of the bHLH family, directly 
bind to the E-boxes of the E-cadherin promoter, repressing its transcription (88). TWIST-
based signaling pathways also heavily influence loss of E-cadherin expression. However, 
as explained below, it is not clear yet how TWIST, another member of the bHLH family, 
promotes the E-cadherin downregulation. Nevertheless, the effect of the different 
transcription factors in E-cadherin expression highly depends on the histological type of 
tumors, not being present or active in all cancer cells (55). 
 
1.4. The Importance of TWIST-based Signaling Pathways in the EMT Program 
 
Due to its recognized importance in EMT activation, a major attention is given to the 
transcriptional regulation of E-cadherin by the transcription factor TWIST, and the 
intracellular pathway that this putative oncogene regulates (89). TWIST and a wide range 
of TWIST-related proteins and genes have been extensively reported as targets for a future 
anticancer gene therapy. 
TWIST is a key transcription factor that regulates E-cadherin expression, induces EMT and 
promotes cell motility. It has a specific role activating the migratory machinery and 
facilitating the invasion step of metastasis (50, 56, 58). Yang J, et al. (2004) identified the 
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transcriptional factor TWIST as being an essential player in metastization (90). In order to 
understand how the inhibition of TWIST expression affects the metastatic ability of the 
highly metastatic cell lines (4T1 cells), siRNAs targeting TWIST were constructed to further 
investigate its effects in lung metastases in vivo.  The results of this experiment showed 
that the number of lung metastasis was significantly reduced in animals treated with TWIST-
siRNA, comparing with a high metastization level observed in the group transfected with the 
siRNA control sequence. Authors also induced TWIST expression in MDCK kidney 
epithelial cells and observed morphological and molecular alterations that characterize 
EMT. Namely, cells lost their cobblestone appearance and acquired a fibroblastic 
morphology whereas at the molecular level, expression of adherent junction proteins such 
as E-cadherin, α- β- and γ-catenins was inhibited and mesenchymal markers strongly 
increased (90). 
Despite the above described TWIST interaction with the E-cadherin promoter remains 
unclear. Thiery JP, et al. (2009) and Yang J & Weinberg RA (2008) support that TWIST 
repress E-cadherin transcription indirectly (56, 58). Conversely, Vesuna F, et al. (2008) 
demonstrated that TWIST binds to the E-cadherin promoter and subsequently 
transcriptionally represses E-cadherin expression in breast cancer cells (89). 
Importantly, TWIST overexpression is also related with chemotherapy failure due to 
acquired drug resistance. Wang X, et al. (2004) described that upregulation of TWIST was 
associated with cellular resistance to Taxol® in nasopharyngeal, bladder, ovarian and 
prostate cancer cell lines. This suggests that inactivation of TWIST expression in human 
cancer cells, could represent an alternative therapeutic strategy to overcome the acquisition 
of paclitaxel (PTX) resistance (91). In addition to its interference with microtubules and the 
consequent mitotic arrest, the cytotoxic effect of PTX occurs through multiple pathways 
related to apoptosis induction. TWIST anti-apoptotic function can occur by i) interfering with 
p-53 related pathways; ii) inhibition of p21waf1 via both p53-dependent and independent 
pathways and iii) modulating NF-κB pathways (91). 
Drug resistance was proved to be related with EMT process and E-cadherin impairment, 
since migratory and metastatic potential appeared increased in PTX-resistant cells, which 
also showed decreased expression of E-cadherin and increased expression of vimentin, 
fibronectin and EMT-regulatory transcription factors, such as Snail and TWIST. In addition, 
highly tumorigenic cells able to evade apoptosis through an increase of AKT2 expression 
with a consequent TWIST transcriptional activity stimulation have proved to become drug 
resistant. Nevertheless, this association between EMT and PTX-resistance should continue 
to be studied in order to develop therapeutic alternatives in cancer therapy.  
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1.4.1. TWIST Mechanism of Action: AKT2 and PI3K as the Leading Players 
 
Specially related to the EMT program is the TWIST capability to target an important group 
of proteins, the AKT (92, 93). AKT 1, 2 and 3 isoforms (or PKB α, β and γ) are some of the 
most frequently overexpressed kinases in epithelial human cancers, playing a crucial role 
on tumor initiation, progression and metastasis formation (94, 95). The three isoforms are 
structurally homologous and present identical mechanisms of activation generally triggered 
by the stimulation of cell growth factors receptors such as the insulin-like growth factor-I 
receptor (IGF-IR) (95-97). PI3-K is one of the signaling proteins that is activated 
downstream of IGF-IR and lies upstream of AKT. PI3-K catalyzes the phosphorylation of 
membrane inositol lipids (PIs) generating second messengers (3-PIs) that activate the 
downstream target proteins by binding to their pleckstrin homology domain (PH) (Figure 
1.7). 
 
 
Figure 1. 7. Schematic representation of PI3K/AKT2 mechanism of action. When activated by 
IGF-1, PI3K phosphorylates its substrate, phosphatidylinositol at the 3 position hydroxyl group of the 
inositol ring. Phosphorylated PI3 binds to pleckstrin domain of AKT, which can be activated by 
phosphorylation of Ser and Thr residues. Once activated, AKT can exert its kinase activity on various 
targets in the cell.AKT: protein (serine/threonine) kinase B (PKB); IGF-1: insulin-like growth factor 1; 
PDK1: 3-phosphoinositide-dependent protein kinase 1; PH: pleckstrin homology domain; PI3K: 
phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; Ser: serine; Thr: threonine; 
TORC2: target of rapamycin complex 2. 
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All AKT isoforms, the major downstream effector of PI3-K, present this PH domain 
constituted by about 100 amino acids in their N-terminal region. Therefore, due to its PH 
domain, AKT is recruited to specific sites on plasma membrane containing increased PIs 
and subsequently is activated by phosphorylation. After its activation, AKT is able to 
phosphorylate several proteins inside the cell, regulating multiple biological functions 
related to cancer progression (95, 96). 
The importance of PI3-K/AKT signaling pathway has been recognized as a key player in 
processes involved in tumor development as well as chemoresistance. A detailed 
knowledge of the structure, regulation and function of PKB/AKT family is nicely reviewed by 
Hanada M, et al. (2004) (98). Singularities between AKT isoforms can be found both on 
their biological activity and tissue distribution. AKT1 and AKT2 are ubiquitously expressed, 
while AKT3 present a more limited distribution, with preferential expression in brain and 
testis (99). 
Some reports have shown that the overexpression of a specific AKT isoform could be 
related with certain type of tumors. For instance AKT1 gene amplification has been 
associated with gastric and lung cancers. AKT2 has been presenting a critical role in 
invasion and metastization of human breast, pancreas, colon and ovarian cancer cells, 
while AKT3 expression has been related with melanoma, brain and steroid hormone-
insensitive carcinomas (84, 100, 101).  
The specific role of each AKT isoform in terms of cell motility and invasion is strongly 
dependent on the type of cancer, and may present opposite effects.  
Even more complex is the relative contributions of the different AKT isoforms in the different 
steps of tumor development; however this lack of functional redundancy is still not well 
understood (102). As an example of this, Dillon RL, et al. (2010) using EMbB2 and PyVmT 
tumor models demonstrated that AKT1 and AKT2 perform opposite roles in mammary 
tumorigenesis and metastastization. AKT2 expression did not affect latency of mammary 
tumor, but has a crucial role triggering invasion and lung metastization in both models. 
Conversely, activated AKT1 promotes mammary tumor development but impairs 
metastastization, attenuating cancer cell migration (103). In the case of Linnerth-Petrik, et 
al. (2014) the AKT1 ablation significantly delays initiation of lung tumor growth, whereas 
AKT2 deficiency dramatically accelerates tumorigenesis in a viral oncogene-induced mouse 
model of lung cancer and AKT isoform-specific knockout mice (102). On the other hand 
Attoub S, et al. (2015) showed that AKT2 silencing reduced the cellular motility and invasion 
in vitro as well reduction of the tumor growth in vivo, showing that AKT2 plays an important 
role in lung cancer progression and can be an interesting target for lung cancer therapy 
(104). 
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This non-overlapping and sometimes opposing function of AKT isoforms leads to some 
contradictory statements in the literature. Therefore, the consequences of AKT genes 
overexpression in epithelial human cancers are critical to determine the way AKT inhibitors 
should be used in cancer treatment (105). A state of art of AKT isoforms silencing studies 
is present in the next section, aiming to understand their specific role in oncogenesis and 
the clinical application potential of AKT silencing based therapies. 
Regarding the cancer types we were working with, major attention was given to the AKT2 
isoform. AKT2 expression undergoes positive transcriptional regulation by the putative 
oncogene TWIST, being a critical player in the TWIST-promoted metastatic process by 
enhancing cell migration/invasion. This suggests that TWIST/AKT2 axis regulates the E-
cadherin silencing in tumorigenic cancer cells (84, 92, 97). Cheng G, et al. (2007) 
investigated their functional connection in 14 highly invasive breast cancer cells and 
concluded that AKT2 is a major downstream target of TWIST playing a crucial role in this 
cells mediated drug resistance, migration and invasion ability. Up to now, their studies 
demonstrated that i) TWIST binds to a specific E-box and activates the transcriptional 
activity of AKT2 promoter gene and positively regulates AKT2 expression; ii) TWIST 
knockdown by siRNA significantly decrease AKT2 expression; iii) ectopic expression of 
TWIST increase AKT2 at protein and mRNA levels in a dose depend manner; iv) siAKT2 
significantly decreased TWIST promoted drug-resistance, invasion and migration; and v) 
re-expression of AKT2 rescue the effects of TWIST knockdown. The clinical significance of 
these results in vivo was assessed, and it was observed that TWIST-AKT2 co-expression 
increased 69% in late stage breast tumors (92, 93). It was also demonstrated that, while 
AKT2 knockdown has a strong effect on EMT morphological changes, the knockdown of 
TWIST had no significant effect, being the AKT2 the critical player in all the TWIST-
mediated effects. 
Moreover, AKT2 oncogene is frequently related with cell survival mechanisms mainly in 
response to stress conditions. According to Arboleda MJ, et al. (2003), this protein is crucial 
in PI3-K dependent signaling pathways involved in cancer cells motility, invasion and 
metastization (84). Regarding cell survival, generally activated AKT2 promote apoptosis 
inhibition by different mechanisms such as i) increasing Bcl-2 like anti-apoptotic factors (Bcl-
2 or Bcl-xL); ii) direct phosphorylation of Bad and Bax, leading to the inhibition of both pro-
apoptotic factors with blockage of cytochrome c release from mitochondria; iii) 
phosphorylation of NF-κB with consequent transcriptional activation of NF-κB-regulated 
anti-apoptotic genes; iv) Inhibition of p53 and p21WAF1/CIP1; v) inactivation of forehead 
transcription factors; and vi) promotion of MDM2 nuclear localization and stabilization (92, 
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96, 106, 107). Thus, phosphorylation of AKT2 may hence prevent programmed cell death 
process. 
For all these, AKT2 became an interesting target to work with, and appear as a relief in the 
control of tumor development and metastization. 
The RNAi mediated AKT2 silencing strategy might prompt TWIST downregulation, avoiding 
the undesirable TWIST-mediated effects, while restoring E-cadherin expression and 
reverting the EMT process. Indeed, silencing of the AKT2 isoform has already shown to 
impair cell chemotaxis, crucial during cellular intra- and extravasation, through the blockage 
of actin polymerization, impairment of cytoskeletal rearrangement and/or cell adhesion 
crucial to mobility of metastatic cells (36, 108). Moreover, AKT2 has been shown to be 
involved in the activation of β-catenin and CD44 expression, fostering the preservation of 
the CSC subpopulation and mesenchymal traits (92, 109, 110). The involvement of AKT in 
maintenance of CSC subpopulation within the tumor by regulating EMT via TWIST 
activation is of special interest.  
This strategy could have important consequences in the design of new cancer therapeutic 
strategies, and special in CSC directed therapeutics. 
 
1.5. RNA Interference Regulation of EMT 
 
Gene therapy is a fascinating strategy that has detained the attention of several researchers 
in the last years since it allows the modulation of aberrant cell pathways, and to overcome 
the high toxicity and/or low specificity of many chemical drug compounds. Additionally, 
many putative protein targets are “non-drugable” due to their inconvenient cellular 
localization, binding and function (i.e. transcription factors). Consequently, gene therapy 
has been increasingly demanded nowadays. The silencing of particular genes through the 
RNAi therapy has been extensively investigated as a promising strategy in the oncological 
field, given the possibility of targeting specific oncogenes involved in proliferation, survival, 
angiogenesis, metastasis, apoptosis suppression or drug-resistance (111, 112).  
RNAi technology that awarded Fire and Craig Mello the Nobel Prize of Physiology and 
Medicine in 2006, is a potent technology based on direct homology dependent post-
transcriptional gene silencing. The RNAi-based therapeutics can be classified accordingly 
to their mechanism of action. There are mainly three types that include shRNA (short hairpin 
RNA), miRNA (micro RNA) and siRNA (small interfering RNA). The differences between 
them are summarized in Table 1.3.  
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Table 1. 3. Main characteristics and differences between miRNA, siRNA, and shRNA. 
 miRNA siRNA shRNA 
Precursor 
70nt dsRNA or 
shRNA 
Long dsRNA or 
shRNA 
Created in cell nucleus 
Origin/Delivery to the 
cell 
Occurs naturally in 
plants and animals. 
Encoded by their 
own genes 
Via viral and other 
gene therapy 
vectors to the 
cytoplasm 
Via viral and other 
gene therapy vectors 
to the nucleus 
Complementary 
Not exact. A single 
mRNA may target 
hundreds of mRNA 
Perfect match 
(higher than the 
shRNA) 
Perfect match (lower 
than the siRNA) 
Dose/Administration - 
High/Local or limited 
systemic injection 
Low/Local and 
systemic injection 
Function 
Inhibit translation of 
mRNA 
Cleave 
complementary 
mRNA 
Cleave 
complementary mRNA 
Persistence - 
99% degraded after 
48 hours. The 
silencing is effective 
up to 5-7 days post-
transfection 
Expressed for up to 3 
years 
Main clinical 
applications 
Expression levels of 
miRNAs can be 
used as diagnostic 
and biomarker tools. 
Therapeutic agents 
for acute disease 
conditions where 
high doses are 
tolerable. 
Therapeutic agents for 
chronic, life 
threatening diseases 
where low doses are 
desirable. 
 
 
shRNA are short hairpin expression vectors that after the nuclear entry, transcribe to small 
RNA molecules that bind to complementary mRNA and inhibit the expression of 
corresponding protein. From the delivery perspective, shRNA delivery is the most 
challenging of the three, since it requires entering the nucleus which also makes it less 
efficient in slowly dividing and non-dividing cells (113). Since, shRNA is produced inside the 
target cell from a DNA construct that has been delivered to the nucleus; the silencing effect 
is persistent during a long period of time (up to 3 years). Contrary to shRNA, miRNA and 
siRNA are small 21–25 base nucleotides that exert its function directly in the cytoplasm 
where they interfere with the target mRNA translation process. miRNA inhibits this 
translation process by binding non-specifically to the 3′UTR (untranslated region) of the 
mRNA,  therefore miRNAs are effective against more than one mRNA with similar 
sequences. However as a consequence, miRNA are less specific and more indiscriminate, 
usually presenting undesired off-target activity. On the other hand, siRNA binds specifically 
to a region of the complementary mRNA knocking down the expression of a certain protein 
(114-116). 
Despite the therapeutic potential associated to the RNAi technology, this strategy is still 
facing the challenge of poor in vivo delivery, uncontrolled off-target effects, and undesired 
immune system modulation associated to the use of viral vectors (117, 118). In order to 
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overcome such problems, gene delivery systems based in nanotechnology have been 
developed and proposed, as further discussed in Chapter 2. 
Despite the existence of several forms of small RNAs, siRNA and miRNA are the most 
commonly used for RNAi therapeutic and diagnosis applications (119, 120). Thus, most 
attention will be given to these two strategies. The mechanism of RNAi associated to both 
is present in Figure 1.8. 
 
 
Figure 1. 8. RNA interference mechanism. For siRNA the process begins with the cleavage of a 
long double-stranded RNA (dsRNA) by the Dicer enzyme complex into small 21-23 nt double 
stranded RNAs. These siRNAs are incorporated into a nuclease-containing multi-protein complex 
RNA-induced silencing complex (RISC). RISC is activated when Argonaute 2 (AGO2), the catalytic 
component of RISC, cleaves the sense strand of the double strand siRNA. Afterwards, RISC 
containing the guide strand binds to the mRNA inducing an endonucleolytic cleavage within the target 
site that is also carried out by AGO2. The miRNA mechanism begins with primary miRNA transcripts 
(pri-miRNAs) that are transcribed by the RNA polymerase II (Pol II). These pri-miRNAs are then 
cleaved by the Drosha enzyme complex into precursor miRNAs (pre-miRNAs) that are then exported 
to the cytoplasm by the exportin 5 and incorporated into the Dicer enzyme complex.  Dicer will 
process the pre-miRNA for loading onto the RISC complex. When the RNA duplex is loaded onto 
RISC the sense strand unwinds, leaving a mature miRNA bound to RISC. This miRNA recognizes 
target the 3'-UTR sequences in the mRNA and inhibits the mRNA translation. 
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1.5.1. miRNA and Cancer  
 
The miRNA, such as other conventional cancer genes, appears over- or sub-expressed 
accordingly to the types of human and animal tumors. Friedman JM, et al. (2009) reported 
that more than half of the total mRNA species encoded in the human genome are controlled 
by miRNAs (121). Moreover, usually, one miRNA is able to modulate the expression of a 
wide range of targets. As a consequence of this, when miRNA activity is affected, significant 
biological consequences are expected. In fact, some human diseases such as cardiac 
disorders and cancer had been related with modifications in the expression of a given 
miRNA (122, 123). As an example, miRNA families, such as the miR-200 and miR-29, 
become a subject for intense scientific investigation regarding their potential as new 
therapeutic targets and biomarkers for certain diseases (124, 125). 
As recently reported, miR-200 regulates E-cadherin expression through its interaction with 
the mRNA of the transcriptional factors ZEB 1 and ZEB 2. It was proved that the inhibition 
of miR-200 reduced the E-cadherin expression and increased vimentin, triggering cell EMT 
events. Additionally, when miR-200 is overexpressed, E-cadherin is upregulated and 
consequently cell motility is reduced. With regards to these findings, was suggested the use 
of miR-200 as a biomarker for the E-cadherin positive/vimentin negative cancer cells, and 
as a potential regulator of the EMT process (126). More interestingly, miRNA-200 family 
was related with the expression of each AKT isoforms. A decrease in the intracellular 
concentration of miRNA-200 was observed when the ratio of AKT1 to AKT2 was reduced, 
resulting in the EMT triggering and, a stem cell-like phenotype acquisition in breast cancer 
cells (124).  
Also extensively explored as potential biomarkers or new targets for cancer treatment, due 
to their preponderant role in different types of cancer, is the miR-29 family, constituted by 
the miR-29a, miR-29b and miR-29c. In fact, the members of this family usually show tumor 
suppressing behavior influencing the expression of several transcriptional factors and cell-
matrix adhesion-related proteins such as integrin-β1. Consequently, their downregulation 
triggers abnormal migration, invasion and proliferation of cells (125, 127). 
 
1.5.2. siRNA-mediated Silencing of AKT Isoforms 
 
In the last years, several studies have resorted to the RNAi technology to silence the AKT 
isoforms in order to understand their specific effects in carcinogenesis. Cheng JQ, et al. 
(1992) were the first who identified AKT gene alterations in human epithelial cancers. They 
demonstrated that the AKT2 is overexpressed in human ovarian carcinomas (128). Later, 
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these authors reported the same overexpression in human pancreatic cancer cells. After 
PANC1 cells transfection with siAKT2 a marked reduction of their tumorigenecity was 
observed, confirming the role of AKT2 overexpression in the malignant phenotype 
acquisition (129). The importance of AKT2 as an EMT promoter were also strengthened by 
Pu P, et al. (2006) who investigated the specific effect of AKT2 inhibition in a malignant 
glioma progression. siAKT2 transfected glioma cells presented both a marked reduction of 
cell proliferation and apoptosis induction. The in vivo studies showed a notable increase in 
the mean survival rate of the treated animals (130). Irie HY, et al. (2005) also silenced AKT1 
and AKT2 isoforms in IGF-IR overexpressing breast epithelial cells and assessed its 
individual effects on the displayed phenotypes. The results obtained indicate that due to 
AKT1 specific role in inhibiting IGF-I-mediated cell migration and ERK signaling pathway, 
its downregulation enhances migration and EMT markers expression. In contrast, 
downregulation of AKT2 inhibits migration and reverts the morphological changes induced 
by AKT1 downregulation (97).  
The study of Virtakoivu R, et al. (2012) about the roles of the different AKT isoforms in 
integrin-β1 regulation represents a good example of the cell type dependent AKT activity. 
They show that for prostate cancer both AKT1 and AKT2 negatively regulate cell migration 
and invasion. Therefore, when AKT1 and AKT2 are silenced, cell surface integrin-β-1 is 
activated, favoring tumor development. They also reported that the mechanism by which 
each AKT isoform regulates the integrin-β1 activity is different. AKT1 silencing stimulates 
integrin-β1 via a feedback downregulation of several receptor tyrosine kinases expression. 
On the other hand, the AKT2 silencing induces the overexpression of miRNA-200 family, 
which in turn is able to activate integrin-β1 and promote cell migration in the PC3 cells (85). 
Besides the well-known importance of AKT in the EMT program, the involvement of AKT 
isoforms in the acquired resistance of cancer cells to anticancer treatment have also been 
explored. Regarding this, Rajput, S. et al. (2015) defend that the silencing of AKT through 
siRNA provides new therapeutic options against the resistance to traditional 
chemotherapeutics. In their study they use acidic milieu-sensitive multilamellar gold 
niosomes (Nio-Au) to targeted delivery of AKT-siRNA and thymoquinone (TQ) to tamoxifen-
resistant and AKT-overexpressing MCF7 breast cancer cells. With this strategy of co-
delivery of siRNA and a chemical compound, they achieved to effectively knockdown AKT, 
thereby sensitizing cells to TQ and induce apoptosis of cancer cells. This result was 
confirmed by in vivo experiments (131). 
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1.6. Conclusions 
 
Despite progress observed in the last decades, an appropriate cure for advanced cancer 
was not yet achieved. Conventional treatment resistance, metastatic growth and tumor 
recurrence are sustained by the presence of CSC within the tumor. Due to the self-renewal 
capacity, CSC represents the essential part of the tumor, while division of any other cell will 
finish by clonal exhaustion. The percentage of CSC within a tumor often increases after 
chemotherapy or radiation which leads to cancer recurrence and metastatic growth since 
only few CSC are necessary and sufficient for tumor regeneration. Therapeutic selective 
targeting of CSC (specific pathways and selective CSC drugs/siRNA) may have the 
potential to remove residual disease and become an important component of any given 
cancer treatment. Currently, there are multiple anti-CSC agents in pre-clinical and clinical 
trials. Among the different therapeutic options, RNAi technology emerged as a tool to 
silence the expression of specific genes. The use of siRNAs or miRNAs in gene therapy to 
reduce the expression of a wide range of oncogenes has been extensively suggested as a 
new therapeutic strategy in cancer. Nevertheless, this ambitious goal is conditioned by the 
need of reliable systems for an efficient intracellular delivery.  
EMT signaling pathways and its upstream and downstream regulators have gained 
importance as therapeutic targets for cancer treatment, once they shown to be involved in 
cell adhesion and disruption, migration, metastization, angiogenesis, apoptosis, and drug 
resistance. Loss of E-cadherin is recognized as a hallmark of EMT since is a decisive signal 
for cell invasiveness properties acquisition; however, the network of the involved 
mechanisms highlights the importance of other crucial players. The enormous complexity 
of EMT regulators lies in the fact that their effects and expression always depend on the 
stage of cancer progression and tumor type, sometimes having completely opposite roles 
during the EMT and MET. This explains the inconsistencies found in different studies on the 
role of a certain gene in tumor progression. In order to be used as therapeutic target, it is of 
utmost importance to identify specific EMT and MET regulators for each cell and tumor type 
since a generalization that comprises all tumors simply does not exist. Special attention has 
been given to the transcriptional regulation of EMT by TWIST and dependent pathways. 
Due to its protagonism in malignant progression and in regulating TWIST mediated effects 
such as intracellular regulation axis in the decrease of E-cadherin expression, AKT2 was 
identified as a promising therapeutic target to revert mesenchymal phenotype in tumorigenic 
epithelial carcinoma cells.  
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2.1. The Problematic Choice of a Vector for Gene Therapy 
 
Gene therapy has caught the attention of several researchers as an opportunity to treat 
both acquired and innate diseases. Considerable attention was concentrated in biology-
driven therapies since a four-year old girl with severe combined immunodeficiency (SCID) 
caused by adenosine deaminase deficiency was treated using a virus based DNA delivery 
system in the first gene therapy clinical trial performed in the 1990s (1, 2). Delivery and 
subsequent expression of an exogenous oligonucleotide encoding for a missing or defective 
gene or to achieve the silence of a particular gene of interest, such as an oncogene are 
different approaches that bring new alternatives and effective resolutions for the treatment 
of several diseases, including hematological, immunological, ocular, and 
neurodegenerative diseases, and especially for the so feared cancer (3).  
The use of gene therapy in cancer seems to be the utmost alternative to overcome the well-
known drug-related secondary adverse effects, chemoresistance and problems associated 
with the radiotherapy. However, in vivo delivery of OGN has precluding the clinical utilization 
of gene-based therapies mainly due to its vulnerability to enzymatic degradation, poor 
cellular uptake and rapid renal clearance. Therefore, the great challenge for the successful 
clinical applications of gene therapy demands the emergence of new tools to enable the 
negatively charged OGN to be effectively delivered into target cells by crossing the 
hydrophobic cell membrane and reach the cytoplasm and/or nucleus (4-6). The case of the 
patient that developed leukemia after successful treatment of SCID using gene therapy 
probably own to an insertional mutagenesis event associated with the retrovirus vector 
used, slowed down the euphoria observed with the positive and encouraging results from 
the first clinical trials and imposed an reassessment of the strategies used for gene transfer 
(7). However, during the last decades, some positive results regarding restoration of vision 
in blind patients, eradication of blood cancers or correction of hemoglobinopathies, 
especially in pediatric patients, gave hope to the researchers to continuing the development 
and clinical evaluation of gene-based therapies (about 2000 clinical studies up to now) (3, 
4). Still, until now only Glybera® (alipogene tiparvovec using an adeno-associated virus as 
vector) was granted with marketing authorization by European Commission in late 2012 to 
treat lipoprotein lipase deficiency (8). 
The vectors used for gene delivery can be divided in two main groups: viral and non-viral 
vectors. Nowadays, viral vectors are still considered the most efficient, being the most 
commonly used for gene transfer in both pre-clinical and clinical research (3). However, the 
well-known drawbacks related with viral-based vectors such as their immunogenicity, 
mutagenesis, carcinogenesis, limited cargo loading, and time consuming/high cost 
procedures, boosted the development of safer vehicles using a wide range of lipids and 
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polymers (9, 10). This explains the enormous outbreak of the non-viral vectors in the last 
years (9, 11-14).  
Nevertheless, several limitations were also identified in some of the different non-viral 
vectors, such as low specificity, cellular toxicity, low biodegradability, rapid blood-circulation 
clearance, or limited transfection efficiencies (5, 15). Additionally, the steps involved in the 
gene delivery mediated by these vectors faces biological barriers as described in Figure 
2.1. As endocytosis represents the leading pathway for nanoparticles internalization, 
endosomal escape is probably one of the most important steps related with the transfection 
efficiency. It is well-known that after endocytosis, nanoparticles remain sequestered in 
vesicles (endosomes) that release the genetic material upon vector degradation; however, 
if naked OGN are not released from the endosome, their degradation will occurs. 
Therefore, for effective gene delivery, the vectors must contain compounds presenting 
endosomal membrane disruptive properties, which allows the genetic material to be release 
into the cytosol, continuing its journey (16-18). The mechanism inherent to endosomal 
disruption and the consequent nucleic acids release into the cytoplasm is the so-called 
“proton-sponge effect”. This phenomenon is defined as the vectors ability to buffer the 
endosomal pH, inducing endosomes osmotic swelling due to the excessive proton and 
chloride accumulation leading to a secondary water movement, and consequent disruption 
(16, 19). 
Regarding siRNA delivery, upon endosomes disruption the siRNA sequences are available 
in the cytosol to initiate its therapeutic RNAi mechanism. The same does not apply to DNA, 
which still faces additional barriers before being able to exert its effect in the nucleus (Figure 
2.1) (17).  
The ideal gene delivery system should be efficient, stable, cost effective, and capable to 
avoid rapid hepatic or renal clearance. Safety issues such as being biocompatible, 
biodegradable and non-immunogenic are also critical. As a pharmaceutical system, their 
functionalization and sustained-release profiles are known advantages among these 
systems. However, it is always necessary an appropriate balance between protection and 
release of the genetic material in order to ensure its biological functionality (5, 20). 
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Figure 2. 1. In vitro barriers for non-viral vectors based gene delivery. i) the nucleic acids 
complexation, that is dependent on the charge of the lipid or polymer, ii) the binding of lipoplexes 
and polyplexes to the cellular membrane that, except in the presence of specific targeting ligands, is 
usually nonspecific, iii) the particles internalization, that usually occurs via one of the five major 
endocytic pathways (phagocytosis, macropinocytosis, clathrin-mediated and caveolae-mediated or 
independent endocytosis), iv) the endosomal escape, one of the more critical phenomenon since is 
dependent on the occurrence of the proton-sponge effect, v) the cytoplasmic transportation, vi) the 
entry to the nucleus, and vii) the decomplexation of DNA-vector within the nucleus and integrate the 
host genome. 
 
2.2. Non-viral Gene Delivery Systems 
 
Different systems based on nanotechnology have been developed and proposed to reach 
the perfect gene delivery system (9, 10). Figure 2.2 summarizes the different types of 
nanoparticles commonly used as non-viral gene delivery systems. 
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Figure 2. 2. Different types of nanotechnology-based systems for gene delivery. The main 
polymer and lipid-based systems that can be used for gene delivery are schematized, as well as the 
components commonly used in its production. CD: cyclodextrin; DOPE: 1,2-di-(9Z-octadecenoyl)-
sn-glycero-3-phosphoethanolamine; DOSPA: 2,3-dioleyloxy-N-[2(sperminecarboxamido) ethyl]-
N,N-dimethyl-1-propanaminium trifluoroacetate; DOTAP: 1,2-dioleoyl-3-trimethylammonium-
propane; DOTMA: 1,2-di-O-octadecenyl-3-trimethylammonium propane; PAMAM: polyamidoamine; 
PCL: poly(ε-caprolactone); PEI: polyethylenimine; PLA: poly(d,l-lactide); PLGA: poly(d,l-lactide-co-
glycolide); PLL: poly(L-lysine); SNALPs: stable nucleic acid lipid particles. 
 
During the design of non-viral vectors, characteristics such as particle size, surface charge 
and presence of biological moieties should be finely tuned in order to improve their biological 
behavior and activity like blood circulation half-life, transfection activity and intracellular 
trafficking (21, 22). For this reason, nanoparticles intended for gene delivery usually 
possess in its composition cationic lipids or polymers that interact with the negatively 
charged nucleic acids by electrostatic interactions and condense into complexes (lipoplexes 
or polyplexes). The resultant polycation-based gene delivery systems net charge dictates 
the interaction with serum proteins and cell membrane surface (23-26). Usually, a positive 
charge promotes the interaction with negatively charged cell membrane, but also undesired 
associations with serum proteins. Therefore, to overcome these safety issues, lipo- and 
polyplexes are usually modified or conjugated with another lipids and/or polymers, affecting 
the nucleic acids condensation, nanoparticle serum stability and cell surface activity (24). 
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The main advantages and disadvantages related with nanoparticles as gene delivery 
systems are summarized in Figure 2.3.  
 
 
Figure 2. 3. Advantages and limitations in nucleic acid nanosystems delivery. Particular 
advantages of nucleic acid therapies are (1) the ability to include tissue specific targeting (or 
transcriptional targeting) and (2) the possibility to systemically deliver genes encoding for proteins 
with toxic properties. Moreover, as macromolecules, nucleic acids can overcome resistance 
mechanisms such as that supported by P-gp. However, nucleic acids are vulnerable in blood 
circulation, and hence they must be protected against enzyme degradation and condensed in the 
form of polyplexes. Physiological barriers, such as reticulo-endothelial system, still present a threat 
for nanosystems, and these must be armed against possible interactions with blood cells that can 
result in opsonization or undesired blood vessel adhesion. Decoration of nanocarriers with PEG or 
HPMA can provide shielding effect, while decoration with ligands that can bind receptors 
overexpressed in tumors can assist in cellular targeting and internalization. TNF: tumor necrosis 
factor; DTA: diphteria toxin A; HPMA: N-(2-hydroxypropyl)methacrylamide; PEG: polyethylene 
glycol; HES: hydroxyethyl starch. 
 
Oncology is the field that has most benefiting from the application of nanotechnology to 
drug delivery, including gene therapy. In addition, to condensate and prevent the 
degradation of genetic material, taking advantage of their lower particle size and the unique 
properties of tumor vasculature, nanotechnology-based vectors easily reach extravascular 
spaces becoming concentrated preferentially inside tumor tissues. Tumor vasculature 
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presents 600-800 nm gaps between adjacent endothelial cells as a result of increased 
levels of vascular mediators such as vascular endothelial growth factor (VEGF), nitric oxide, 
prostaglandins and bradykinins. This characteristic leaky architecture of tumor vessels, in 
combination with a poor lymphatic drainage is responsible for the enhanced permeability 
and retention (EPR) effect, the drug/gene-loaded nanoparticles natural tendency to 
accumulate into tumor tissue is the base of the passive targeting strategy (27-31). Of note, 
ubiquitously targeting cells within a tumor is not always feasible because some drugs cannot 
diffuse efficiently. The random nature of the passive targeting makes difficult to control 
drugs’ pharmacological effectiveness and this may induce MDR events. In order to increase 
the specificity of the vectors to tumor cells, beyond this passive targeting, chemical 
modification of the particles surface with specific moieties like antibody fragments or ligands 
that recognize and interact with membrane receptors or antigens specifically overexpressed 
in the target cancer cell surfaces represents a suitable approach (22, 27, 32, 33). As reffered 
in Chapter 1, special attention has been given to the targeting of CSC in order to provide 
new innovative treatments for patients with advanced cancer and reduce tumor relapse 
(Figure 2.4). An additional advantage is related with the fact that some drugs will benefit 
from entering inside tumor cells by receptor-mediated endocytosis, providing higher 
concentration levels of the active agent compounds within the tumor cell. These second 
generation of vectors might be especially useful in tumors that do not exhibit EPR effect or 
cases where the permeability of the vessels is not compromised (i.e.small metastases).  
 
 
Figure 2. 4. Schematic representation of the mechanisms of nanoDDS for CSC targeting. EPR 
effect versus active targeting. CSC: cancer stem cells; DDS: drug delivery system; EPR: enhanced 
permeability and retention. 
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2.2.1. Polymer-based Delivery Systems (Polyplexes) 
2.2.1.1. Cationic polymers 
 
Biodegradable polymeric nanoparticles have been highly proposed as gene delivery 
systems, not only due to higher complexation capacity, but also to the improved endosomal 
escape properties, resulting in enhanced transfection efficiencies (22, 34-38). Due to an 
easiest interaction with the negatively charged OGN and cellular membranes, greater 
attention is given to the cationic charged polymers (39-41) since its first proposal in 1987 
by Wu GY & Wu CH (42). 
The most commonly used polycations are synthetic cationic polymers such as chitosan (CS) 
and its derivatives, branched or linear PEI and its derivatives, polyamidoamine (PAMAM), 
poly(b-amino ester)s (PAEs), poly(2-aminoethyl ethylene phosphate) (PPEEA), and poly(2-
(N,N-dimethylamino)ethyl methacrylate) (PDMAEMA) (15, 43, 44). Cationic peptides and 
polypeptides such as the ones based on histidine (45, 46), protamine (47, 48), lysine 
(poly(L-lysine) (PLL)) (49, 50) are also been proposed as polymeric non-viral vectors (51-
54). CS is a natural cationic mucopolysaccharide obtained as a raw material from chitin 
deacetylation that has been shown to be biocompatible, non-inflammatory, non-toxic and 
biodegradable. This polymer unique structural feature is associated to the presence of the 
primary amine at the C-2 position of the glucosamine residues that promotes a high positive 
charge responsible for the polyelectrolyte complexes formation with negatively charged 
nucleotides (55). The properties of CS mainly for siRNA and DNA-mediated gene therapy 
depend on the molecular weight (MW) and degree of deacetylation (DD) as it affects the 
charge density, solubility, hydrophobicity and its ability to interact electrostatically with 
polyanions (56, 57).  A high DD (over 80%) has been identified as the most influential factor 
in efficient siRNA-mediated knockdown. Regarding the MW, Liu X, et al (2007) reported 
that CS molecules 5–10 times the length of the siRNA, could form stable nanoparticles 
resulting in high gene silencing efficiency in H1299 human lung carcinoma cells (58). The 
molar ratio (N/P ratio) between the positive charges of the polymer (amine groups) and the 
negative charges of the OGN (phosphate groups) also influences the polyplexes gene 
knockdown efficiency, partially due to the increase in nanoparticle stability specially 
observed at high ratio values. For example, polyplexes prepared with a 170 kDa (DD 84%) 
CS were only able to promote Green Fluorescent Protein (GFP) knockdown in H1299 
human lung carcinoma at higher N/P ratios (50 and 150) (59). Despite its well-established 
advantages, CS has a limited buffering capacity when compared with PEI (16, 18). 
Therefore numerous studies are centered in CS modifications or conjugation with lipids or 
other polymers in order to improve nucleic acid transfection efficiency. Conjugation with PEI 
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(60, 61), modification with urocanic acid (62), addition of poly(propyl acrylic acid) (63), 
introduction of imidazole moieties (64) and CS grafting with stearic acids (65) are few 
examples of studies that have been performed aiming to improve the buffering and 
transfection properties of CS. 
PEI and its derivatives, are a type of high cationic charge density polymers, presenting 
branched or linear forms, available in a broad range of MW (34, 66). PEI-based particles 
are well-known and well characterized non-viral vectors for efficient delivery of nucleic acids 
including DNA and RNA both in vitro and in vivo (22, 35, 67). The high transfection 
efficiencies of PEI-based vectors has been mainly related to their substantial buffering 
capability at the endosomal pH (from pH 6.0–6.5 in early endosomes to pH 4.5–5.5 in late 
endosomes and lysosomes (68)) and ability to promote the endosome osmotic swelling and 
rupture, releasing the genetic material into the cytoplasm, thus avoiding its traffic and 
degradation in the lysosomal environment (22, 35, 36, 38, 69). Additionally, PEI protonable 
amine groups provide a powerful electrostatic capacity, which can promote strong 
interactions with the negatively charged nucleic acids molecules, explaining the ability of 
this polymer to effectively condense nucleic acids into nanoscale entities, protecting them 
from degradation. Moreover, PEI cationic surface charge has also a crucial role in the 
binding of polyplexes with cell membrane and consequent internalization (38, 69). 
Unfortunately, the formed positively charged polyplexes usually become unstable, showing 
a tendency to aggregate throughout the incubation time, depending on the surface charge 
and ionic strength of the medium (69, 70). Furthermore, this high cationic charge density is 
also responsible for PEI well-known toxicity and side effects such as membrane damage, 
interaction with blood cells and activation of the complement system (38, 71).  
As with other polymers, key factors such as the linear versus branched structure, the 
branching degree and the MW are likely to affect the final PEI-based polyplexes efficiency 
and cytotoxicity profile (71-75). In fact, several studies demonstrate that linear PEI presents 
lower cytotoxicity compared to the branched ones with similar MW. However, a decreased 
condensation capacity of OGN due to lower amount of primary amines and lower 
transfection efficiencies are consequently observed (71, 72, 74, 76). Concerning the MW; 
high PEI MW, present increased buffering capacity and consequently high transfection 
efficiencies due to a higher content of primary, secondary and tertiary amines. 
Nevertheless, higher MW values increase cytotoxicity due to polymer precipitation and 
further adherence to the outer cell membrane, inducing cell necrosis (19, 71, 72, 77). The 
N/P between the nitrogen groups presented in the polymer and the phosphorous atom 
content in the nucleic acids, also proved to be a factor affecting significantly the polyplexes’ 
efficiency. In general, complexes formed at low molar ratio in the range of 2-5 tend to 
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aggregate due to hydrophobic interactions. In contrast, higher N/P ratios reduce 
aggregation as a result of electrostatic repulsion of the higher positive surface charge of the 
complexes (70, 78). 
The demand for non-viral vector-based solutions in the gene therapy field prompted an 
extensively research towards the development of PEI derivatives (34, 66). Grafting PEI with 
poly(ethylene glycol) (PEG), although rendering polyplexes with lower transfection 
efficiencies, is one of the most commonly used strategies to reduce cytotoxicity, avoid 
aggregation and decrease nonspecific interactions (19, 79). Alternatively, grafting with 
lipophilic chains such as cholesterol, propionic, succinic or palmitic acid, alkyl chains, and 
fatty acids demonstrated to improve PEI-based vectors characteristics such as polyplex 
stabilization or cell membrane interaction (19, 75, 80, 81). For example, Oskuee R, et al. 
(2010) proposed a novel carrier for siRNA delivery based on the carboxyalkylation of a 
branched PEI molecule. This chemical modification reduced the particles positive surface 
charge leading to a more hydrophobic polyplex without limiting its buffering capacity. In vitro 
results demonstrated that carboxyalkylation strongly reduced cytotoxicity of PEI and 
improved silencing efficacy of the delivered siRNA (19). Another example is the hydroxyl-
modified PEI prepared by Dong X, et al. (2013) that also show lower cytotoxicity and better 
transfection efficiency than the unmodified PEI. Additionally, this PEI derivative also 
presented a greater serum-resistance capacity (82). 
 
2.2.1.2. Amphiphilic polymers 
 
Amphiphilic copolymers are heterogeneous polymers composed by both hydrophilic and 
hydrophobic units disposed in sequential or grafted blocks (generally di- and triblock-
copolymers) (Figure 2.5).  
Varying the type or the chain length of the different units it is possible to modulate the 
polymer properties and its suitability for both industrial and pharmaceutical applications (83, 
84). Regarding the last one, they have been used as excipients for a long time as 
emulsifiers, wetting, thickening and stabilizing agents of suspensions and colloidal 
dispersions or gel forming agents; however, they gained an increased interest in the last 
decades in the development of new drug delivery systems (DDS) driven by the progresses 
seen in the pharmaceutical sciences and nanomedicine field (84, 85). Applications in 
nucleic acid delivery systems are particular exciting, once they demonstrate to improve 
biological activity while protecting nucleic acids from degradation and clearance by serum 
nucleases and immune system components (84, 85).  
 
AKT2 siRNA-Nanoparticulate System as a New Tool to Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
 
_______ 
     52 
 
Figure 2. 5. Diagram of an amphiphilic polymers-based micelle. 
 
The main characteristics of amphiphilic copolymers and copolymer-based structures that 
make them suitable for human administration are water-solubility, biodegradability, 
biocompatibility and low immunogenicity (Figure 2.6).  
 
 
Figure 2. 6. The main features of amphiphilic copolymers and their based structures. 
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Among the different structures available, the most extensively researched for the production 
of DDS are composed of PEG as hydrophilic block and a variety of hydrophobic blocks, 
namely: (i) polypropylene oxice (PPO); (ii) poly(ester)s like poly(ε-caprolactone) (PCL) or 
poly(d,l-lactide-co-glycolide) (PLGA); (iii) poly(amino acid)s such as poly(L-aspartic acid) 
and poly(L-glutamic acid); or (iv) lipids like phosphoethanolamine (PE) (86, 87). Particular 
interest has been given to PEG-PPO block copolymers (poloxamers and poloxamines) (88, 
89).They are commercialy accessible in a wide range of compositions and MW 
(Pluronic®/Lutrol®/Kolliphor® and Tetronic®).  
 
2.2.1.3. Characteristics of amphiphilic copolymers and copolymer-based 
structures 
a) Self-assembly 
 
Amphiphilic polymers are able to the form nanoscopic structures of different morphologies, 
e.g. polymersomes, nanocapsules, nanospheres, nanogels or dendrimers, although 
polymeric micelles (PM) are the most commonly used and researched (85, 90, 91). 
Micellization into spherical nanosized particles with a hydrophilic corona and hydrophobic 
core occurs at or above a specific threshold level of polymer concentration (critical micellar 
concentration - CMC) and temperature (critical micellar temperature - CMT) (86, 87). In 
water this process is driven by an increase in entropy of the solvent molecules in contact to 
the hydrophobic units of the polymer and a consequent decrease of free energy (Δ°Gm) as 
the hydrophobic components are withdrawn from the aqueous media originating the micelle 
core (92). Δ°Gm is given by Equation 2.1 where, R is the gas constant and T is the 
temperature of the system. 
 
∆°𝐆𝐦 = 𝐑𝐓 𝐥𝐧 𝐂𝐌𝐂                                                                                                                     Equation 2.1 
 
Different parameters such as chemical composition, MW, molecular architecture (linear 
versus branched, double bounds, etc.), concentration, temperature, solvent-polymer 
interactions, or salt concentration influence the self-assembly of polymers. By increasing 
the temperature of the system, the solvency of hydrophilic unit as well as the CMC value 
will decrease, promoting the micellization. Similarly, this phenomena is favored when the 
attractive hydrophobic interactions increases as a result of a gain in the MW of the 
hydrophobic domain (93). For example, PEG-b-PHOHH copolymers with PHOHH 
segments of 1500 and 7700 g/mol present a CMC value of 5.50 and 0.93 mg/L, respectively 
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(94). PM have been developed to modify several major intrinsic characteristics of drugs, 
including drug aqueous solubility, release pattern, pharmacokinetics, biodistribution, and in 
vivo stability (87). In general, the solubilisation capacity of hydrophobic drugs into micelles 
is proportional to the hydrophobicity of the micelle core (95). PM have an higher core 
hydrophobicity then surfactant micelles, conferring them higher thermodynamic and 
kinetical stability, thus presenting slower and delayed disintegration and drug release in 
circulation even upon dilution below the CMC value (84).  
 
Table 2. 1. Examples of self-assembled particles under clinical trials evaluation.  
Formulation Copolymer Drug Indication 
Clinical 
phase 
Reference 
SP1049C 
Pluronic® 
L61 and 
F127 
Doxorubicin 
Advanced 
adenocarcinoma of 
the esophagus, 
gastroesophageal 
junction and stomach 
III (96) 
Genexol-PM® PEG-PLA PTX 
Breast cancer, non-
small cell lung cancer, 
advanced pancreatic 
cancer and ovarian 
cancer 
II/III/IV (97-101) 
NK012 
PEG-poly(L-
glutamic 
acid)-SN-38 
conjugated 
SN-38 
Advanced breast 
cancer and small cell 
lung cancer 
II (102, 103) 
NK105 
PEG-poly(L-
aspartic acid) 
PTX 
Advanced or recurrent 
breast cancer 
III (104) 
NK-911 
PEG–
poly(aspartic 
acid)-
doxorubicin 
conjugated 
Doxorubicin Solid tumors I (105) 
NC-4016 
PEG-DACH-
platin 
Oxaliplatin 
Advanced solid 
tumors or lymphoma 
I (106) 
NC-6004 
(Nanoplatin®) 
PEG-poly(L-
glutamic 
acid)-
cisplatin 
conjugated 
Cisplatin 
Solid tumors, non-
small cell lung, biliary 
and bladder cancer, 
pancreatic cancer 
II/III (107, 108) 
Paxceed® PEG-PLA PTX 
Rheumatoid Arthritis, 
Psoriasis 
II (109, 110) 
IT-101 
Polymer-
cyclodextrin-
camptothecin 
conjugated 
Camptothecin 
Advanced solid 
tumors, ovarian 
cancer 
I/II (111, 112) 
AquADEK® 
D-alpha-
tocopheryl-
co-
PEG 1000 
succinate 
Vitamins and 
antioxidants 
Multivitamin 
supplement in Cystic 
fibrosis 
II (113) 
DACH-platin: diaminocyclohexane platinum; PEG: polyethylene glycol; PLA: poly(d,l-lactide); PTX: 
paclitaxel 
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Due to their therapeutic efficacy, some PM-based formulations passed from the pre-clinical 
assessment to enroll clinical trials (Table 2.1) (114-117). One of them (Genexol-PM®, 
Samyang Co.) firstly approved in 2007 in Korea and being evaluated in European Union 
and America with the name Cynviloq® for the treatment of breast, non-small cell lung and 
ovarian cancers (118-120), while SP1049C (Surpatek Pharma, Inc.) granted orphan drug 
designation by FDA for the treatment of gastric cancer (121).  
 
b) Surface hydrophilicity and functionalization 
 
While the hydrophobic core of micelles, in addition to the solubilisation and protection of 
hydrophobic drugs, provides appropriate mechanical properties for the desired application; 
hydrophilic shell allows the encapsulation of hydrophilic compounds, and masks the particle 
from the biological environment, thereby reducing the protein absorption and cellular 
adhesion, and enhancing the particle stability (122, 123). Opsonin proteins present in the 
blood serum promptly bind to particles, allowing their recognition by macrophages and 
consequent elimination of the encapsulated drugs from bloodstream (124). The presence 
of a hydrophilic layer on the surface of particles will provide them with stealth properties by 
reducing or delaying the opsonization via steric repulsion forces, thus increasing the plasma 
circulation time of particles and the half-life of drugs (124, 125). PEG and poloxamers are 
commonly used as hydrophilic polymer to covers the surface of many nanoDDS creating 
the so called stealth systems (126). Moreover the resultant functionalization potential by 
either chemical modification or bioconjugation could be used to bind targeting moieties to 
the particles surface  allowing a better control of the biodistribution of DDS (127). A variety 
of ligands such as peptides, antibodies, folate, transferrin or polysaccharides, can be used, 
accordingly to the required application.  
 
c) Stimuli-responsive properties 
 
Among all the characteristics presented by some amphiphilic polymers for the development 
of advanced controlled DDS, stimuli-responsiveness appears as one of the most interesting 
(128, 129). Stimuli-responsive polymers are a class of “smart” polymers that undergo 
chemical or physical alterations as response to a specific stimulus, e.g. temperature, pH, 
redox potential, magnetic field or light (129-131). Acrylate/methacrylate derivatives and 
monomers of N-alkyl substituted acrylamides are commonly used in the production of pH-
responsive and thermo-responsive copolymers, respectively (129, 132). At acidic pH the 
existence of intermolecular polymer complexes lead to the formation of compact gels that 
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swells and became loose just at basic pH (133, 134). Multi-stimuli-responsive polymers (to 
light, temperature, and pH) with possible applications in biomedical field can be also 
developed (135).  
 
2.2.1.4. Amphiphilic polymers-based gene delivery systems  
 
Amphiphilic polymers have been proposed as gene carriers in the last years. As an example 
Guo S, et al. (2011) engineered ternary complexes by coating the surface of 
polycaprolactone-graft-poly(N,N-dimethylaminoethyl methacrylate) (PCL-g- PDMAEMA) 
nanoparticles/DNA with polyglutamic acid-graft-poly(ethylene glycol)(PGA-g-mPEG), in 
order to decrease the zeta potential of the system without interfere with DNA condensation 
ability. In in vitro studies, this non-covalent post-PEGylated ternary complexes presented 
high stability, low cytotoxicity, pronunced transfection efficiency, and improved DNA 
endosomal escape ability over the binary complexes. Moreover, in vivo results, namely 
histochemical analysis of tumor sections showed that the tumor expression of a red 
fluorescent protein encoded by the RFP plasmid is higher when the ternary complex was 
intravenously administrated (52). 
In another study, Liu Y, et al. (2011) constructed a library of mono-methoxyl-poly(ethylene 
glycol)-block-poly(ε-caprolactone) (mPEG-PCL)-modified hyperbranched PEI copolymers 
(hy-PEI-PCL-mPEG) varying mPEG and PCL segments length, graft density, and hy-PEI 
MW in order to explore the influence of polymer compositions on siRNA delivery. Longer 
mPEG and PCL segments with higher graft density improve the stability and formation of 
polyplexes, reducing their cytotoxicity and zeta-potential. Hy-PEI-PCL-mPEG with very 
short PCL segments presented greater transfection efficiencies compared with those 
without PCL (hy-PEI25k) (136). 
Amino acid-based polymers have also been proposed. In this context, PEO-PLAA-based 
structures emerge as an opportunity for the development of more effective therapeutic PM. 
The presence of carboxyl or amine groups in the PLAA block is advantageous for chemical 
conjugation and electrostatic interactions with drugs and nucleic acids and facilitates the 
chemical modification of the micellar core (85). 
Poly(d,l-lactide) (PLA) and PLGA have also been formulated into micelles or nanoparticles 
and extensively used for sustained nucleic (137). Yang XZ, et al. (2011) produced a 
polymeric nanoparticle system for efficient siRNA encapsulation and delivery based on 
poly(ethylene glycol)-b-poly(d,l-lactide) (mPEG-PLA) and an amphiphilic cationic lipid 
(BHEM-cholesterol) by a non-condensation process and a double-emulsion solvent 
evaporation technique. In vitro assays showed that these nanoparticles allow efficient 
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siRNA cell internalization with further adequate endosomal escape, which results in the 
selective knockdown of the specific gene of interest, in this case, a significant 
downregulation of luciferase expression in HepG2-luciferase cells and suppression of polo-
like kinase 1 (Plk1) expression in HepG2 cells. In addition, the nanoparticles encapsulating 
siRNA targeting the Plk1 gene showed to induce notable apoptosis in HepG2 and MDA-
MB-435 cancer cell lines. In vivo studies on an orthotopic murine metastatic liver cancer 
model (MDA-MB-435 xenographs) further confirm the in vitro data, where luciferase 
expression was significantly inhibited and tumor growth suppressed after nanoparticles 
systemic administration (137). All these results suggest that mPEG-PLA nanoparticles have 
great potential for gene therapy. More recently, Sun J, et al. (2016) tested the amphiphilic 
triblock copolymer poly(hydroxyletheyl methacrylate-L-lysine)-b-poly(L-lactide)-b-
poly(hydroxyletheyl methacrylate-L-lysine)s (PHML-b-PLA-b-PHML) to efficiently 
condensate a plasmid DNA and protect it from degradation by DNase I, and promoted a 
strong transfection efficiency without significant toxicity. The endocytosis of this particles 
seems to be through the lipid-raft-mediated endocytosis pathway, similar to that of SV40 
virus-based vectors (138).   
Murata N, et al. (2008) produced a biodegradable long-term sustained release PLGA 
microsphere through the water-in-oil-in-water drying method for encapsulation of anti-VEGF 
siRNA in order to suppress angiogenesis and tumor growth in vivo. Arginine or branched 
PEI was used as transfection agent/carrier for siRNA delivery. Using mice bearing S-180 
tumors they demonstrated that after an intra-tumor injection of these microspheres VEGF 
gene expression and consequently the tumor growth were highly suppressed which indicate 
that this formulation is an useful approach to cancer treatment (139). 
Worth to note is the research of Alshamsan A, et al. (2010), that investigated the 
incorporation of siRNA/PEI and siRNA/PEI-stA (the stearic derivative of PEI) complexes 
into PLGA nanoparticles for STAT3 knockdown in dendritic cells (DC). The in vivo and in 
vitro cytotoxicity that already had been detected for PEI or PEI-StA based polyplexes, was 
significantly reduced with this systems. They observed that the successful and specific 
STAT3 silencing is associated with the reestablishment of DC maturation and functionality, 
therefore this formulation represents an interesting strategy for targeted siRNA delivery to 
DCs and a promise for combined cancer immunotherapy (140). 
 
2.2.1.5. Pluronic® and its role as biological response modifier 
 
Pluronic® amphiphilic block copolymers have been shown high stability and the capacity to 
improve significantly the transfection efficiency and gene expression via different delivery 
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routes (24, 89, 141). The mechanism by which poloxamers enhance gene expression is not 
clearly understood but seems to be related to its ability to bind to cellular membranes and 
further activation of cell signalling pathways, such as the Nf-κB pathway. Nf-κB is a 
transcription factor able to bind pDNA in the cytoplasm and transport it to the nucleus using 
the nuclear transport machinery. Yang Z, et al. (2008) demonstrate for the first time that 
Pluronic® enhances both cellular uptake and nuclear transport of polyplex-delivered pDNA 
into NIH 3T3 cells, underling the role of poloxamers as a biological response modifier. On 
the other hand, poloxamer did not affect the naked DNA uptake, emphasizing the 
importance of delivering pDNA using polyplexes (24).  
Another study from Kuo JH, et al. (2003) compared the serum stability of PEI/DNA and 
Pluronic-PEI/DNA complexes with different hydrophilic lipophilic balances (HLB) in terms of 
DNA delivery capacity to NIH/3T3 cells. The presence of Pluronic® especialy with higher 
HLB values, such as F68, conferred higher stability and increased significantly the gene 
expression (142). Also, Wang M, et al. (2014) investigated a series of small-size PEI-
conjugated Pluronic® polycarbamates (PCMs) for the ability to modulate the delivery of 2′-
O-methyl phosphorothioate RNA (2′-OMePS) both in vitro and in dystrophic (mdx) mice for 
the treatment of muscular dystrophy or other appropriate myodegenerative diseases. They 
conclude that the effective PCMs, especially those composed of moderate MW (2k–5kDa) 
and intermediate HLB of Pluronic®, enhanced exon-skipping of 2′-OMePS with low toxicity 
as compared with Lipofectamine® 2000 in vitro or PEI 25k in vivo (143).  
Taking into account the different reports, the use of Pluronic® in the development of non-
viral gene delivery systems seems to be a simple and safer approach that enhances both 
the in vitro and in vivo gene expression without inducing significant cytotoxic effects or 
inflammatory responses.  
 
2.2.1.6. Polymer-based non-viral vectors on the way to clinical trials 
 
The emerging advances observed in the area of gene delivery using polymeric 
nanoparticles technology, including the ones based in amphiphilic polymers, allowed the 
opportunity to bring these concepts to the clinical practice. In 2008, CALAA-01 becomes 
the first targeted delivery of siRNA to be tested in a phase I clinical trial to treat solid tumors 
refractory to standard therapies. CALAA-01 consists in a cyclodextrin-containing polymer 
(CDP)-based delivery system loaded with siRNA against ribonucleotide reductase subunit 
2 (RRM2) and was design to inhibit tumor growth. The formulation also contains PEG as a 
stabilizing agent, and human transferrin (Tf) as a targeting ligand for binding to 
overexpressed transferrin receptors (TfR) of cancer cells (144). Besides CALAA-01, 
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Calando Pharmaceuticals already announced the development of CALAA-02, based on the 
same platform but encapsulating a siRNA against the HIF-2alpha. 
 
Table 2. 2. Examples of polymeric nanoparticles for gene delivery at different stages of 
development. 
Polymer vector 
Genetic 
material 
Utility State Reference 
Dendritic PLL-block-poly(L-
lactide)-block-dendritic PLL 
pGFP GFP expression in vitro (145) 
CS siRNA luc Gl3 
Luciferase (luc) 
reporter gene 
downregulation 
in vitro (146) 
Derivatives of low 
molecular- weight PEI 
pGL3 
Luciferase 
expression 
in vitro (147) 
PEI-PEG-TAT peptide pGFP-N3 GFP expression in vitro (148) 
CTAB 
p-ialB and p-
omp25 DNA 
vaccines 
Protection 
against Brucella 
melitensis 
in vivo (149) 
CS oligomers 
pCpG-Luc, 
gWiz-Luc, 
pCpG-GFP and 
gWiz-GFP 
Luciferase and 
GFP expression 
in vivo (150) 
ARC-520 (Dynamic 
PolyConjugates) 
siRNA against 
apolipoprotein B 
and peroxisome 
proliferator-
activated 
receptor alpha 
Hepatitis B in vivo (151, 152) 
PEG-PLL sFlt-1 pDNA Solid tumors in vivo (153) 
PEG-poly[N’-[N-(2-
aminoethyl)-2-
aminoethyl]aspartamide] 
pGL4.13 and 
sFlt-1 pDNA 
Solid tumors in vivo (154, 155) 
Pluronic® P85 pGFP GFP expression in vivo (156) 
CALAA-01 
siRNA against 
ribonucleotide 
reductase M2 
Melanoma 
Phase 
I 
(157, 158) 
Polyvinylpyrrolidone 
pIFN-alpha, pIL-
12 and phIGF-1 
Cubital tunnel 
syndrome, 
oropharyngeal 
cancer, 
squamous cell 
carcinoma and 
malignant 
melanoma 
Phase 
I/II 
(159-161) 
PHML-b-PLLA-b-PHML pDNA 
Not tested for a 
specific disease 
in vitro (138) 
CTAB: cetyltrimethylammonium bromide;PHML-b-PLLA-b-PHML: poly(hydroxyletheyl methacrylate-
L-lysine)-b-poly(L-lactide)-b-poly(hydroxyletheyl methacrylate-L-lysine).  
 
In the next years it is expected that new polymeric non-viral vectors based on amphiphilic 
polymers for both RNAi and DNA therapeutic strategies reach clinical evaluation, thus 
contributing for the progress of gene therapies in a variety of diseases. In Table 2.2 are 
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summarized some of the many works proposed involving polymeric nanoparticles for gene 
delivery at different stages of development. 
 
2.2.2. Lipid-based Delivery Systems (Lipoplexes) 
 
Lipid-based non-viral vectors including liposomes, lipidic micelles, solid lipid nanoparticles 
(SLN), among others, became under the spotlight of many research teams as a strategy to 
overcome positively charge polyplexes toxicity and some possible lack of biocompatibility 
and/or biodegradability, while protecting the nucleic acid from nuclease degradation, 
allowing systemic delivery, and enhancing cellular uptake (162, 163). 
Lipoplexes are usually produced through a simple interaction between nucleic acids and 
different lipids through different techniques such as the hydration of a lipid film, the 
dehydration-rehydration method, the ethanolic injection, the reverse-phase evaporation or 
the detergent dialysis technique (70). 
Three types of lipids are usually selected to form the lipoplexes: i) anionic (e.g. cholesteryl 
hemisuccinate (CHEMS)), ii) neutral (e.g. 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
phosphoethanolamine (DOPE) and cholesterol), and iii) cationic (e.g. 1,2-di-O-octadecenyl-
3-trimethylammonium propane (DOTMA) or Lipofectin®, 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 2,3-dioleyloxy-N-[2(sperminecarboxamido) ethyl]-N,N-dimethyl-1-
propanaminium trifluoroacetate (DOSPA) or Lipofectamine®, 1,3-dioleoyloxy-2-(6-
carboxyspermyl)-propyl amide (DOSPER), and Oligofectamine®). 
The cationic lipids, due to its high capacity to complex the anionic ONG are commonly 
chosen. The final charge of the lipoplex, probably one of the most important factors affecting 
lipoplexes stability and transfection efficiency, depends on the ratio between the differently 
charged lipid vector and the nucleic acid molecules. Besides its charge and composition, 
the size and morphology of the lipoplexes also tremendously affect their transfection 
activity. Cationic lipoplexes, for example, does have a vast heterogeneity in terms of shape 
and size and different morphologic forms (such as cubic, beads on a string, spaghettis, 
meat balls, multilamellar, map-pin, sliding columnar and inverted hexagonal phase 
structures) have been reported (164). Regarding lipoplexes size, there is still a large 
controversy about which size range promotes better transfection activities. Some authors 
such as Esposito C, et al. (165) or Massoti A, et al. (166) advocate that lipoplexes within 
200-400 nm or even 1-2 μm are more efficient, arguing that larger particles have a faster 
sedimentation process, present a higher contact with cells and form larger intracellular 
vesicles, that are more easily disrupted, improving the endosomal escape (165, 166). 
However, other authors report that higher transfection efficiencies are obtained using 
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particles with a smaller size of around 100 nm or less (167, 168). Although the optimal size 
for particles in vitro is still unclear, for the in vivo applications is of general consensus that 
small diameter nanoparticles are the more effective ones due to their avoidance from 
reticuloendothelial system and improved biodistribution (164). 
The lipoplexes internalization by cells depends on the type of lipid used and the type of 
genetic material that is delivered, being reported two main mechanisms. The majority of the 
cases it is processed by endocytosis and in a low percentage of the cases by direct fusion 
with the cellular membrane. As example, Rejman J, et al. (169) demonstrated that 
DOTAP/DNA lipoplexes uptake occurs via clathrin-mediated endocytosis, while according 
to Wong AW, et al. (170), the uptake of a plasmid DNA associated with DMRIE-C 
transfection reagent occurs via the caveolin pathway. For synthetic siRNAs another 
mechanism was recently reported by Lu JJ, et al. (171), which showed that besides around 
95% of siRNA lipoplexes enter the cells by endocytosis, the functional siRNA delivery 
occurs via minor pathways that involve simply the fusion with the plasma membrane. It was 
observed that when clathrin, caveolin or macropinocytosis mediated uptake is inhibited, the 
knockdown of the protein of interest continues to happen. On the other hand, when the 
cholesterol from the plasma membrane is depleted there are a significant reduction of the 
knockdown of the protein (171). 
 
2.2.2.1. Cationic lipoplexes 
 
Cationic lipids are generally amphiphilic molecules formed by a positively charged polar 
headgroup attached via a linker to a hydrophobic domain, which hydrocarbon chains 
lengths vary commonly between C8:0 and C18:1. The characteristics of the headgroup are 
responsible for the transfection efficiency of the lipoplexes; therefore several synthetic 
cationic lipids with variations in the headgroup composition have been produced. 
Headgroups consisting on amines groups with different substitution degrees, guanidinium 
or pyridinium groups, amino acids and peptides have been reported (9, 12, 13).  
Despite their unquestionable advantages in terms of transfection efficiency, the toxicity of 
cationic lipids is a well-known problem that needs to be addressed. Eventhough, 
Lipofectamine® 2000 is widely used as transfection reagent in mechanistic studies and gold 
standard to assess the efficacy of other systems. Therefore, with the final objective of 
reaching an ideal gene delivery system with minimal toxicity and adequate transfection 
efficiency, numerous cationic lipids based formulations have been continuously designed 
and produced, presenting adequate in vitro and in vivo results and some of them enrolled 
already clinical assessment (Table 2.3). These new cationic lipids are obtained through 
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structural modifications performed in the headgroup, in the linker and/or in the hydrophobic 
tail domains that are known to regulate transfection efficiency and cytotoxicity (172).  
 
2.2.2.2. Anionic and neutral lipids 
 
The use of anionic or neutral lipids as gene delivery systems is another strategy that some 
authors explore with the objective of override the cationic lipids associated toxicity. 
However, due to their negative or neutral charge and the consequent impossibility to 
establish electrostatic interactions with negatively charged molecules, the delivery systems 
based on anionic or neutral lipids always require the incorporation of a third moiety such as 
divalent or monovalent cations (Ca2+, Na+, Mg2+, Mn2+ or Ba2+) to promote the complexation 
between the nucleic acids and the lipids (173-175). 
Kapoor M, et al. (175) designed a siRNA delivery system using physiologically occurring 
anionic lipids (DOPG/DOPE) and calcium ions bridges. The obtained lipoplexes presented 
high stability in the presence of serum components, efficient cellular uptake and effective 
endosomal release, and a significant silencing capacity comparable with the control cationic 
complexes (Lipofectamine® 2000), showing lower toxicity (175). 
In another study, Mignet N, et al. (173) proposed an innovative system throughout the 
combination of a cationic lipoplex and pegylated anionic liposomes. The ratio between 
anionic and cationic lipids was optimized in order to form an anionic pegylated lipoplex 
sensitive to pH changes (5.5-6.5). Reversion to a cationic net charge at an adequate pH 
value was observed during endosomal acidification which leads to the DNA release and 
consequent increase of the gene expression. These result was comparable with the control 
CHEMS formulation and more importantly, showed an improved ability to deliver DNA to 
tumor tissues (173). 
 
2.2.3. Lipid Nanoparticles 
 
Different types of liposomes (cationic, neutral and anionic) have been developed and 
successfully used for nucleic acids administration (57, 176, 177). Among them, Stable 
Nucleic Acid Lipid Particles (SNALPs) have been enjoying special interest for the treatment 
of several diseases. They consist in a lipid bilayer system composed by a mixture of cationic 
and fusogenic lipids shielded with PEG to provide a neutral hydrophilic surface, avoiding 
opsonization and rapid systemic clearance in vivo, as well as allowing an efficient particle 
targeting (Figure 2.7) (162, 178-182). Neutral lipids such as DOPE, cholesterol or (1,2-
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dioleoyl-sn-glycero-3-phosphocholine) (DOPC), also called helper lipids, are many times 
added to the system, since play an important role improving particles robustness and 
physiologic stability (9, 183, 184). 
 
 
Figure 2. 7. Schematic representation of a SNALP and its main components. PEG: polyethylene 
glycol 
 
 
For example, TKM-PLK1 and ALN-VPS are both SNALP-based siRNA systems that 
recently enrolled in clinical trials (185, 186).  
Despite the favorable biocompatibility profiles of the majority of the components presented 
in liposomes, some major concerns arise mainly related to the cationic reactivity-related 
toxicity and lower entrapment efficiency presented by many of the proposed systems (162).  
Regarding the usual drawbacks related with cationic liposomes such as their cytotoxicity, 
non-specific interactions with negatively charged cellular components, short half-time life 
and high immunogenicity, many efforts have been done to circumvent these problems. As 
an example, Semple SC, et al. (2001) developed liposomes using the pH-sensitive ionizable 
aminolipid DOTAP, presenting a neutral charge at physiological pH, that becomes cationic 
at the endosomal pH (187).  
Another common strategy is based in the addition of neutral lipids such as DOPC, DOPE, 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and phosphocholine (PC) to reduce 
the total cationic surface charge (163, 188). Atu027 (based on AtuPLEX® system), is an 
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example of this approach, a cationic liposomal formulation containing neutral fusogenic 
lipids, designed for delivery of siRNA against the protein kinase PKN3. In phase I clinical 
trials, the system has proved to be well tolerated in the administered doses, being a hopefull 
antiangiogenesis therapeutic strategy for the treatment of advanced solid tumors  (189).  
Apart from liposomes, SLN have also been proposed as non-viral vectors due to their 
proposed advantages such as high stability, protection of the encapsulated agents, high 
entrapment ability, small and uniform sizes, easily modulated via the composition, sustained 
controlled release properties, biodegradability, ease manufacture and scale up at relatively 
low cost, or suitability for sterilization and lyophilization. They showed to be capable of 
encapsulating OGN, mainly using plasmids as a model, in the lipid core or on the particle 
surface (190). 
Bondi L, et al. (2007), proved the suitability of cationic SLN based on acylglicerol lipids, able 
to form stable complexes with DNA and to protect DNA against DNase I digestion. The in 
vitro studies performed on human liver cancer cells also demonstrated a low degree of 
toxicity of both SLN and SLN–DNA complexes (191). With the objective to assess the in 
vivo transfection potential of SLN, Rodríguez A, et al. (2010), demonstrated for the first time 
the capacity of SLN-DNA vectors to induce the expression of a foreign protein in mice. They 
use SLN as a vector to transfect the pCMS-GFP plasmid that encodes the GFP and 
observed protein expression in hepatic and splenic tissues (192). 
Regarding siRNA delivery, Lobovkina T, et al. (2011), demonstrated that SLN can 
incorporate and provide a sustained release of siRNA. SLN were intradermic injected in 
mouse footpads and a prolonged siRNA release over a period of 10-13 days was observed, 
with retention of the siRNA activity (193). In another study, Yu Y, et al. (2012), proposed a 
formulation of cationic SLN for co-delivery of PTX and human myeloid leukemia cell 
differentiation protein (MCL1)-specific siRNA (siMCL1). This system significantly reduced 
the MCL1 mRNA levels in KB cells, contrary to the group treated with siMCL1 alone. 
Additionally, the in vivo results shown significant reduction of the tumor growth in KB cell-
xenografted mice (194). 
Some examples of the lipidic non-viral vectors for gene delivery are summarized in Table 
2.3. 
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Table 2. 3. Examples of lipidic nanoparticles for gene delivery at different stages of 
development.  
 
DMRIE: 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium bromide; DOPE: 1,2-di-(9Z-
octadecenoyl)-sn-glycero-3-phosphoethanolamine; DOTAP: 1,2-dioleoyl-3-trimethylammonium-
propane; DOTMA: 1,2-di-O-octadecenyl-3-trimethylammonium propane; LinOS: N4-linoleoyl-N9-
oleoyl-1,12-diamino-4,9-diazadodecane; NK: natural killer; PCSK9: Proprotein convertase 
subtilisin/kexin type 9; PLAS: PEGylated lipoplex-entrapped alginate scaffold; PLK1: polo-like kinase 
1. 
 
2.2.4. Combination of Polymers and Lipids: does it meet the ideal system? 
 
In order to benefit from the advantages of both polymeric and lipidic systems, 
Lipopolyplexes (LPP) (Figure 2.8) i.e. ternary complexes composed essentially by cationic 
lipids, a cationic polymer/peptide, and nucleic acids, were conceived (210-213). This hybrid 
Lipid vector Genetic material Utility State Reference 
LinOS/cholesterol GFP siRNA 
GFP delivery and 
silencing 
in vitro (195) 
PEGylated 
liposomes 
Surviving siRNA Tumor reduction in vivo (167) 
PEGylated 
lipossomes 
Argonaute2 
siRNA 
Anti-angiogenesis effect 
and tumor growth 
suppression 
in vivo (196) 
DOTMA CpG DNA 
Prevent pulmonary 
metastasis and 
peritoneal dissemination 
through via NK cell 
activation. 
in vivo (197) 
PLAS Lamin A/C  siRNA 
Sustained delivery of 
siRNA to vaginal 
epithelium. 
in vivo (198) 
PEI-PEGylated 
liposomes 
AML1/MTG8 
Decrease leukemic 
clonogenicity in CD33-
positive acute myeloid 
leukemia cells 
in vivo (199) 
Atu027 (AtuPLEX® 
system) 
Protein kinase N3 
siRNA 
Advanced solid tumor 
and pancreatic cancer 
Phase 
I/II 
(200, 201) 
DMRIE/DOPE pGT-1 gene Cystic fibrosis Phase I (202) 
DOTAP/cholesterol Fus 1 gene 
Non-small-cell lung 
cancer 
Phase 
I/II 
(203, 204) 
SNALP (ALN-PCL) PCSK9 Hypercholesterolemia Phase I (186) 
SNALP (TKM-PLK1) PLK1 
Refractory 
neuroendocrine tumors, 
adrenocortical 
carcinoma and 
metastatic cancers 
Phase 
I/II 
(205, 206) 
QPI-1002 p53 siRNA 
Acute kidney injury and 
prevention of delayed 
graft function 
Phase 
II/III 
(207, 208) 
PF-655 RTP801 siRNA 
Diabetic macular edema 
and wet age-related 
macular degeneration 
Phase II (209) 
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system combine the delivery capabilities of cationic liposomes with the advantages of 
cationic polymers/peptides given rise to a more efficient complexation, delivery and 
transfection efficiencies compared to the first generation ones represented by lipoplexes 
and polyplexes (211, 212, 214-222). Several authors have reported an additional OGN 
protection against enzymatic degradation, and  superior physical stability (223), reduced 
cytotoxicity (224, 225) as well as an elevated transfection efficiency (211) when the nucleic 
acid is incorporated in a polymer-lipid complex. 
 
 
Figure 2. 8. Schematic representation of a type of lipopolyplex and its main components. 
 
PEI is one the cationic polymers highly proposed to be complexed with lipoplexes to form 
the LLP (214, 216, 226, 227). Kurosaki T, et al. (2009), have developed a LPP formulation 
for pulmonary gene delivery composed of PEI, DOTMA and pDNA (227). Markedly 
transfection efficiencies in HepG2 cells, without any cytotoxicity or aggregation with 
erythrocytes were proved. Moreover, further in vivo studies revealed high levels of 
transfection efficiency in lung cells after intravenous administration (227). A similar LPP 
formulation combined with folic acid at the surface of the system significantly enhanced its 
transfection efficiency and gene-silencing activity without a significant cytotoxic effect (213). 
Pelisek J, et al. (2006), investigated a combination of linear and branched PEI with 
liposomes of DOSPER and DOTAP for gene transfer to slow-proliferating human colon 
carcinoma cell lines (214). In all cases, LPP were between 5 to 400 times more efficient 
compared to the corresponding lipoplexes or polyplexes, being therefore favorable 
nanocarriers for in vitro and in vivo gene transfer in colorectal cancer cells (214). 
Another system taking profit of the LPP advantage was proposed by Alshamsan A, et al. 
(2011) for the knockdown of the signal transducer and activator of transcription 3 (STAT3) 
through the use of stearic acid modified with PEI. This system was tested in B16 melanoma 
in vitro and in vivo, showing good results namely in terms of  a significant increase in IFN-
γ, IL-2 and IL-12, and TNF-α within the tumor microenvironment (228).  
Regarding LPP complexes compromising liposomes, nucleic acids and cationic peptides, 
the most commonly used peptide is protamine (215, 217, 219, 221, 223, 229), but lysine 
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(215, 230-232), arginine and histidine (222, 231) have also been studied. The strong 
association between peptides and nucleic acids confers to such LPP particles an enhanced 
transfection efficiency and gene silencing. Moreover, this complexation promotes the 
capacity to transfect cells in the presence of serum (184, 233). Cationic lipid-protamine-
OGN complexes have presented an increased OGN protection against enzymatic digestion, 
a superior physical stability, and higher gene expression in cancer cells after intravenous 
administration (219, 223, 229). Li SD & Huang L (219) and Tseng YC, et al. (2009) have 
developed a tumor-targeted LPP for siRNA delivery (234). The nucleic acid was condensed 
with protamine and the resulting nanoparticles were coated with DOTAP and cholesterol 
(219, 234). Further PEGylation of the LPP complex significantly increased the tumor 
localization of siRNA by four-fold, while a two- to three-fold increase in the silencing effect 
was observed in an in vivo human lung cancer model (219, 220).  
Anionic lipids have also been used for the development of LPP systems, comprising pH-
sensitive liposome and protamine, for macrophage gene therapy. In vitro tests revealed a 
safety profile and increased transfection efficiency of LPP compared to Lipofectamine® 
2000 or protamine/DNA complexes (235). 
Another type of LPP nanocarriers is the pegylated immuno-lipopolyplexes (PILP). In these 
complexes, the nucleic acids are firstly compacted by a cationic polymer, and complexed 
with anionic liposomes to produce the LPP. The surface of LPP is covered with PEG, in 
order to promote stabilization in the bloodstream, and the PEG strands are functionalized 
with targeting moieties. The system (mAb-PEG2000/DSPE-PEI/DNA) developed by Hu Y, 
et al. (2010) demonstrated to be highly effective in protecting DNA from degradation, and 
to accumulate at the liver promoting a high efficiency in gene delivery and gene silencing in 
cancer cells without significant cytokines production or liver injury (236-238). LPP have also 
been described as an efficient system for mRNA (210, 218, 221, 222, 239) and DNA-based 
cancer vaccines (217, 218, 240).  
Mockey M, et al. (2007) has developed a LPP for the delivery of mRNA encoding a tumor 
antigen (MART-1) against the progression of B16F10 melanoma. MART-1 was condensed 
in 50 nm particles of PEGylated histidylated PLL and then added to liposomes prepared 
with L-histidine-(N,N-di-n-hexadecylamine)ethylamide and cholesterol. Intravenous 
administration of this formulation induced the production of IFN-γ and the activation of 
cytotoxic T lymphocytes. No effect was observed when the mRNA was complexed with 
liposomes or with the cationic polymer alone (222). A similar nanosystem for the vaccination 
of B16F10 melanoma was also developed adding mannosylated and histidylated liposomes 
to mRNA-PEGylated histidylated PLL polyplexes. Authors were able to enhance the 
transfection of tumor antigen mRNA in splenic dendritic cells in vivo inducing therefore an 
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anticancer immune response (210, 239).  
A DNA-based vaccine approach was proposed by Whitmore MM, et al. (241) consisting of 
DOTAP:cholesterol cationic liposomes, protamine sulfate, and pDNA with unmethylated 
CpG motifs. This complex was capable to stimulate a potent Th-1 cytokine response 
producing TNF-α, IL-12, and IFN-γ, and was also able to trigger the antitumor NK activity. 
The combination of these two innate immune responses was effective in inhibiting the 
growth of established tumors in mice as they provide an acquired tumor-specific cytotoxic 
T cell response (241). 
LPP stability, efficacy and lack of toxicity justify their fostering arriving to clinical trials. In 
fact, EGEN-001 is a LPP formulation that undergoes phase I and II clinical trials, composed 
by IL-12 plasmid formulated in PEG-PEI-cholesterol to treat a variety of cancers such as 
ovarian, peritoneal, fallopian tube, and colorectal cancer (242-245). 
 
2.3. Conclusions 
 
Despite viral vectors are still the most common systems for gene therapy in clinical trials 
and the only ones that already reach the clinical practice, there are no doubts that the 
application of non-viral vectors for gene delivery was an amazing and essential discovery 
of the last years. Gene therapy mediated by lipoplexes, polyplexes or lipopolyplexes is a 
field that is clearly growing both in basic research and pre-clinical stages. It is expected that 
very soon new formulations enter in clinical trials while others grant market authorization for 
a variety of diseases. Given the chance to promote the silencing of different oncogenes or 
correct the expression of other absent or mutant genes, among the different healthcare 
areas to which new non-viral vectors based delivery systems are being developed, oncology 
is the one where research work is invested and where greater applicability is predictable. 
Although lipopolyplexes seems to overcome some of the major drawbacks presented by 
the other systems, the assumption that an ideal non-viral system is far from being reached, 
lead us to recognize a pressing and urgent need for innovative and improved approaches. 
New advances should help to meet quality requirements, which demands a balance 
between effectiveness, safety and technological possibilities, aiming market approval. 
Attempting this balance with non-viral vectors is a worthy effort to meet critical patients 
needs. 
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3.1. Introduction 
 
Different types of non-viral systems for siRNA delivery have been proposed in the last years, 
many of them based on cationic polymers or polypeptides such as PEI, CS, PLL, among 
others. 
As previously referred, CS is a natural cationic polysaccharide composed of glucosamine 
and N-acetyl glucosamine, whose ability to interact with the negatively charged OGN is 
related, among other factors, with its MW and DD. Usually a higher DD enables a better 
interaction with the genetic material and, while higher MW CS promotes a better stability of 
the complexes, low MW ones leads to a better intracellular OGN release (1-3). Therefore, 
CS MW should be regulated in order to achieve a balance between protection and release 
of the OGN. To improve the transfection efficiency of CS-based carriers different chemical 
modifications, such as the combination of CS with dextran, N-dodecyl, glycyrrhizin, folic acid 
or even with PEI have been investigated (4-10). Additionally, the use of the water-soluble 
salt forms of CS (chloride, acetate, aspartate, glutamate or lactate salts) is another possible 
strategy to improve the transfection efficiency (1, 2).  
Regarding PEI, despite its high transfection efficiencies, by itself cannot be used as a DDS 
since presents some drawbacks mainly related with its high cationic charge density (11-13). 
The transfection efficiency and cytotoxicity of these polymers are highly dependent on their 
linear versus branched structure, the branching degree or their MW (12, 14-17). Usually 
PEI branched forms present higher transfection efficiencies than the linear forms. 
Furthermore, higher PEI MW are usually associated with higher buffering capacity, higher 
transfections efficiencies but also increased cytotoxicity. The adequate N/P ratio should be 
optimized for each formulation in order to find an equilibrium of charges to achieve 
maximum silencing efficacy with minor toxicity (12, 14, 16, 18). In order to improve PEI 
transfection efficiency by reducing cytotoxicity, avoid aggregation and decrease nonspecific 
interactions, many different strategies have been explored being PEI grafting with PEG one 
of the most common ones (19, 20).  
With the objective of develop an innovative and efficient nanosystem for the delivery of 
siRNA, different polymeric-based formulations were designed until reach the optimal 
formulation proposed in this study, consisting in the combination of PEI and amphiphilic 
polymers. Thereby, we were able to reduce the PEI-related toxicity and improve the 
biological efficacy of the PEI-siRNA complexes. 
The poloxamers (Pluronic®) are polymers consisting of ethylene oxide (EO) and propylene 
oxide (PO) chains arranged in a triblock structure (EOa-POb-EOa) (Figure 3.1) (21, 22). 
They were chosen to be included in formulation due to their recognized ability to enhance 
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the transfection efficiency of genetic material, and their PEGylated surface, offering stealth 
properties to the system (23). In order to assess the best polymer features, different types 
of Pluronic® were tested (Table 3.1). 
 
 
Table 3. 1. Poly(ethylene glycol) (a) and polypropylene oxide (b) units, molecular weight 
(MW) and critical micelle concentration (CMC) values of the different Pluronic® used 
(according to the manufacturer). 
Type of 
Pluronic® 
Number 
of a units 
Number 
of b units 
Average MW of the 
polymer (g/mol) 
CMC 
(M) 
Approximate MW of 
PEG chains (g/mol) 
F68 80 27 7,680 – 9,510 4.8x10-4 4000 
F108 141 44 12,700 – 17,400 2.2x10-5 7000 
F127 101 56 9,840 – 14,600 2.8x10-6 5000 
 
 
 
 
Figure 3. 1. General structure of Pluronic® and PEI polymers. 
 
 
3.2. Materials and Methods 
3.2.1. Materials 
 
Different types of CS with the DD of ∼86% (Protasan Ultrapure) were gently provided by 
NovaMatriX (USA), namely, glutamate-CS low (G113 - 160 kDa) and high (G213 - 470 kDa) 
MW, and hydrochloride-CS low (CL113 - 110 kDa) and high (CL213 - 270 kDa) MW (22, 
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24-26). Glycol-CS was purchased from Sigma Aldrich (Madrid, Spain). Pluronic® F68, F108 
and F127 were kindly provided by BASF (Ludwigshafen, Germany), while 10k branched 
and 25k branched PEI were provided by Alfa Aesar (Thermo Fisher GmbH, Karlsruhe, 
Germany) and Sigma-Aldrich (Madrid, Spain), respectively. 
siRNA against GFP (GFP-siRNA) and the scramble sequence (siC) were provided by two 
companies, Shangai Gene Pharma (China) and LifeTechnologies (Spain). siRNA-
AlexaFluor 488 was brought from GE Healthcare Europe GmbH (Barcelona, Spain). 
RXO-C colon cancer cells expressing GFP were generously provided by Dr. Diego Arango 
from CIBBIM-Nanomedicine. Breast cancer cell lines MDA-MB-231 (ATCC number HTB-
26) and MCF7 (ATCC number HTB-22) were obtained from American Type Culture 
Collection (ATCC, LGC Standards, Barcelona, Spain). RPMI medium, phosphate buffered 
saline (PBS), and fetal bovine serum (FBS) were purchase from Lonza (Barcelona, Spain). 
Penicillin-streptomycin, L-glutamine, non-essential amino acids, sodium pyruvate, 0.25% 
Trypsin-EDTA, Lipofectamine® 2000, 4′,6-diamidino-2-phenylindole (DAPI), and 
LysoTracker® Red are brought from Life Technologies Ltd. (Madrid, Spain).  
Other used reagents are methanol, ethanol, dimethyl sulfoxide (DMSO), 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), gelatin, paraformaldehyde, 
Triton X-100, and 5-([4,6-dichlorotriazin-2-yl]amino)fluorescein hydrochloride (5-DTAF) 
from Sigma-Aldrich (Madrid, Spain), and Type 1 ultrapure water (18.2 MΩ.cm at 25 ºC, Milli-
Q®, Billerica, MA, USA).  
 
3.2.2. Polyplexes Preparation 
 
Polymer-siRNA complexes were prepared by simple complexation, adding the polymer 
solution dropwise to an equal volume of siRNA solution and quickly vortexed during few 
seconds before incubating them at room temperature for 30 minutes. 
The CS-siRNA complexes were prepared at different N/P ratios calculated according to 
Equation 3.1 and at different conditions (Table 3.2). 
 
𝑵
𝑷
𝒓𝒂𝒕𝒊𝒐 =
𝑴𝒂𝒔𝒔 𝒐𝒇 𝑪𝑺
𝑴𝒂𝒔𝒔 𝒑𝒆𝒓 𝒄𝒉𝒂𝒓𝒈𝒆 𝒐𝒇 𝑪𝑺 (=𝟏𝟔𝟎
𝒈
𝒎𝒐𝒍
)
𝑴𝒂𝒔𝒔 𝒐𝒇 𝒔𝒊𝑹𝑵𝑨
𝑴𝒂𝒔𝒔 𝒑𝒆𝒓 𝒄𝒉𝒂𝒓𝒈𝒆 𝒐𝒇 𝒑𝒉𝒐𝒔𝒑𝒉𝒂𝒕𝒆 (=𝟑𝟑𝟎
𝒈
𝒎𝒐𝒍
)
                                                                Equation 3.1 
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For the PEI-based polyplexes, two types of branched PEI, namely 10k and 25k, were used. 
Different N/P ratios were tested ranging from 5 to 75 (Table 3.4) and calculated according 
to Equation 3.2.  
 
𝑵
𝑷
𝒓𝒂𝒕𝒊𝒐 =
𝑴𝒂𝒔𝒔 𝒐𝒇 𝑷𝑬𝑰
𝑴𝒂𝒔𝒔 𝒑𝒆𝒓 𝒄𝒉𝒂𝒓𝒈𝒆 𝒐𝒇 𝑷𝑬𝑰 (=𝟒𝟑
𝒈
𝒎𝒐𝒍
)
𝑴𝒂𝒔𝒔 𝒐𝒇 𝒔𝒊𝑹𝑵𝑨
𝑴𝒂𝒔𝒔 𝒑𝒆𝒓 𝒄𝒉𝒂𝒓𝒈𝒆 𝒐𝒇 𝒑𝒉𝒐𝒔𝒑𝒉𝒂𝒕𝒆 (=𝟑𝟑𝟎
𝒈
𝒎𝒐𝒍
)
                                                              Equation 3.2 
 
3.2.3. PEI- and CS-based Micelles Preparation 
 
Micelles were prepared using the thin-film hydration (FH) technique. Briefly, each 
amphiphilic polymer was individually weighted and dissolved in a mixture of 
methanol:ethanol (1:1). This mixture of solvents was chosen because the polymers are 
insoluble in ethanol alone (Class 3 solvent), but soluble in methanol (Class 2 solvent). By 
mixing both solvents was possible to solubilize the polymers and reduce the use of 
methanol, as previously described (27, 28). Then, the solvent was removed under vacuum 
and the formed film was left to dry overnight at room temperature to eliminate any remaining 
solvent. Afterwards, the film was hydrated with PBS for empty micelles or with the previously 
prepared polymer-siRNA polyplexes dispersion and vortexed during 1 minute. The obtained 
dispersion was filtered through a 0.22 μm syringe filter to remove possible aggregates.  
In order to compare different preparation methods, PEI-based polyplexes containing 
micelles were also prepared by the direct dissolution method (DM). For that, the amphiphilic 
polymer was dissolved in an aqueous solution and added to the polyplexes solution. After 
vortexing, the mixture was left to incubate for 30 minutes and filtered through a 0.22 μm 
syringe filter. 
 
3.2.4. Association Efficiency (AE) 
 
The non-associated siRNA present in the aqueous phase of the polyplexes was separated 
by centrifugation with filtration (10,000 rpm, 10 minutes) using centrifugal devices with a 
100K membrane (Nanosep® Centrifugal Devices, Millipore, USA) and measured by a 
spectrophotometry method (Nanodrop NP-1000, Thermo Scientific, USA). The association 
efficiency was calculated according to Equation 3.3. The polyplexes association efficiency 
was also assessed by agarose gel electrophoresis. 
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AE= 
total amount of siRNA – free siRNA in filtrate
total amount of siRNA
 × 100                                           Equation 3.3 
 
 
 
3.2.5. Particles Physicochemical Properties Characterization 
 
Particles mean hydrodynamic diameter (md) and polydispersity index (Pdi) were measured 
by dynamic light scattering (DLS) and zeta potential was assessed by laser doppler micro-
electrophoresis using a NanoZS (Malvern Instruments, UK). For each formulation, at least 
three batches were produced and analyzed.  
Particle shape and morphology were observed by transmission electron microscopy (TEM) 
and Cryo-scanning electron microscopy (CryoSEM) (external services from IBMC and 
CEMUP, University of Porto, Portugal respectively). 
 
3.2.6. Serum Stability 
 
To assess the stability of formulations in the presence of serum the particles were incubated 
in a proportion of 1:1 with 50 % FBS and the mean diameter measured by DLS at different 
time-points: 0, 6, 12 and 24 hours.  
 
3.2.7. Cell lines Culture Conditions 
 
MDA-MB-231, MCF7 and RXO-C cells were cultured in RPMI medium supplemented with 
10% FBS, 1% penicillin-streptomycin, 1% L-glutamine, 1% non-essential amino acids, and 
1% of sodium pyruvate and maintained at 37 ⁰ C under a 5% CO2 water saturated 
atmosphere. The medium was changed every other day and, upon confluence, cells were 
harvested from plates with a 0.25% trypsin-EDTA solution and passed to continue the 
expansion.  
 
3.2.8. GFP Reporter Gene Silencing Assay 
 
RXO-C colon cancer cells expressing GFP were used to assess the systems silencing 
efficacy. Polyplexes and micelles prepared using a GFP-siRNA and different cationic 
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polymers were added to cells seeded at a concentration of 5 x 104 cells/ml in 96 well plates. 
As positive controls were used complexes formed between Lipofectamine® 2000 and the 
GFP-siRNA prepared accordingly to the supplier instructions but at the same concentration 
of siRNA used for the tested polyplexes. On the other hand, cells transfected at the same 
conditions with polyplexes prepared with a siRNA of a random sequence (siC) were used 
as negative control. The expression of GFP in cells after transfection was assessed with a 
fluorescence microscope (Olympus, USA). The intensity of cells fluorescence was also 
measured using a Fluorescent Microplate reader FLX800 (BioTek, Germany). 
 
3.2.9. In vitro Cytotoxicity Assay  
 
The cytotoxicity of different components in MDA-MB-231 cells was assessed using the MTT 
assay. 5000 cells/well/100μl were seeded in 96-well plates and left to attach for 24 hours. 
Then, cells were incubated in the presence or absence of increasing concentrations of 
polymers/formulations for 24 hours. After this incubation time, the medium was changed 
and the cells left for 72 hours. Complete medium was used as negative control and 10% 
DMSO as positive control of toxicity. After the 72 hours incubation, 0.5 mg/ml of MTT was 
added to each well. The plates were incubated for an additional 4 hours at 37ºC, the medium 
discarded, and the formazan crystals produced by mitochondrial succinate dehydrogenase 
dissolved with DMSO. The absorbance of each well was read on a microplate reader 
(ELx800 absorbance reader, BioTek, Germany) at 590 nm and the cell viability calculated. 
The results of cell viability were used for the determination of IC50 index by nonlinear 
regression of the concentration-effect curve fit using Prism 6.02 software (GraphPad 
Software, Inc., CA, USA). 
 
3.2.10. Conjugation of F127 with 5-DTAF  
 
F127 was fluorescently conjugated with 5-DTAF in an aqueous medium via nucleophilic 
aromatic substitution by an addition-elimination pathway as previously described (Figure 
3.2) (29).  
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Figure 3. 2. Reaction schematic for the conjugation of F127 with 5-DTAF via nucleophilic 
aromatic substitution by an addition-elimination mechanism. At basic pH (9.3), the terminal 
hydroxyl group of PEG blocks presented in F127, attack the reactive moiety (2-amino-4,6-dichloro-
s-triazine) on the 5-DTAF molecule, promoted by strong electron-withdrawing groups (N) of the s-
triazine ring. 
 
Briefly, a stock solution of 20 g/L 5-DTAF in DMSO was diluted in 0.1M sodium bicarbonate 
(pH 9.3) and added to a 6 % (w/v) F127 solution in 0.1M sodium bicarbonate (pH 9.3) to a 
final molar ratio of 1:2 (F127:5-DTAF). The reaction proceeded overnight in the dark at room 
temperature. The labeled polymer was purified from the excess of unreacted 5-DTAF by 
dialysis (12,000-14,000 MWCO Spectra/Por® membrane from Spectrum Europe BV, The 
Netherlands) against Type I ultrapure water. The dialyzed polymer solutions were 
lyophilized and stored in closed containers protected from light. 
 
3.2.11. Internalization Assays 
 
Flow cytometry and confocal microscopy were used to assess quantitatively and 
qualitatively the nanosystem internalization capacity in MDA-MB-231 breast cancer cells. 
For the quantitative Fluorescence-activated cell sorting (FACS) assays, 2x105 cells were 
seeded in 6 well plates and incubated for 24 hours. After this time, 5-DTAF-labelled micelles 
were added to cells and incubated during 2 and 4 hours after which the cells were washed 
with 1x PBS, detached with 0.25% trypsin-EDTA, resuspended in PBS supplemented with 
10% FBS and DAPI (1 μg/mL) used for vital staining. The plate was analyzed in a cytometer 
Fortessa (BD Biosciences, USA). Data was analyzed with FCS Express 4 Flow Research 
Edition software (De Novo Software, Los Angeles, USA). Contaminants were removed by 
forward and side scatter gating. For each sample, at least 10000 individual cells were 
collected and the mean fluorescence intensity was evaluated.  
For the qualitative confocal microscopy assay (Spectral Confocal Microscope MFV1000 
Olympus, USA), cells were cultured in 0.1% gelatin-treated coverslips at a density of 
2.5x105 cells per well in 6 well plates.  After 24 hours, the PM containing siRNA-AlexaFluor 
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488 were added to cells and incubated during 4 hours and further incubated for 30 minutes 
with the LysoTracker® Red. Subsequently cells were fixed to the coverslips using 4% 
paraformaldehyde and permeabilized with Triton X-100. Finally the nucleus was stained 
with DAPI (0.2 mg/mL) for 5 minutes in the dark and the cells visualized. 
 
3.2.12. Statistical Analysis 
 
At least three batches of each polyplexes and PM were produced and characterized and 
the results expressed as the mean±standard deviation (SD).  For biological studies, at least 
3 replicates, each involving at least two technical replicates were involved in final results 
expressed as the mean±SD. Statistical analysis was performed in Microsoft Office Excel™ 
2007 using the unpaired Student's t-test. Differences were regarded as statistically 
significant when p-value were smaller than 0.05. 
 
3.3. Results  
3.3.1. CS-based Polyplexes 
 
For a preliminary screening of the best conditions and type of CS to form polyplexes for 
siRNA delivery, the association efficiency, the in vitro cytotoxicity, and the biological efficacy 
of the different polyplexes was determined.  
As possible to observe in the Figure 3.3, all the CS were able to efficiently complex the 
siRNA. A significant decrease in the concentration of free siRNA is observed 
spectrophotometrically upon complexation with CS at low ratios. Additionally, in the agarose 
gel assay, a small amount of free siRNA is only detected when 1:1 ratio of CS:siRNA is 
used. Since the low N/P ratios that are sufficient to complex the siRNA are not enough to 
obtain biological efficacy, higher N/P ratios were tested in terms of cell toxicity in MDA-MB-
231 breast cancer cells. Figure 3.4 demonstrate that CL113, G113, CL213 and G213 have 
a similar toxicity pattern, being the N/P ratio 80 the maximum N/P ratio that can be used 
without cause severe toxicity. The Glycol-CS appears to be the one causing the higher 
toxicity even at lower N/P ratios.  
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Figure 3. 3. Polyplexes association efficiency. A) Concentration of free siRNA detected in the 
supernatant by spectrophotometry after formulation filtration by centrifugation using different N/P 
ratios. Results are expressed as mean±SD, n=3. B) Agarose gel electrophoresis for the CL213-
based polyplex. 1 – free siRNA; 2 – 1:10 ratio; 3 – 1:5 ratio; 4 – 1:2.5 ratio; 5 – 1:1 ratio.  In number 
5, it is possible to see some free siRNA (marked with the circle).  
 
 
 
Figure 3. 4. In vitro cytotoxicity of CS-siRNA polyplexes at different N/P ration in MDA-MB-231 
cells. Results are expressed as mean±SD, n=3. 
 
 
As described in Table 3.2, the most promising polyplexes, i.e. the ones that were able to 
cause a visible decrease in the number of cells expressing GFP without promote significant 
toxicity, were obtained with the following conditions: GFP-siRNA at a concentration of 200 
nM in the well, complexed with CL213 and G213 CS at a N/P ratio of 80 and pH 4.5, and at 
a post-transfection incubation time of 72 hours.  
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Table 3. 2. Summary of the different tested conditions regarding the CS-based polyplexes. 
Tested Conditions Observations 
siRNA final 
conc. in the well 
50 nM No effect 
100 nM No effect 
200 nM Effective (at certain conditions) 
Polyplexes 
Glycol-CS Toxic (at ratios > 60) 
G113 No effect 
CL113 No effect 
G213 Effective (at certain conditions) 
CL213 Effective (at certain conditions) 
N/P ratios 
< 10 No effect 
20 No effect 
30 No effect 
40 No effect 
60 No effect 
80 
Knockdown detected (at certain 
toxicity) 
100 Toxicity 
>100 Highly toxic 
pH 
4.5 (in acetate buffer) Higher efficacy 
7 (in water) Low effect 
Time-points 
24 hours No effect 
48 hours No effect 
72 hours Knockdown detected 
Micelles CL213 (N/P 80, pH 4.5) + F127 (1%) Effect < than Lipofectamine® 2000 
  Time-point 72 h  
 
 
In Figure 3.5 are depicted the results of the silencing efficacy of the CL213-based GFP-
siRNA polyplexes formed at the chosen optimal conditions. It is observed a partial silencing 
in the expression of GFP 72 hours after transfection with the polyplexes. On the contrary, 
no decrease in GFP expression was observed in the cells transfected with the siC. It is also 
possible to observe that for the cells transfected with the Lipofectamine® 2000 the GFP 
silencing is much stronger than the one obtained with the polyplexes. Similar results were 
obtained with the polyplexes composed by G213; however the silencing effect was not so 
reproducible. On the other hand, no significant silencing efficacy was observed with the 
other types of CS tested. The MW of CS seems to be involved in its transfection efficiency, 
since higher transfections efficiencies were obtained with the CS presenting the higher MW, 
possibly due to the higher capacity to complex and protect the genetic material.  
After choosing the best conditions, for polyplexes preparation, in terms of cytotoxicity and 
biological efficacy, they were further characterized in terms of their physicochemical 
features. 
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Figure 3. 5. Polyplexes CS-siRNA silencing efficacy 72 hours after transfection in RXO-C 
colon cancer cells expressing GFP. The biological activity was assessed based on the reduction 
of GFP expression in the cells transfected with CS polyplexes with GFP-siRNA versus siC, using a 
fluorescence microscope.  Lipofectamine® 2000-based complexes were used as the positive control. 
 
 
Figure 3. 6. Polyplexes physicochemical characterization using CL213 CS. Mean diameter 
(md), polydispersity index (Pdi) and Zeta potential (Zp) values for polyplexes Cs-siRNA (results are 
expressed as mean±SD, n=3) and TEM image of the same formulation. 
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The polyplexes of CS-siRNA produced with the CL213-CS shown to be small (< 17 nm) and 
positively charged (+ 15 mV) particles with spherical shape (Figure 3.6). The next step of 
the work consisted in the conjugation of this polyplexes with Pluronic® based micelles in 
order to improve the siRNA protection and biological activity. 
 
3.3.2. Pluronic®-based Micelles Containing CS-polyplexes 
 
Pluronic®-based empty micelles were prepared using different polymers. The micelles 
presented a size lower than 150 nm (inferior to 50 nm for Pluronic® F108 and F127) and 
near neutral surface charge (Table 3.3).  
 
Table 3. 3. Physicochemical characterization of different Pluronic®-based micelles. Results 
are expressed as mean±SD, n=3. 
 
 
 
 
 
Due to the high polydispersity of micelles and a low reproducibility obtained with the F68 
polymer, this polymer was discarded from further studies. 
Concerning the cytotoxicity assessment, both Pluronic® F108 and F127 presented an IC50 
superior to 10 mg/ml (Figure 3.7), but since Pluronic® F127 originates the micelles 
presenting the lowest values of md and with the less polydispersed population,  this polymer  
was the chosen one for the production of micelles combined with the CS-based polyplexes. 
For further experiments CL213-CS-based GFP-siRNA polyplexes were formed at the 
chosen optimal conditions previously referred. These polyplexes were used to hydrate the 
Pluronic® F127 film, forming the final micelles-based formulation (CS-siRNA-Pluronic®).  
For the biological studies, these micelles were posteriorly incubated with RXO-C colon 
cancer cells expressing GFP, being possible to observe that GFP expression was silenced, 
conversely with what happens in cells transfected with the siC (Figure 3.8). Despite the 
improvement in the silencing efficacy observed in the presence of Pluronic®, the efficacy of 
the systems is still lower that the previously obtained using the positive control 
(Lipofectamine® 2000).  
 
Polymer Md (nm) Pdi Zp (mV) 
F68 128.6±31.2 0.5±0.2 -2.9±1.0 
F108 42.6±8.4 0.3±0.2 -2.1±1.2 
F127 25.0±3.4 0.1±0.05 -2.7±1.8 
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Figure 3. 7. Comparative cytotoxicity and IC50 values of Pluronic® F127 and F108 in MDA-MB-
231 cells. Results are expressed as mean±SD, n=3. F127 and F108 IC50 > 10 mg/ml. 
 
 
Figure 3. 8. CS-siRNA-Pluronic® micelles silencing efficacy 72 hours after transfection with 
the siGFP and siC in RXO-C colon cancer cells. 
 
3.3.3. PEI-based Systems 
 
Besides the micelles prepared by the FH technique described in the Chapter 5, it was 
decided to produce and characterize micelles prepared also by the direct dissolution 
method in order to assess the possibility of producing the formulations without using organic 
solvents. For the design of these nanoparticles, the different conditions tested and results 
obtained are summarized in Table 3.4.  
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Table 3. 4. Summary of the different tested conditions regarding the branched PEI-based 
systems. 
Tested Conditions Observations 
siRNA final conc. in 
the well 
200 nM Effective (at certain conditions) 
Polymers 
combinations 
PEI 10K Low effect 
PEI 25K Low effect 
PEI 10K + F127 (0.5%) Effect < than Lipofectamine® 2000 
PEI 25 K + F127 (0.5%) Effect < than Lipofectamine® 2000 
PEI 10K + F127 (1%) Effective (at N/P 50) 
PEI 25 K + F127 (1%) Effective ( at N/P 25 and 50) 
N/P ratios 
PEI:siRNA 
5 No effect 
25 Effective only for PEI 25K 
50 Effective 
75 Toxic 
 
In the assessment of the biological efficacy no significant differences were observed 
between both types of PEI (Figure 3.9), but since the 10K branched PEI presented lower 
toxicity profile (30, 31), it was chosen for further studies.  
 
 
Figure 3. 9. PEI-siRNA polyplexes and PEI-siRNA-Pluronic® micelles (obtained by DM) 
silencing efficacy in GFP expressing RXO-C cells. A) Differences on the intensity of gene 
expression upon incubation with different formulations using as reference the Lipofectamine® 2000. 
B) Fluorescent microscopy photos confirming the GFP silencing efficacy of the selected formulation. 
No gene inhibition was observed in cells transfected with siC. The values of GFP silencing were 
normalized to the ones obtained with Lipofectamine® 2000. The red square represents the selected 
formulation. Results are expressed as mean±SD (n≥3). * p≤0.05 compared to the polyplexes without 
Pluronic® F127. 
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Formulations composed by PEI:siRNA polyplexes of N/P ratio 50 present higher 
transfection efficacy then polyplexes at lower N/P ratios (Figure 3.9). Also, the presence of 
1% Pluronic® F127 in the form of micelles (prepared by DM) improved significantly the 
transfection efficiency of the polyplexes as observed both quantitatively and qualitatively by 
an increase of the gene expression inhibition (Figure 3.9). Thus, Pluronic® 127 micelles 
encapsulating PEI:siRNA polyplexes at a N/P ratio 50 were chosen to proceed with further 
studies and posteriorly characterized in terms of its internalization profile, md, Pdi, zeta 
potential, serum stability, and entrapment efficiency. 
 
 
Figure 3. 10. PEI-siRNA-Pluronic® internalization behavior. A) Flow cytometry analysis of labelled 
particles internalization. B) Confocal Microscopy analysis of particles internalization containing a 
fluorescent siRNA (siRNA-AlexaFluor 488). The yellow arrow illustrates the respective intracellular 
distribution of nanoparticle and Lysotracker (DND-99, red). 
 
The internalization of the PEI-siRNA-Pluronic® micelles was assessed quantitatively by flow 
cytometry (Figure 3.10A) and qualitatively by confocal microscopy (Figure 3.10B). For the 
FACS experiments, cells were incubated with 5-DTAF-labeled micelles during 4 hours. For 
the qualitative analysis, MDA-MB-231 cells were incubated during 4 hours with micelles 
carrying a fluorescent-labeled siRNA (siRNA-AlexaFluor 488) and observed by confocal 
microscopy. As expected, in both assays it is possible to observe total micelles 
internalization after the incubation time. In the confocal microscopy images it is also 
AKT2 siRNA-Nanoparticulate System as a New Tool to Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
 
_______ 
     106 
possible to see that the green-labelled siRNA is not co-localized with the endosomal 
vesicles, being already available in the cytoplasm where will exert its effect. 
 
 
Figure 3. 11. Physicochemical characterization of PEI-siRNA-Pluronic® micelles. The table 
shows the values of mean diameter, polydispersity index and zeta potential for the loaded and the 
unloaded formulation and the value of association efficiency calculated based on the undirected 
method described before. In the TEM images represent: A) Different particles subpopulations, B) 
Particles with around 70 nm, C) Particles with around 200 nm, D) Aggregates. Results are expressed 
as mean±SD, n=3. 
 
Regarding the physicochemical characterization of the chosen formulation, it is possible to 
see in Figure 3.11 that these nanoparticles present a higher size and Pdi compared to the 
micelles prepared by FH technique (Figure 5.2 of Chapter 5). These results were confirmed 
by TEM analysis that shows different sub-populations of particles with different sizes and 
also the presence of aggregates. Despite the high tendency to aggregate, that result in their 
low storage stability, these nanoparticles present high siRNA entrapment efficiency Figure 
3.11. 
The results of stability of particles in serum are depicted in Figure 3.12. It can be noted an 
increase in the mean diameter of particles over time after the first 6 hours of incubation, 
which indicates the formation of aggregates with the serum proteins. 
Despite the higher size and Pdi compared to the micelles prepared by FH technique, 
micelles prepared by DM have shown to be also less stable and more toxic (Table 3.5). 
 
Chapter 3 | Formulation Studies and Efficacy Assessment of Different siRNA Delivery Systems 
 _______________________________________________________________________________  
 
 
_______ 
                                                                                                                                                          107 
 
Figure 3. 12. Serum stability of PEI-siRNA-Pluronic® formulation. The graphic despites the mean 
diameter of micelles after incubation with serum at different time-points. Results are expressed as 
mean±SD, n=3.  
 
 
Table 3. 5. Main differences between micelles obtained through preparation methods. DM: 
direct method; FH: thin-film hydration technique. 
 DM FH 
Preparation Method Simple Simple (more steps) 
Mean Diameter/Zeta <100 nm <100 nm 
Polydispersity > 0.3 < 0.2 
Encapsulation Efficiency > 95% > 95% 
Internalization > 95%, 6 hours > 95%, 6 hours 
Biological Efficacy ≥ Lipofectamine® 2000 ≥ Lipofectamine® 2000 
Stability < 1 day > 1 week 
Toxicity ↑↑↑ - 
Reproducibility No Yes 
 
3.4. Discussion 
 
The objective of the present Chapter relies on the development of an efficient and safe 
siRNA delivery system. As well-known, a good gene delivery system requires the presence 
of a cationic component able to complex and condense the genetic material in order to 
promote its cellular internalization and exert its biological effect (32-34).  
Different polymeric-based formulations were designed and tested over the period of work 
to reach the one that best fits the proper characteristics for siRNA delivery. Although several 
formulations were dropped during the time course of the work due to their toxicity and/or 
low biological efficacy, all of them supplied important information that allowed us to reach 
the system with which we are currently working, and whose results are described in Chapter 
5. The Figure 3.13 summarizes different strategies and the related challenges that we have 
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faced during the formulation process. Nevertheless, some of the dropped formulations, if 
improved and properly optimized in the future, have the potential to become interesting 
gene delivery systems. 
 
 
Figure 3. 13. Diagram resuming the different developed tested formulations for gene therapy 
and the main results. 
 
Since CS is a well-established biopolymer with recognized advantages in terms of gene 
delivery, our first approach consisted in the production of polyplexes composed by CS and 
siRNA (CS-siRNA) (35, 36). Different types of CS were tested at different conditions of 
concentration, pH and N/P ratio, in order to achieve the correct silencing efficacy/toxicity 
balance when compared with the positive control of transfection (Lipofectamine® 2000).  
RXO-C colon cancer cells expressing GFP were used to test the silencing efficacy of 
polyplexes prepared with a GFP-siRNA. The biological activity was assessed based on the 
reduction of GFP expression in the transfected cells with GFP-siRNA versus PM-siC, using 
a fluorescence microscope. The ones presenting the best characteristics were the CS with 
higher MW, which could be explained by its higher positive charge and capacity to better 
complex and protect the siRNA. Similar results were observed by others using plasmids 
and siRNA (37-41). However, the biological efficacy of the CS polyplexes observed was 
low. Although the higher MW CS seems to condense and protect the siRNA to be delivered 
to cells, it is possible that the strong interaction results in a low dissociation between the 
genetic material and CS after endosomal disruption, and consequentely low biological 
efficacy. As referred previously and observed by others, it is necessary a balance between 
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the MW and DD able to efficiently complex and protect the genetic material, promote the 
endosomal escape, and release the genes into the cytoplasm (40, 41). Regarding the 
polyplexes association efficiency, different polymer:siRNA ratios were tested, being 
possible to confirm the so well recognized capacity of CS to complex OGN, even at lower 
ratios (38, 39). Although a 1:2.5 ratio is enough to complex the siRNA, the GFP reporter 
silencing assays demonstrate that in order to promote the endosomal swelling and to obtain 
biological efficacy it is necessary to use much higher polymer concentrations (N/P ratio 80). 
This highlights that although the complexation of the genetic material is essential for its 
proper delivery, is not the unique condition for the existence of biological effect. 
The final goal of the work was to find the most effective polyplex to be posteriorly combined 
with another nanoparticulate system, namely PM composed of Pluronic®. These types of 
polymers have been described as enhancers of the transfection of genetic material; 
however, since poloxamers present neutral charge at the physiological pH, as estimated in 
silico using the Marvin Suite software (ChemAxon, Hungary), it was necessary to introduce 
a cationic component to formulation in order to garnish it with the required positive charge 
to complex the anionic siRNA. Thus, the developed CS- and PEI-based polyplexes were 
combined with Pluronic®-based micelles previously developed by members of the group for 
delivery of biopharmaceuticals (42). 
Different Pluronic® (F68, F108, F127) were tested, being the Pluronic® F127 selected due 
to its better technological features. The smaller size and Pdi of F127-based micelles can be 
explained by its lower CMC, hydrophilic-lipophilic balance (HLB) and CMT (24 ºC for 1% 
w/v (37, 43)), whereas F68 presents the higher CMC and CMT (54-56.21 ºC for 1% w/v 
(44)) and consequently higher diameter. The same behavior was observed previously (45). 
Although, the silencing efficiency of the CS-based polyplexes appears to be improved with 
the presence of Pluronic® F127 in the formulation, it is lower then the obtained with 
Lipofectamine® 2000. Taking into account that the presence of Pluronic® improved the 
transfection efficiency of CS-based polyplexes, the next step of the present work consisted 
in the substitution of CS for another cationic polymer, in this case PEI.  
In order to rapidly screen different formulation compositions regarding its transfection 
efficiency, the reduction of fluorescence in RXO-C colon cancer cells GFP expressing cells 
after transfection was quantified using a fluorescent microplate reader and qualitatively 
assessed on a fluorescent microscope. It was observed that PEI polyplexes were able to 
inhibit a certain level of gene expression, presenting the N/P ratio 50 higher transfection 
efficiency than N/P ratio 25. Also, the presence of 1% Pluronic® (w/v) in the form of micelles 
improved significantly the transfection efficiency of the polyplexes as observed both 
quantitatively and qualitatively by an increase of the GFP gene expression inhibition. The 
AKT2 siRNA-Nanoparticulate System as a New Tool to Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
 
_______ 
     110 
formulations composed by PEI:siRNA polyplexes of N/P ratio 50 with F127 1% (w/v) present 
similar transfection efficacy and GFP silencing than Lipofectamine® 2000. 
Since no significant differences in terms of biological efficacy were observed between both 
types of PEI, the 10K branched PEI was chosen due to its recognized lower toxicity profile 
(30, 31). Thus, after the first approach based on the assessment of transfection efficiency, 
the formulation where PEI 10k was complexed with the siRNA at the N/P ratio of 50 and 
further incorporated in Pluronic® F127-based PM was selected to further technological and 
biological experiments. 
Contrary to the complex chemical modifications proposed by other studies (46, 47), in this 
work we propose a simple association of PEI-based polyplexes with Pluronic® F127 based 
PM, that significantly increased the polyplexes biological efficacy. This result can be 
explained by the reported capacity of poloxamers to enhance themselves the transfection 
efficiency of genetic material. Although not completely understood and explained, 
poloxamers present the capacity to interfere to some extent to the cell membranes reducing 
its structure and microviscosity/fluidity (33, 48), and to improve the escape from the 
endosomal compartment via membrane disruption and pore formation (49, 50). Poloxamers 
with an intermediate HLB value like F127 (HLB=18-23), have shown higher ability to 
interfere with membranes than poloxamers with higher HLB like F68 and F108 (HLB>24) 
(51). 
In this work, PEI-containing micelles were prepared by two methods in order to compare 
their characteristics and to choose the best preparation method: DM (direct dissolution 
method described in this chapter) and FH (thin-film hydration technique described in 
Chapter 5. Micelles prepared by DM present the advantage of being prepared by a simpler 
method avoiding also the use of organic solvents; however, they have shown higher size 
and polydispersity, as well as lower stability and higher toxicity profile when compared to 
the micelles presented in Chapter 5, which could be related to a less effective coating of 
PEI-polyplexes. 
 
3.5. Conclusions 
 
This chapter described the rational design and experimental sequence beyond the 
development of a nanocarrier system for siRNA intracellular delivery. Different cationic 
polymers for the production of polyplexes and different systems to carry the polyplexes were 
tested.  
The choice of PM composed by Pluronic® as a possible delivery system is based on their 
amphiphilic properties opening the possibility to design a multifunctional-targeted particle 
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that can be used in the future for multi-therapy, i.e. the blend of gene and chemotherapy in 
one single nanoparticle formulation. 
It results clear that the presence of Pluronic® in the formulations improved the biological 
efficacy of CS-based polyplexes. Nevertheless, even this combination presented limited 
transfection efficiency. Thus, the well-establish PEI was used for the production of 
polyplexes and for the development of PEI-siRNA-Pluronic® systems. 
In the present work was possible to develop a formulation composed by PEI 10k branched-
based polyplexes at an N/P ratio of 50 combined with micelles of Pluronic® F127 to a final 
concentration of 1% (w/v) presenting adequate technological properties, biological efficacy 
and safety profile. It was also possible to emphasize the importance of the presence of 
Pluronic® F127 in the formulation not only to improve the silencing activity but also to reduce 
the PEI-associated toxicity.  
The direct dissolution method to prepare micelles is easiest and less time consuming, in 
addition of avoiding organic solvents; however it presented some disadvantages when 
compared with the FH technique to produce the PEI-siRNA-Pluronic® systems. Despite the 
observed gene silencing efficacy and safety profile, the higher size and polydispersity of 
particles associated to high physical instability observed make us decide to change the 
method of micelles production to FH, maintaining the composition of the formulations 
(Chapter 5). 
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4.1. Introduction  
 
As mentioned previously, in the last years, accumulating evidences suggest that cancer 
dormancy, treatment resistance, and metastatic growth are sustained by the presence of 
CSC within the tumor, which provides a reservoir of highly malignant cells that are able to 
cause tumor recurrence after the therapeutic regimen (1-4).  
Despite the effectiveness of many chemotherapeutic agents and anticancer treatments in 
terms of apparent tumor regression, the problematic of drug resistance observed for CSC 
and the consequent tumor recurrence arise as an important barrier and a great challenge 
to tumors eradication. Thereby, other therapeutic strategies have emerged, in particular the 
gene therapy approach and/or its combination with conventional therapies. One of the most 
interesting potentialities regarding gene therapy is the RNAi technology (5-7). To be able to 
implement effectively this strategy into the clinical practice, it is of utmost importance the 
complete understanding of the biological pathways involved in tumor development and 
progression in order to select an adequate target gene to be silenced.  
AKT2 is one of the three isoforms of the PKB family highly expressed in breast and colon 
cancer tumors, which appears generally associated with the acquisition of a malignant 
phenotype by cancer cells (8-10). AKT/PKB is a key regulator of various cell processes and 
its signaling outcome, similarly to what happens in all cancer-related molecular mechanism, 
is highly dependent on cellular background, cell type and phenotype. AKT2 may act via 
different signaling mechanisms being TWIST and mTOR the main effectors downstream of 
AKT2 (11-14). In the context of CSC, TWIST arose as an interesting cancer target due to 
its important and well-known role in tumor invasion, migration, dissemination and drug 
resistance (15, 16) Signaling cascades initiated by TWIST-mediated effects regulated by 
AKT2 or those involved in EMT through the decrease of E-cadherin expression, bring 
reasonability to the expectancy over the selective silencing of this oncogene as an effective 
strategy to reduce cell malignancy (12, 14). EMT, usually defined as the process during 
which cells loose epithelial traits and acquire a mesenchymal phenotype, is commonly 
accepted as the critical step for the acquisition of malignance in epithelial cancer cells  and 
in some cases as an activator of the CSC phenotype (14, 17-21). At the molecular level, 
the EMT is mainly characterized by the downregulation of E-cadherin, an essential cell-cell 
adhesion protein whereas mesenchymal markers such as Vimentin and N-cadherin tend to 
gradually raise their expression (14, 22). Regarding the importance of EMT in cancer 
development and CSC activation, the targeting of EMT related signaling axis like 
AKT2/TWIST in order to revert the EMT process and restore the initial epithelial phenotype, 
appears to be a promising strategy in cancer gene therapy.  
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Similarly, PI3K/AKT2/mTOR signaling axis is also involved in acquisition of malignant 
phenotype mainly through the over-activation of the mTOR signaling, as a result of 
increased activity of PI3K or AKT. mTOR activity was found to be deregulated in many types 
of cancer including breast, prostate, lung, melanoma, bladder, brain, and renal carcinomas. 
Moreover, recent studies have shown the links between PI3K/AKT2/mTOR signaling 
pathway and CSC biology (13, 23-28). 
Despite that AKT2 silencing was previously investigated in various tumor types, its precise 
function in CSC was not addressed yet. Here, in order to assess if also in the CSC 
population, the AKT2 knockdown is able to impair the increased cellular tumorigenic ability, 
we silenced the AKT2 expression using a siRNA against AKT2 in different cancer cells lines 
with a defined CSC population.  
 
4.2. Materials and Methods 
4.2.1. Materials  
 
RPMI medium, PBS, and FBS were purchase from Lonza (Barcelona, Spain). McCoy’s 
medium, DMEM F-12 medium, L-glutamine, non-essential amino acids, 10000 U/mL 
penicillin and 10000 μg/mL streptomycin, 0.25% Trypsin-EDTA, blasticidin and sodium 
pyruvate were purchased from Gibco (Life Technologies Ltd., Madrid, Spain). 
Lipofectamine® 2000, trypan blue, DAPI, and SYBR Green were purchased from Molecular 
Probes (Life Technologies Ltd., Madrid, Spain). Cell Lytic M reagent and protease inhibitor 
cocktail were obtained from Sigma-Aldrich Quimica (Madrid, Spain).  
Primary antibodies against TWIST and actin were obtained from Abcam (Cambridge, UK) 
while the antibodies against AKT2, mTOR, and E-cadherin purchased from Cell Signaling 
Technology (Leiden, The Netherlands) and Invitrogen (Life Technologies Ltd., Madrid, 
Spain), respectively. HRP-conjugated secondary antibodies (anti-mouse P0447) and anti-
rabbit (P0217) were purchased from Dako (Barcelona, Spain). 
siRNAs were designed by Shanghai Gene Pharma (Shanghai, China). The sense siAKT2 
sequence used was 5’-GCUCCUUCAUUGGGUACAATT-3’, while a non-specific sequence 
5’-UUCUCCGAACGUGUCACGUTT-3’ was used as control (siC). 
 
4.2.2. Cell Lines and Culture Conditions 
 
Breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-468, and SKBR3; and colon cancer 
cell line HCT8 were obtained from American Type Culture Collection (ATCC, LGC 
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Standards, Barcelona, Spain) and are examples of both mesenchymal and epithelial cell 
lines (Table 4.1).  
MDA-MB-468, MDA-MB-231 and HCT8 cells were cultured in RPMI medium supplemented 
with 10% FBS, 1% penicillin-streptomycin, 1% L-glutamine, 1% non-essential amino acids, 
and 1% of sodium pyruvate.  
SKBR3 cells were cultured in McCoy’s medium supplemented with 10% FBS and 1% 
penicillin-streptomycin, while MCF7 cells were cultured in DMEM F-12 medium 
supplemented with 10% FBS and 1% penicillin-streptomycin.  
Blasticidin (0.5 mg/ml) was used as a selective antibiotic for ALDH1A1/tdTomato cell lines. 
All cell lines were maintained at 37ᵒC under a 5% CO2 water saturated atmosphere. The 
medium was changed every other day and, upon confluence, cells were harvested from 
plates with a 0.25% trypsin-EDTA solution and further used in in vitro studies or frozen. 
 
Table 4. 1. List of the cell lines used in this study and their main phenotype. 
Name ATCC® number Type Main Phenotype 
MDA-MB-231 HTB 26™ Breast (Triple Negative) Mesenchymal 
MDA-MB-468 HTB-132™ Breast (Triple Negative) Mesenchymal 
MCF7 HTB-22™ Breast (ER+) Epithelial 
SKBR3 HTB-30™ Breast (HER2+) Mesenchymal 
HCT8 CCL-244™ Colon Epithelial 
 
4.2.3. Fluorescence-Activated Cell Sorting (FACS) 
 
FACS was used to sort CSC and non-CSC subpopulations from a heterogeneous 
population of MCF7, MDA-MB-231 and HCT8 cells. For the cell sorting, a starting amount 
of 5x106 cells were used. Cells were detached, and re-suspended in PBS supplemented 
with 10% FBS with DAPI (1 μg/mL) used for vital staining. Cells were sorted according to 
tdTomato and DAPI expression in a FACS Aria cell sorter (BD Biosciences, Madrid, Spain) 
(29). Sorted cells were collected in complete medium without antibiotic and used for 
posterior applications. 
 
4.2.4. Cell Transfection 
 
The siRNAs were transfected into cells using Lipofectamine® 2000 accordingly to the 
manufacture instructions in medium without antibiotics. The medium was changed 6 hours 
after the transfection and cells were harvested after further 72 hours. 
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4.2.5. RNA Extraction and Quantitative RT-PCR (qRT-PCR) 
 
Total RNA was extracted from cells using the RNeasy Micro Kit (Qiagen, Madrid, Spain) 
and the obtained RNA was reverse transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Madrid, Spain) according to the manufacturer 
instructions.  
 
Table 4. 2. List of the primers used in the study and their sequences. 
Oligo name Oligo Sequence (5’ to 3’) 
TWIST F GCAGGGCCGGAGACCTAG 
TWIST R TTTTTAGTTATCCAGCTCCAGAGTCTCTA 
E-Cadherin F TACGCCTGGGACTCCACCTA 
E-Cadherin R CCAGAAACGGAGGCCTGAT 
Vimentin F CTCCGGGAGAAATTGCAGG 
Vimentin R AGACGTGCCAGAGACGCATT 
N-Cadherin F TCAAAGCCTGGAACATATGTGATG 
N-Cadherin R GTATACTGTTGCACTTTTTCTCGTACAA 
hAKT2F CAAGGATGAAGTCGCTCACACA 
hAKT2R GAACGGGTGCCTGGTGTTC 
18s F AGT CCC TGC CCT TTG TAC ACA 
18s R GAT CCG AGG GCC TCA CTA AAC 
Actin 01F CATCCACGAAACTACCTTCAACTCC 
Actin 01R GAGCCGCCGATCCACAC 
GADPH F ACCCACTCCTCCACCTTTGAC 
GADPH R CATACCAGGAAATGAGCTTGACAA 
mTOR F CCTTAACGTCATTCGAGTCTGTGA 
mTOR R TCACAAAGGACACCAACATTCC 
p53 F GAAGAAACCACTGGATGGAGAATATT 
p53 R CAGCTCTCGGAACATCTCGAA 
Bcl-2 F ACCTGCACACCTGGATCCA 
Bcl-2 R AGAGACAGCCAGGAGAAATCAAA 
GSK3b F CTGCTTCAACCCCCACAAAT 
GSK3b R GATGCAGAAGCAGCATTATTGG 
AKT1 F GGCTCCCCTCAACAACTTCTC 
AKT1 R ACATGGAAGGTGCGTTCGA 
 
The cDNA reverse transcription product was amplified with specific primers (Table 4.2) by 
qPCR using the SYBR Green method. The reaction was performed in triplicate in a 7500 
real time PCR system (Applied Biosystems, Madrid, Spain). Actin and S18 were used as 
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endogenous controls. The relative mRNA levels were calculated using the comparative Ct 
method (2e- ΔΔCt). 
 
4.2.6. Protein Extraction and Western Blotting (WB) 
 
Cell pellets were lysed with the Cell Lytic M reagent containing a protease inhibitor cocktail. 
Proteins in the crude lysates were quantified using the BCA Protein Assay (Pierce 
Biotechnology, Madrid, Spain) and 20 μg of whole-cell lysates were separated by SDS-
PAGE and transferred onto nitrocellulose membranes (Merck Millipore, Madrid, Spain). 
Blots were probed using primary antibodies listed in Table 4.3. Proteins were detected 
using corresponding HRP-conjugated secondary antibodies (anti-mouse or anti-rabbit) and 
incubated as described in Table 4.3. 
 
Table 4. 3. List of primary antibodies used in the study and their specifications. ON – 
overnight, RT – room-temperature. 
Primary 
antibody 
Host Dilution Incubation 
AKT2 Rabbit 1:1000 ON, 4°C 
TWIST Mouse 1:500 ON, 4°C 
mTOR Rabbit 1:1000 ON, 4°C 
Actin Rabbit 1:1000 1 hour, RT 
 
 
4.2.7. Proliferation Assay 
 
Breast cancer cell lines were seeded into six-well plates at a density of 2.5X105 cells per 
well and allowed to adhere overnight. The next day cells were transfected as described 
previously. For cell counting, cells were trypsinized and stained with trypan blue and viable 
cells were counted at times 0, 24, 48 and 72 hours after transfection. 
 
4.2.8. Wound Healing Migration Assay 
 
For these assay, the different cells were seeded into six-well plates and cultured until high 
confluence. The monolayer was “wounded” by scraping it with a sterile tip. The wells were 
washed twice with medium without serum before being left in complete culture medium. 
Immediately after do the wound, the cells were transfected as explained before. The healing 
AKT2 siRNA-Nanoparticulate System as a New Tool to Restoration of E-Cadherin and Eradicate 
Tumor Metastic Phenotype 
 ______________________________________________________________________________  
 
_______ 
     124 
process was examined during the time with an optical microscope and microphotographs 
were obtained at 0, 24, 48 and 72 hours. Areas were measured with the Image J software 
and compared with the wound area at time 0, in order to evaluate the migration rate of cells. 
 
4.2.9. Cell Transformation Assay (Anchorage-independent Growth Assay) 
 
The anchorage-independent growth of the different breast cancer cell lines were assessed 
by the CytoSelect™ Cell Transformation Assay Kit (Cell Biolabs, San Diego, CA, USA). A 
semisolid agar media were prepared accordingly the manufacturer instructions being the 
complexes Lipofectamine-siAKT2 or Lipofectamine-siC added to each well. After 6-8 days 
of incubation the colonies were observed under the microscope and the viable transformed 
cells counted using trypan blue.  
 
4.2.10. Invasion Assay 
 
The invasiveness of MDA-MB-468 and SKBR3 cells was assessed using the CytoSelect™ 
Laminin Cell Invasion Assay Kit (Cell Biolabs, San Diego, CA, USA). The polycarbonate 
membrane inserts coated with a uniform layer of Laminin I are used to discriminate invasive 
cells from noninvasive cells. The invasive cells are able to degrade the laminin matrix layer 
and pass through the pores of the polycarbonate membrane, clinging to the bottom of the 
insert membrane, while the noninvasive cells stay in the upper chamber. Briefly, the inserts 
were placed in a 24-well plate and a cell suspension containing 1X106 cells/ml, previously 
transfected with the siAKT2 and the siC, was added to the insert. After 48 hours incubation, 
the invasive cells were dissociated from the membrane, lysed and quantified using the 
CyQuant® GR Fluorescent Dye (Cell Biolabs, San Diego, CA, USA). 
 
4.2.11. Statistical Analysis 
 
All the assays were run at least in triplicate, each involving at least two technical replicates. 
All results are expressed as the mean±SD. Statistical analysis was performed in Microsoft 
Office Excel™ 2007 using the unpaired Student's t-test. Differences were regarded as 
statistically significant when p-value were smaller than 0.05. 
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4.3. Results 
4.3.1. AKT2 Silencing Impairs Proliferation and Migration of Cancer Cells 
 
In order to determine the consequence of AKT2 inhibition on cell malignance, we investigate 
its effect in various cell lines (MDA-MB-231, HCT8, MCF7, MDA-MB-468, SKBR3). We 
confirmed the specificity of the siAKT2 sequence used, since 80% reduction of AKT2 
expression was achieved and no reduction of AKT1 isoform was observed (Figure 4.1A). 
The downregulation of AKT2 was confirmed also at the intracellular protein level (Figure 
4.5D).The effects of AKT2 downregulation in the different cell lines was firstly assessed by 
the proliferation and the migration assays. We observed a significant impairment of cell 
proliferation in MDA-MB-231, HCT8, MDA-MB-468 and SKBR3 transfected with the siAKT2 
in comparison with the cells transfected with the siC or with the untreated cells. On the 
contrary, no effect in proliferation was observed after the AKT2 silencing in MCF7 cells 
(Figure 4.1B). Similar results were observed for the migration capacity after AKT2 silencing, 
particularly in MDA-MB-231, MDA-MB-468 and SKBR3 cells where the migration rates were 
significantly impaired. Again, no changes on migration were observed in MCF7 cells (Figure 
4.1C). HCT8 showed just minimal migration ability and was thus excluded from the analysis 
(data not shown).  
 
4.3.2. AKT2 Inhibits Anchorage-independent Growth and Invasion of CSC 
 
After the functional assessment of the AKT2 silencing effect in parental cells, the behavior 
of the CSC fraction isolated from three different cell lines (MDA-MB-231, HCT8, MCF7) was 
investigated, after being transfected with siAKT2. CSC were isolated from the parental cells 
population by FACS based on the stable expression of ALDH1A1/tdTomato reporter vector. 
Only CSC are able to express tdTomato (red fluorescence) since its expression is driven by 
CSC specific promoter (ALDH1A1), while the non-CSC are not detected as red fluorescent 
cells in the total cell culture mixture (29). The CSC nature of tdTomato+ cells was previously 
confirmed by expression of stemness markers, tumorspheres formation and high in vivo 
tumorigenic capacity (29).  
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Figure 4. 2. siAKT2 transfection reduces cells transformation ability of MDA-MB-231 (A), HCT8 
(B) and MCF7 (C) CSC and non-CSC. The graph represents the number of transformed cells 
comparing CSC and non-CSC transfected with siAKT2 and siC. The images are photographs of the 
colonies formed after 7 days of incubation with siAKT2 and siC. Results are expressed as mean±SD 
(n≥3) (* p< 0.05; ** p<0.01, ***p<0.001). 
 
The most accurate and stringent in vitro assay for detecting malignant transformation of 
cells is the assessment of their capacity for anchorage-independent growth. Malignant 
transformation occurs via a series of genetic and epigenetic alterations that allow the cell 
population to proliferate independently of both external and internal signals that normally 
restrain growth. Generally, transformed cells have lower requirements for extracellular 
growth and is not restricted by cell-cell contact (30). We investigated the anchorage-
independent growth capacity in fraction of non-CSC and CSC from three different cell lines: 
MDA-MB-231, HCT8, and MCF7. We observed significantly higher capacity of anchorage-
independent growth in fraction of CSC sorted from all investigated cell lines compared to 
non-CSC, which confirmed the CSC nature of tdTomato+ cells (Figure 4.2). Upon siAKT2 
transfection the colonies formation ability was reduced predominantly in the CSC fraction 
of MDA-MB-231, HCT8 and MCF7. These results can be further confirmed by the significant 
decrease in the number of transformed cells. The number of transformed cells also 
decrease for the MDA-MB-231 and HCT8 non-CSC after transfection with the siAKT2; 
however no changes was observed in MCF7 non-CSC (Figure 4.2). Significant reduction 
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of transformation capacity after AKT2 silencing was also observed in MDA-MB-468  and 
SKBR3 cell lines, that are CSC enriched cells with high expression of ALDH1A1 (Figure 
4.4A).  
 
 
Figure 4. 3. Effects of siAKT2 in cells invasive capability of MDA-MB-231 (A), HCT8 (B) and 
MCF7 (C) CSC and non-CSC. The graph represents the number of cells that presented invasive 
capacity comparing CSC and non-CSC transfected with siAKT2 and siC. Results are expressed as 
mean±SD (n≥3) (* p<0.05; ** p<0.01, ***p<0.001). 
 
Next, we investigated effect of siAKT2 transfection in the invasive potential of CSC. The 
capacity of malignant tumor cells to invade the normal surrounding tissues largely 
contributes to the cancers associated morbidity and mortality. Invasiveness is related with 
EMT process and involves several distinct cellular functions including adhesion, motility, 
and detachment (31). Worthy to note, is that CSC from MDA-MB-231 and MCF7 cell lines 
shown to be significantly more invasive than non-CSC. No significant differences were 
observed in the invasive potential of HCT8 CSC versus non-CSC. Importantly, in all cases 
the invasiveness of CSC was significantly reduced after AKT2 inhibition (Figure 4.3). This 
behavior was also observed in MDA-MB-231 and HCT8 non-CSC. Even though CSC 
fraction from MCF7 cells showed a significant impairment of invasion after AKT2 silencing, 
no effect was observed in MCF7 non-CSC (Figure 4.3). Moreover, the silencing of AKT2 
promoted a significant reduction of invasion capacity in CSC enriched MDA-MB-468 and 
SKBR3 cell lines (Figure 4.4B). 
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Figure 4. 4. Effects of siAKT2 in cells transformation ability and invasive capability of MDA-
MB-468 and SKBR3.  Graphs represent the number of transformed cells (A) and number of cells 
that presented invasive capacity (B) comparing CSC and non-CSC transfected with siAKT2 and siC. 
Results are expressed as mean±SD (n≥3) (* p<0.05; ** p<0.01, ***p<0.001). 
 
4.3.3. AKT2 Inhibition is Achieved via Diverse Signaling Pathways  
 
As mentioned previously, TWIST/AKT2 signaling is important for EMT regulation. 
Interestingly, CSC tend to have a more mesenchymal phenotype when compared to bulk 
tumor cells. Accordingly, CSC sorted from cell lines with epithelial phenotype (MCF7, HCT8) 
presented lower levels of the epithelial marker E-cadherin and higher levels of typical cell 
mesenchymal markers such as Vimentin and N-cadherin (Figure 4.5B). Similarly, MDA-
MB-468 and SKBR3, mesenchymal cell lines with high expression of ALDH1A1, also 
present low expression of E-cadherin and high expression of N-cadherin and Vimentin 
(Figure 4.5C).  
In this context, we investigated the expression of TWIST and mTOR in all studied cell lines. 
Despite the constant presence of AKT2 and mTOR (mRNA, protein), we found differences 
in terms of TWIST expression, being this transcription factor positively expressed in MCF7, 
MDA-MB-468 and SKBR3, while MDA-MB-231 and HCT8 shown to be TWIST negative 
(TWIST-) cells (Figure 4.5A and D). As expected after the silencing of AKT2, TWIST and 
the mTOR are downregulated (Figure 4.5D).  
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Figure 4. 5. Cell lines phenotypes based in the EMT/stemness markers. A) Amplification plot for 
TWIST, mTOR and AKT2 expression for MDA-MB-231, HCT-8 and MCF7 cells. B) qPCR 
quantification of several genes expression levels for MDA-MB-231, HCT-8 and MCF7 CSC. The 
presented values are relative to their non-CSC population. C) qPCR quantification of several genes 
expression levels for MDA-MB-468 and SKBR3 cells. D) Western Blot for AKT2, TWIST and mTOR 
protein expression levels in different cells after the treatment with siAKT2 and siC. β-actin was used 
as the housekeeping gene. Results are expressed as mean±SD (n≥3). 
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Figure 4. 6. Impact of AKT2 silencing in key regulators of EMT reversion and mTOR-dependent 
signaling pathways. Expression levels of different genes were quantified by qPCR in different cell 
lines after the treatment with siAKT2 and siC. Results are expressed as mean±SD (n≥3). 
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Accordingly, we observed MET gene expression signature in cell lines expressing TWIST 
(MDA-MB-468, SKBR3) after AKT2 silencing like a decrease in the expression of 
mesenchymal markers like Vimentin and N-cadherin. Notably, this trend is accompanied by 
cell restoration of E-cadherin expression, confirming our expectation that in this conditions 
cells will experiencing a switch from a mesenchymal to a more epithelial phenotype (Figure 
4.6A and B).  
The observation of MET-related events in mesenchymal CSC isolated from epithelial MCF7 
cell line upon AKT2 silencing, also related with the restoration of E-cadherin and further 
decrease in N-cadherin and Vimentin expression, stresses this players interchangeability 
triggered by this knockdown strategy (Figure 4.6C). Even though we observed a 
downregulation of TWIST after AKT2 silencing, EMT reversion it was not observed in the 
case of non-CSC MCF7 epithelial cell line (Figure 4.6D).  
 
 
Figure 4. 7. Effects of AKT2 silencing in different signaling pathways. A) Efects of AKT2 
silencing in the mTOR pathway for TWIST+ cells. B) Efffects of AKT2 silencing in the EMT reversion 
for TWIST- cells. Results are expressed as mean±SD (n≥3). 
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In accordance with our proposed mechanism, TWIST- cells (MDA-MB-231, HCT8) didn’t 
show the typical MET gene signature (Figure 4.7B). 
Although AKT2-TWIST cross talk is a key event for malignancy, in non-expressing TWIST 
cell lines the observed decrease in CSC malignance upon AKT2 silencing was related 
predominantly by the downregulation of mTOR. The essential contribution of mTOR for the 
regulation of cell growth arrest and inhibition of apoptosis was sustained by the finding that 
in response to the intracellular decrease of AKT2, was detected a constant decrease of 
mTOR expression and increase in GSK3b and p53 expression. This was observed in MDA-
MB-231 and HCT8 cells (Figure 4.6F and H). Similar results were observed in the fraction 
of sorted MDA-MB-231 CSC and HCT8 CSC (Figure 4.6E and G). As expected, for the 
TWIST expressing cells, the downregulation of mTOR after AKT2 silencing didn’t produce 
the mTOR-related effects in GSK3b, p53 and Bcl-2 (Figure 4.7A). 
The above described findings highlight that AKT2 silencing lead to the decrease of cell 
migration, proliferation, invasion and transformation via different signaling axis depending 
on the presence or absence of TWIST expression (Figure 4.8). Regardless the signaling 
pathway, AKT2 silencing affects CSC malignancy and should be considered as prospective 
for successful anti-cancer therapies. 
 
 
Figure 4. 8. Summary of AKT2 silencing effects in cancer development in the different cell 
lines, accordingly their phenotype and TWIST expression level. 
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4.4. Discussion 
 
Due to their unique phenotype, CSC are resistant to the conventional chemo- and 
radiotherapy clinically practiced nowadays (4, 32). In addition, CSC are gaining relevance 
as triggering agents of cancer progression and malignancy, showing higher invasive 
capability than their non-CSC counterpart. Hereupon, even though several new promising 
anti-cancer treatments have been proposed over the past years, just few of them were 
extensively studied regarding their therapeutic efficacy also in population of CSC. Moreover, 
several reports have shown that if a therapy is not effective against CSC, the reservoir of 
resistant CSC will cause recurrence of aggressive tumor and metastatic growth over the 
time (33, 34). Study specifically the silencing effects of some genetic players like AKT2 in 
the CSC subpopulation is thus essential to develop new therapies that could impact in the 
clinical treatment of cancer.    
In this study, a CSC model based on the tdTomato vector expression under the control of 
CSC specific ALDH1A1 promoter was used in order to study the efficacy of AKT2 silencing 
in CSC fraction. This CSC model was previously extensively validated both in vitro and in 
vivo (29). Moreover, here we observed higher anchorage-independent growth ability of 
tdTomato+ CSC than the tdTomato- non-CSC, which further confirms this population 
malignant nature (Figure 4.2). Importantly, after effective AKT2 silencing, the 
transformation and invasion capacity in all studied CSC fractions (MDA-MB-231, MCF7, 
HCT8) was significantly reduced. These results suggest that AKT2 silencing strategy may 
be successful also in fraction of highly aggressive CSC (Figure 4.2 and 4.3).  
AKT2 silencing also decreased the proliferation and migration capacity of various breast 
and colon cancer cell lines, such as MDA-MB-231, SKBR3, MDA-MB-468 and HCT8, with 
the remarkable exception of bulk MCF7 cells. No differences in terms of proliferation, 
migration, invasion and anchored independent growth capacity were observed in MCF7 
bulk cells (Figure 4.1). Of note, these were the only epithelial cells presenting expression 
of TWIST used in this study. Active AKT2/TWIST signaling axis leads to the acquirement of 
more mesenchymal phenotype. Contrary, AKT2 silencing confers to the cells more epithelial 
phenotype triggering MET (21). Since MCF7 cells regularly shown an epithelial phenotype 
with high expression of E-cadherin, the MET triggered via AKT2 silencing had no effect on 
bulk MCF7 cell population. On the other hand, CSC subpopulations isolated from MCF7 
epithelial cells present a more mesenchymal phenotype than the non-CSC, with a 
decreased E-cadherin expression and an increased Vimentin and N-cadherin expression 
(Figure 4.5B). In this mesenchymal CSC fraction (1-2%) isolated from epithelial MCF7 cells 
we observed a significant effect after AKT2 silencing in terms of reduced transformation 
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and invasion capacity (Figure 4.2 and 4.3). Owing these cells involvement in tumor growth 
and maintenance, its reduction would suppose an important strike for further tumor 
progression. We observed similar results in the TWIST+ MDA-MB-468 and SKBR3 
mesenchymal cell lines that are also characterized by their high levels of ALDH1A1 
expression, conferring them CSC-like properties (35) (Figure 4.4). MET process after AKT2 
silencing was confirmed by the genetic expression profile in mesenchymal TWIST+ cell 
lines. We demonstrated that the AKT2 silencing is able to restore the levels of E-cadherin 
and decrease the levels of TWIST and other EMT markers like N-Cadherin, Vimentin and 
Fibronectin (Figure 4.6A-C). In unsorted MCF7 cells, the only gene affected after AKT2 
knockdown was TWIST, confirming the direct cross talk between AKT2 and TWIST, 
previously reported by Cheng GZ, et al. (2007) (11, 12) (Figure 4.6D). Mani SA, et al. 
(2008), previously demonstrated a tight relationship between EMT activation and CSC in 
breast cancer. It was shown, that the ectopic expression of several EMT inducers (TWIST, 
Snail, TGF-β) triggers the expression of stem cell markers (CD44+ and CD24-) and 
enhances tumor development (36). Furthermore, EMT was observed also in vivo in CD8T 
immune cells which secrete EMT-inducing factors such as the TGF-β, presenting the 
resultant tumors characteristics of breast CSC (CD44+ and CD24-) (37). 
In our study, CSC isolated from the TWIST- epithelial cell line, HCT8, shown to be more 
mesenchymal than the non-sorted bulk cells, with higher expression of N-cadherin and 
Vimentin and lower expression of E-cadherin (Figure 4.5B). Despite the clear effect on the 
transformation and invasion capacity after AKT2 silencing in these cells, we did not 
observed MET phenotype in HCT8 CSC fraction (Figure 4.7B). However, contrary to MCF7 
epithelial cell line, we observed a decrease in the proliferation, invasion and transformation 
capacity of HCT8 tumor cells after AKT2 silencing (Figure 4.1, 4.2 and 4.3). Moreover 
despite the reduction of the aggressiveness of both sorted CSC and unsorted cells, we have 
not observed any effect on EMT genes expression in other mesenchymal cell lines with 
TWIST- background (MDA-MB-231) (Figure 4.7B). Taking into account these results, we 
conclude that for TWIST- cells, the AKT2 silencing is able to impair invasion and colony 
formation via a different pathway. We observed the blockage of the PI3/AKT2/mTOR 
signaling and consequent increase of GSK3b and pro-apoptotic genes such as p53 in both 
CSC and non-CSC subpopulations of mesenchymal TWIST- cells (Figure 4.6E-H).  
The novelty of this work lies in the comparison between CSC and non-CSC regarding the 
AKT2 silencing effects and the observation that, specifically for CSC, this inhibition is able 
to reverse the EMT phenotype in terms of gene expression, protein expression, migration, 
proliferation, anchorage-independent growth and invasion ability, being special interesting 
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this effect in the CSC population that usually present resistance against the conventional 
treatments. 
 
4.5. Conclusions 
 
The biggest challenge in cancer treatment is tumor recurrence and resistance. Both 
phenomena are sustained by the presence of CSC within the tumor. In this context, the 
potential of new targeted therapies should be investigated especially in fraction of CSC to 
provide its real probability to succeed in clinics. Since the RNAi therapy demonstrated 
important prospect in targeted cancer treatment, we investigated the efficiency of siAKT2 in 
CSC isolated from breast and colon cancer cell lines with different phenotypes. The 
obtained results demonstrated that the AKT2 inhibition is effective in terms of reducing cells 
migration, invasion, and transformation via different mechanisms and are not dependent on 
the presence of TWIST in the tumor. In cell lines expressing TWIST, AKT2 inhibition acts 
via MET, while in those cells not expressing TWIST, AKT2 silencing hampers mTOR 
pathway and alters the expression of apoptotic genes such as the Bcl-2 and p53. 
Regardless the signaling pathway, AKT2 silencing affects CSC malignancy, reverting their 
mesenchymal phenotype, reducing cell invasion, inhibiting colony formation or inducing 
apoptosis, and should be thus validated in further pre-clinical studies. Due to the beneficial 
effect of AKT2 silencing in both bulk cells and CSC, the therapy with AKT2 could be used 
i) to revert the tumor to its primary stage for easier chirurgical removal, and/or ii) prevent 
the tumor recurrence through the inhibition of CSC tumorigenicity. 
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CHAPTER 5 
 
 
 
Functional Validation of Amphiphilic-based Polymeric 
Micelles for siRNA Delivery and Cancer Stem Cells Genes 
Inhibition 
 
 
The information presented in this chapter was partially published in the following publication: 
 
1) D Rafael, P Gener, F Andrade, J Seras, S Montero, Y Fernandez, I Abasolo, S 
Schwartz Jr., M Videira, Functional Validation of Amphiphilic-Based Polymeric 
Micelles for siRNA Delivery and Cancer Stem Cells Genes Inhibition, Article in 
preparation. 
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5.1. Introduction 
 
The major challenge regarding the RNAi bases therapies is the delivery of OGN to the cells 
without suffering premature degradation by serum nucleases. In this context, PM for siRNA 
delivery were design based on amphiphilic block-co-polymers previously developed within 
the group (1). Pluronic® polymers were chosen due to their recognized ability to enhance 
the transfection efficiency of genetic material, and their PEGylated surface, offering stealth 
properties to the system (2).  
Based on the compounding and formulation development studies presented in Chapter 3, 
here is proposed a new system for siRNA delivery that combines i) polyplexes 
spontaneously formed by electrostatic interaction between the negatively charged siRNA 
molecules and the positively charged chains of 10K branched PEI, with ii)  Pluronic® F127-
based PM formed by FH technique.  
To access the biological efficacy of these PM we firstly produced the micelles using a siRNA 
against GFP in breast cancer cells, which obtained a gene silencing higher than 80%, the 
same or even greater than the gold standard vector Lipofectamine® 2000. After we 
produced our micelles with the siRNA against AKT2 and tested them in breast CSC isolated 
from two different cell lines. With these micelles we were able to observe a reduction of the 
CSC invasion and transformation capacities.  
 
5.2. Material and Methods 
5.2.1. Materials 
 
Pluronic® F127 was kindly provided by BASF (Ludwigshafen, Germany), while 10k 
branched PEI was purchased from Alfa Aesar (Thermo Fisher GmbH, Karlsruhe, Germany). 
DMSO, MTT, 5-DTAF were from Sigma-Aldrich (Madrid, Spain), while sodium bicarbonate 
and paraformaldehyde (PFA) were obtained from Merck KGaA (Darmstadt, Germany). 
RPMI medium, PBS, and FBS were purchase from Lonza (Barcelona, Spain). L-glutamine, 
non-essential amino acids, 10000 U/mL penicillin and 10000 μg/mL streptomycin, 0.25% 
Trypsin-EDTA, blasticidin and sodium pyruvate were purchased from Gibco (Life 
Technologies Ltd., Madrid, Spain). siRNA-GFP positive and negative control, 
Lipofectamine® 2000, LysoTracker® Red DND-99, DAPI, SYBR Green, and ProLong® Gold 
Antifade Mountant were purchased from Molecular Probes (Life Technologies Ltd., Madrid, 
Spain). Angarose and TBE buffer (10X) were obtained Sigma-Aldrich (St. Louis, MO, USA). 
siRNAs were designed by Shanghai Gene Pharma (Shanghai, China); sense siAKT2 
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sequence used was 5’-GCUCCUUCAUUGGGUACAATT-3’, while a non-specific sequence 
5’-UUCUCCGAACGUGUCACGUTT-3’ was used as control (siC).  
Other reagents used are methanol, ethanol and acetic acid from analytical grade (Merck, 
Germany) and Type 1 ultrapure water (18.2 MΩ.cm at 25 ºC, Milli-Q®, Billerica, MA, USA). 
 
5.2.2. Polyplexes PEI-siRNA Production 
 
PEI-siRNA complexes were prepared by simple complexation by adding either the 10k PEI 
aqueous solution dropwise to an equal volume of siRNA aqueous solution followed by a 10 
seconds vortex mixing before incubating them at room temperature for 30 minutes. The 
PEI-siRNA complexes were prepared at N/P ratio 50 calculated according to the previously 
described Equation 3.2.  
 
 
Figure 5. 1. Schematic representation of micelles production. 
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5.2.3. Production of Micelles 
 
PM were prepared using the FH technique previously described (1). Briefly, the polymer 
was individually weighted and dissolved in a mixture of methanol:ethanol (1:1). Then, the 
solvent was removed under vacuum in a rotary evaporator and the formed film was left to 
dry overnight at room temperature to eliminate any remaining solvent. The film was then 
hydrated with the previously prepared polyplexes and vortexed during 1 minute (Figure 
5.1). The obtained dispersion was filtered through a 0.22 μm syringe filter for sterilization 
and remove possible aggregates.  
 
5.2.4. Micelles Physicochemical Characterization 
 
PM mean hydrodynamic diameter and polydispersity index were measured by DLS and 
zeta potential was assessed by laser doppler micro-electrophoresis using a NanoZS 
(Malvern Instruments, UK). Each type of formulation was produced and analyzed in 
triplicate. 
The morphology of PM was assessed by TEM. For that, samples were placed on a grid, 
treated with uranil acetate and then observed in a JEM-1210 Transmission Electron 
Microscope (JEOL Ltd., Tokyo, Japan). 
The encapsulation efficiency were assessed by quantification of the free siRNA in filtrates 
using a UV-Vis spectrophotometers (Nanodrop 2000, Thermo Scientific, USA) after filtration 
of the formulations by centrifugation for 10 minutes at 10,000 rpm and 4ºC, using 100k pore 
filters (Nanosep® Centrifugal Devices, Pall Corporation, Spain).  
Gel electrophoresis was also performed to evaluate siRNA condensation. The PM were 
loaded onto 1% agarose gel with 6× loading buffer. The mixture was separated in 0.5× 
Tris/Borate/EDTA (TBE) buffer at 100V for 25 minutes. The siRNA bands were visualized 
using an ultra violet (UV) imaging system (Uvidoc, UVItec Ltd, Cambridge, UK).  
The osmolality of formulations was determined at room temperature using a Micro-
Osmometer M3320 (Advanced Instruments, Inc., MA, USA). Triplicates of each formulation 
were analyzed. 
 
5.2.5. Cell Lines and Culture Conditions 
 
MCF7 (ATCC number HTB-22) and MDA-MB-231 (ATCC number HTB-26) breast cancer 
cell lines were obtained from American Type Culture Collection (ATTC, LGC Standards, 
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Barcelona, Spain). The cells were cultured in RPMI medium supplemented with 10% FBS, 
1% penicillin-streptomycin, 1% L-glutamine, 1% non-essential amino acids and 1% of 
sodium pyruvate. Blasticidin (0.5 mg/ml) was used as a selective antibiotic for 
ALDH1A1/tdTomato cell lines. All cell lines were maintained at 37ºC under 5% CO2 
saturated atmosphere. The medium was changed every other day and, upon confluence, 
cells were harvested from plates with 0.25% trypsin-EDTA to be passed to other plates to 
continue expansion, be frozen or used in in vitro studies. 
 
5.2.6. Cell Transfection with the PM 
 
The different PM-siRNA were transfected into cells accordingly Table 5.1. For silencing 
efficacy assays the medium was changed after 4 hours of incubation with the PM. For the 
toxicity assays the cells were left 24 hours in contact with the PM, while for the 
internalization assays the cells were incubated with the PM at several time points (from 3 
seconds to 24 hours) 
Cells were harvested 72 hours after the transfection. For the internalization experiments the 
particles were diluted 1:10 
For some experiments, Lipofectamine® 2000 (Life Technologies, Madrid, Spain) were used 
as a transfection positive control accordingly the supplier protocol in order to obtain a final 
siRNA concentration in the well of 200 nM. 
 
Table 5. 1. Transfection conditions accordingly the different experiments. 
 Day 0: before transfection Day 1: during transfection time (4 hours) 
Plates 
Cells 
seeded 
(cells/well) 
Vol. of 
medium (µl) 
Vol. of 
medium 
(µl) 
Vol. of 
formulation 
(µl) 
Final siRNA 
concentration 
(nM) 
96 well 5.0x103 100 50 50 200 
24 well 5.0x104 1000 100 100 200 
6 well 2.0x105 2000 250 250 200 
 
5.2.7. Serum Stability Assay  
 
To study the PM stability in serum, a special medium containing a concentration of FBS 50 
% was prepared in order to predict the nanoparticles aggregation pattern in vivo. The PM 
were incubated with medium-FBS (50%) and samples were collected at different time-points 
(0, 4, 6, 12 and 24 hours) for DLS measurement.  
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5.2.8. Assessment of Micelles Toxicity 
 
In order to assess the effect of formulations on the viability of breast cancer cell lines, 5000 
cells/well were seeded in 96-well plates and left to attach for 24 hours. Then, cells were 
incubated with increasing concentrations of PM:siC, PEI, F127 and PEI:siC complexes for 
24 hours. After this incubation time, the medium was changed and the cells left for 72 hours. 
Complete medium was used as negative control and 10% DMSO as positive control of 
toxicity. Cell viability was measured 72 hours upon transfection by MTT assay. The 
absorbance of each well was read on an absorbance microplate reader ELx800 (BioTek, 
Germany), at 590 nm. The results of cell viability were used for the determination of IC50 
index by nonlinear regression of the concentration-effect curve fit using Prism 6.02 software 
(GraphPad Software, Inc., CA, USA). 
 
5.2.9. Fluorescence-Activated Cell Sorting (FACS) 
 
FACS was used to sort CSC and non-CSC subpopulations from a heterogeneous 
population of MCF7 and MDA-MB-231 cells. For the cell sorting, a starting amount of 5X106 
cells were used. Cells were detached with 0.25% trypsin-EDTA and resuspended in PBS 
supplemented with 10% FBS and DAPI (1 μg/mL) used for vital staining. Cells were sorted 
according to tdTomato and DAPI expression in a FACS Aria cell sorter (BD Biosciences, 
Madrid, Spain). Sorted cells were collected in complete medium without antibiotic and used 
for posterior applications. 
 
5.2.10. Micelles Internalization 
 
To assess the internalization behavior of PM in MCF7 and MDA-MB-231 cells, 5-DTAF-
fluorescently labeled PM were used (conjugation method described in Chapter 3, Figure 
3.2).   
 
a) Confocal microscopy (qualitative analysis) 
 
For confocal microscopy analysis, 2.5x105 cells were cultured into glass coverslips coated 
with 0.1% gelatin in 6 well plates for 24 hours to allow adhesion. Then, cells were incubated 
for 4 hours with the labeled PM and after this time, the lysosomes were stained using the 
Lysotracker® Red during 30 minutes at 37 ºC. Subsequently, the cells were fixed in 4% PFA 
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at 4ºC for 30 minutes followed by nuclei staining with DAPI (0.2 mg/mL) for 5 minutes in the 
dark. Cells were viewed under a Spectral Confocal Microscope MFV1000 Olympus 
(Olympus, USA). The 561 nm excitation wavelength of the green laser (10mW) was used 
for selective detection of the red fluorochrome (Lysotracker® Red). The 488 nm excitation 
wavelength of Argon multiline laser (40 mW) was used for selective detection of the green 
fluorochrome (5-DTAF). The nuclear staining DAPI was excited at 405 nm with a violet laser 
(6 mW). Minimal single optical sections were collected for each fluorochrome sequentially. 
The generated images were merged and analyzed with the FV10-ASW 3.1 Viewer software 
(Olympus, USA) and exported as jpg image format. 
 
b) Flow cytometry (quantitative analysis) 
 
Flow cytometry analysis was used to verify internalization of nanoparticles in MDA-MB-231 
and MCF7 ALDH1A1 tdTomato cells with around 50% of tdtomato+ cells. 2x105 cells were 
seeded in complete medium in 96 well plates for 24 hours to allow adhesion. Micelles were 
added to cells at different time points: 1, 3, 10, 30 minutes and, 1, 2, 4, 6, 8 and 20 hours. 
Then, cells were washed with 1x PBS, detached with 0.25% trypsin-EDTA, and 
resuspended in PBS supplemented with 10% FBS and DAPI (1 μg/mL) used for vital 
staining. The plate was analyzed in a cytometer Fortessa (BD Biosciences, USA). Data was 
analyzed with FCS Express 4 Flow Research Edition software (De Novo Software, Los 
Angeles, USA). Contaminants were removed by forward and side scatter gating. For each 
sample, at least 10000 individual cells were collected and the mean fluorescence intensity 
was evaluated. 
 
5.2.11. Green Fluorescent Protein Silencing Efficacy 
 
MDA-MB-231 cells expressing GFP were used to assess the micelles silencing efficacy. 
Micelles prepared using a siRNA against the GFP were added to cells at a concentration of 
5x104 cells/ml in 96 well plates. For these test, as a positive control were used cells 
transfected with the complexes formed between the Lipofectamine ® 2000 and the GFP 
prepared accordingly to the supplier instructions. On the other hand, cells transfected in the 
same conditions with PM prepared with a siC were used as negative control. The expression 
of GFP in cells after transfection was assessed with a fluorescence microscope (Olympus, 
USA). A video of the cells during 72 hours after transfection was recorded using Motorized 
Fluorescent Microscope BX61 (Olympus, USA) in order to confirm GFP decreasing over 
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the time. Fluorescence intensity per cell over all the time of the experiment was quantified 
using the ImageJ 1.48v software (National Institutes of Health, MD, USA). The intensity of 
cells fluorescence was also measured using a Fluorescent Microplate reader FLX800 
(BioTek, Germany). 
 
5.2.12. RNA Extraction and Quantitative RT-PCR (qRT-PCR)  
 
Total RNA was extracted from cells using the RNeasy Micro Kit (Qiagen, Madrid, Spain) 
and the obtained RNA was reverse transcribed with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Madrid, Spain) according to the manufacturer 
instructions. The cDNA reverse transcription product was amplified with specific primers for 
AKT2 (hAKT2 F: 5’ CAA GGA TGA AGT CGC TCA CAC A 3’; hAKT2 R: 5’ GAA CGG GTG 
CCT GGT GTT C 3’) GADPH (hGADPH F: 5’ ACC CAC TCC TCC ACC TTT GAC; hGADPH 
R: 5’ CAT ACC AGG AAA TGA GCT TGA CAA 3’) and Actin (hActin F: 5’ CAT CCA CGA 
AAC TAC CTT CAA CTC C 3’; hActin R: 5’GAG CCG CCG ATC CAC AC 3’) by qPCR using 
the SYBR Green method. The reaction was performed in triplicate on a 7500 Real time PCR 
system (Applied Biosystems, Madrid, Spain). Actin, GADPH, and S18 were used as 
endogenous controls. The relative mRNA levels were calculated using the comparative Ct 
method (2e- ΔΔCt). 
 
5.2.13. Cell Transformation Assay (Anchorage-independent Growth Assay) 
 
The anchorage-independent growth of the different breast cancer cell lines were assessed 
by the CytoSelect™ Cell Transformation Assay Kit (Cell Biolabs, San Diego, CA, USA). A 
semisolid agar media were prepared accordingly the manufacturer instructions prior 
addition of PM-siAKT2 or PM-siC to each well. After 6-8 days of incubation the colonies 
were observed under an optical microscope and the viable transformed cells counted using 
trypan blue.  
 
5.2.14. Invasion Assay 
 
Cells invasiveness was assessed using the CytoSelect™ Laminin Cell Invasion Assay Kit 
(Cell Biolabs, San Diego, CA, USA) as previously described in Chapter 4. Briefly, the inserts 
were placed in a 24 well plate and 2.5x104 cells previously transfected (24 hours before) 
with the PM-siAKT2 and the PM-siC, were added to the upper chamber. After 48 hours 
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incubation, the invasive cells were dissociated from the membrane, lysed and quantified 
using the CyQuant® GR Fluorescent Dye using a fluorescent microplate reader FLX800 
(BioTek, Germany). 
 
5.2.15. In vivo Maximum Tolerated Dose (MTD) Determination 
 
Female athymic nude mice (Hsd:Athymic Nude-Foxn1 nu/nu; Harlan Interfauna Iberica, 
Barcelona, Spain) were kept in pathogen-free conditions and used at 6 weeks of age. 
Animal care was handled in accordance to guidelines for the Care and Use of Laboratory 
Animals of the Vall d’Hebron University Hospital based on Federation of Laboratory Animal 
Science Associations (FELASA) recommendations and the European Union legislation 
(European Parliament and Council Directive 2010/63/EU). The experimental procedures 
were approved by the Animal Experimentation Ethical Committee of the institution.  
Animals were randomly divided in 4 groups (n=3) and intravenously administered in the tail 
vein with PBS 1X (control group) or PM at doses of 20, 40 or 80 mg per kilogram of body 
weight (single administration). Body weight changes and side effects were monitored during 
12 days post-administration. For side effects evaluation the reduction of voluntary 
movement, irregular breathing, motor disturbances, seizures, sudden death, flushed skin, 
lacrimation, dehydration and hunched position was monitored. 
 
5.2.16. Statistical Analysis 
 
At least three batches of each PM were produced and characterized and the results 
expressed as the mean±SD.  For biological studies, at least 3 replicates, each involving at 
least two technical replicates were involved in final results expressed as the mean±SD. 
Statistical analysis was performed in Microsoft Office Excel™ 2007 using the unpaired 
Student's t-test. Differences were regarded as statistically significant when p-value were 
smaller than 0.05. 
 
5.3. Results 
5.3.1. PM are Technologically Favorable for siRNA Delivery 
 
In order to characterize physicochemically the proposed formulation, several technological 
tests were performed. The combination of poloxamer F127 and 10K branched PEI-based 
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polyplexes originated particles with ideal characteristics for siRNA delivery and intravenous 
administration.  
 
Figure 5. 2. Micelles physicochemical characterization. (A) mean hydrodynamic diameter 
distribution of PM-siC represented trough the graph of size dispersion by intensity, (B) summary of 
size, polydispersity and zeta potential, (C) TEM images of PM at different magnifications, (D) siRNA 
entrapment efficiency determined by a spectrophotometer method, (E) agarose gel retardation 
assay, and (F) osmolarity values of PM and PBS. Results are expressed as mean±SD (n≥3). 
 
The micelles present a mean diameter around 26 nm, both for loaded and unloaded 
formulations, and low polydispersity indexes (≤ 0.2). Despite the positively charges 
associated with PEI, micelles present a neutral charge mainly caused by the presence of 
PEG at the surface (Figure 5.2A and B). The mean diameter values as well as the low 
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polydispersity were also confirmed by TEM images, where it is possible to observe micelles 
of small size and characteristic spherical morphology (Figure 5.2C). 
In order to confirm if the siRNA was correctly complexed with PEI and associated with 
micelles, the entrapment efficiency was determined by two distinct methods. The indirect 
method, that measures the free siRNA concentration at the supernatant after PM 
centrifugation with filtration, shows entrapment efficiencies higher than 96% (Figure 5.2D). 
Additionally, no free siRNA fraction was detectable by agarose gel retardation assay in the 
micelles sample (Figure 5.2E).   
Micelles present an osmolarity value slightly superior to the PBS but < 350 mOsm/Kg, which 
corroborates their adequate applicability for systemic administration (Figure 5.2F). 
 
5.3.2. Complete PM Internalization Occurs After 4 hours of Incubation 
 
The internalization of the fluorescent-labelled micelles was assessed quantitatively by flow 
cytometry (Figure 5.3) and qualitatively by confocal microscopy (Figure 5.4). In order to 
study the uptake kinetics the cells were incubated with PM at different time-points. With the 
objective to check if there is any difference in the internalization pattern between CSC and 
non-CSC cells, MDA-MB-231 and MCF7 ALDH1A1 cells with around 50% of tdTomato+ 
(CSC) were used (Figure 5.3C and G). It was possible to observe that particles start to be 
internalized 10 minutes after incubation, but only after 4 hours an internalization of 90% is 
reached (Figure 5.3D and H). Interestingly, although no significant differences were 
observed between CSC and non-CSC cells regarding the amount of cells that internalize 
micelles (Figure 5.3A and E), is possible to observe superior values of fluorescence 
intensity for CSC cells, which possibly represents a higher number of PM inside each cell 
(Figure 5.3B and F). Thus, it is possible to predict that tdTomato+ cells internalize 
significantly more micelles than the tdTomato- ones. This result needs to be further explored 
in the future to clarify the endocytic pathways and understand the possible different behavior 
between CSC and non-CSC. 
For the qualitative analysis, MDA-MB-231 cells incubated with fluorescent-labeled PM were 
observed by confocal microscopy. As expected, it is possible to observe micelles 
internalization as well as co-localization with the cell endosomal vesicles (Figure 5.4). 
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Figure 5. 3. FACS quantification of micelles uptake by MDA-MB-231 and MCF7 ALDH1A1 
tdTomato+ versus tdTomato-. The cells were incubated with the 5-DTAF labeled PM and the 
percentage of cells emitting green fluorescence (Graph A and E) as well as the intensity of 
fluorescence (Graph B and F) were quantified at different time-points. The bidimensional plots 
showing the internalization of PM in both subpopulation of CSC and non-CSC at time 0 and time 4 
hours are presented in graphs C,D,G and H. Results are expressed as mean±SD (n=3), ** p≤0.01 
for de comparison between CSC and non-CSC. 
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Figure 5. 4. PM internalization visualization throught confocal microscopy. The PM are labeled 
in green with the 5-DTAF, the endossomal vesicles are labeled in red (Lysotracker® RED and the 
cells nuclei labeled in blue (DAPI). 
 
 
Figure 5. 5. In vitro cytotoxicity of PM and its isolated components. A) Assessment of the effects 
of PM and isolated components concentration in the cell viability. To facilitate the comparison 
between samples, the concentration presented for the isolated components is not the real one, but 
corresponds to the one present in the final PM concentration (for example, in the plot is not being 
assessed the toxicity corresponding to 5 mg/ml of PEI, but instead the toxicity of the PEI 
concentration present in 5 mg/ml of PM). B) IC50 values for each component and for PM. The values 
were obtained by interpolation of y=50 from the dose-effect curves fitting using the real 
concentrations used for each sample. Results are expressed as mean±SD (n=3). 
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5.3.3. PM do not Present in vitro or in vivo Toxicity 
 
Effects on cell viability of PM-siRNA as well as its isolated components were assessed in 
vitro via MTT assay in MDA-MB-231 and MCF7 (Figure 5.5A) breast cancer cells, with the 
additional estimation of their IC50 values (Figure 5.5B). As observed in both dose-effect 
graphs and the IC50 values, F127 do not cause significant toxicity to the cells. On the other 
side, PEI alone is highly toxic. However, this PEI-related toxicity appears to be reduced 
when it is complexed with the negatively charged siRNA and even more reduced in the 
presence of the F127 shell. Since the concentrations of PM that have demonstrated to be 
efficient in vitro (5 mg/ml) are inferior to their IC50 value, is possible to conclude that PM are 
not expected to significantly cause toxicity after administration. 
Before to administrate the PM in vivo, a serum stability assay was perform in order to predict 
the amount of aggregation between the PM and the serum components in vivo. Figure 5.6 
represents the mean size distribution curves by intensity for the PM-siRNA incubated with 
medium-FBS (50%) at the different time-points (Figure 5.6A) and for the medium-FBS 
(50%) (Figure 5.6B). 
 
 
Figure 5. 6. Serum stability assay PM-siRNA. The graphs represent the DLS size distributions by 
intensity after incubation at different time-points. (A) PMs with siC mean curves at different time-
points (0-24 hours). (B) Medium-serum 50% curve. All measurements were performed in triplicate, 
with three technical samples. 
 
A 
B 
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The distribution curves demonstrate some aggregation of the PM with the serum 
components over the time since it can be observed a reduction of the medium particles 
fraction (20-100nm) with a consequent increase in the percentage of particles with higher 
sizes (>100nm). This behavior was especially observed after 12 hours of incubation. Taking 
into account that we expect that the PM are eliminated before the 12 hours, the verified 
aggregation do not constitute a major problem for the intravenous in vivo administrations of 
the formulation. 
 
 
Figure 5. 7. PM toxicity in vivo. In the graph is presented the body weight variation of animals up 
to 12 days post-administration of the samples. The table shows the register of adverse side effects 
monitored during the time of the experiment. Results are expressed as mean±SD (n=3). 
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The safety of PM was also assessed in vivo. For this, PM were administered to healthy mice 
at increasing concentrations in order to determine the MTD. A maximum administrated dose 
of 80 mg of PM per kilogram of body weight was well tolerated, without inducing adverse 
side effects up to 12 days post-administration. As observed in Figure 5.7, no significant 
changes in weight gain neither weight loss were seen in the animals treated with the PM 
when compared to the control group of animals injected with PBS (p≤0.05).  
 
5.3.4. PM-siGFP Efficiently Silence the GFP Reporter Gene Expression 
 
PM entrapping a siRNA against GFP were incubated at different times with GFP expressing 
MDA-MB-231 breast cancer cells. As shown in Figure 5.8, a clear and strong qualitative 
(Figure 5.8A) and quantitative (Figure 5.8B) reduction of GFP expression were observed 
24 hours post-transfection in cells treated with GFP-siRNA when compared with the cells 
transfected siC. 
 
5.3.5. PM-siAKT2 Reduce the Metastatic Potential of CSC 
 
Next, we examined whether the PM platform could be used to silence a potential therapeutic 
target related with breast CSC. PM were prepared using the siAKT2 and siC and transfected 
into MDA-MB-231 and MCF7 breast cancer cells as well as in their CSC fractions isolated 
as explained in Chapter 4. During our study we verified the stemness gene expression after 
each sorting to guarantee the purity of the samples. The decrease of AKT2 expression in 
both cell lines was confirmed by qPCR (Figure 5.9A). Subsequently, in order to determine 
the effects related to AKT2 inhibition in the fraction of CSC, cells invasion and anchorage-
independent growth ability were assessed for MDA-MB-231 Td-Tomato+ and MCF7 Td-
Tomato+ cells after treatment with the PM-siAKT2 and PM-siC. Regarding the invasive 
potential of CSC, for both cases the invasiveness of CSC was significantly reduced after 
PM-siAKT2 transfection (Figure 5.9B). Next, the assessment of the anchorage-
independent growth capacity revealed a reduced number of transformed cells for both MDA-
MB-231 and MCF7 CSC after treatment with the PM-siAKT2 (Figure 5.9C). Accordingly, it 
was observed an accentuated impairment of colonies formation after the treatment with PM-
siAKT2 (Figure 5.9D). 
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Figure 5. 8. GFP reporter assay for PM-siGFP biological efficacy assessment. (A) Fluorescent 
images of MDA-MB-231/GFP cells were taken 24, 48 and 72 hours after incubation with PM-siGFP 
and PM-siC. (B) Time-lapse experiment in which fluorescent images of cells incubated with siGFP 
and siC associated with PM or Lipofectamine® 2000 were captured at each 30 minutes during 72 
hours. The values represent the fluorescent intensity detected for each time-point. Results are 
expressed as mean±SD (n=3), *** p≤ 0.001 for the comparison between PM-siGFP and PM-siC. 
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Figure 5. 9. PM-siAKT2 effects in MDA-MB-231 and MCF7 cells. (A) The reduction of AKT2 gene 
expression was detected in both cell lines through qPCR. The presented values are normalized to 
the housekeeping genes (Actin and GADPH). (B) Quantification of the number of invasive cells after 
incubation with PM-siAKT2 versus PM-siC. (C) Quantification of the number of transformed cells 
after incubation with PM-siAKT2 versus PM-siC. (D) Colonies formation on the soft agar after 
incubation of cells with PM-siAKT2 versus PM-siC. Results are expressed as mean±SD (n=3), *** 
p≤ 0.001 for the comparison between PM-siC and PM-siAKT2. 
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5.4. Discussion 
 
In this work PM were chosen as siRNA delivery systems due to their well-known versatility 
to produce, among others, systems presenting long circulating profiles in the bloodstream 
and able to improve the cellular uptake of compounds, increasing its therapeutic efficacy 
(3, 4). Among the amphiphilic polymers used to produce micelles, poloxamers enjoy special 
prominence due to their biocompatible and biodegradable nature, well-established status 
as drug delivery and biomedical excipients, capacity to improve the transfection of genetic 
material, and to support endosomal release of endocytosed nanocarriers (2, 5, 6). 
Regarding the choice of the amphiphilic polymer, the Pluronic® F127 presented adequate 
physical properties regarding size and Pdi as referred in Chapter 3. Similar 
physicochemical results were obtained with PM of poloxamers encapsulating insulin (1). 
Since poloxamers present neutral charge at the physiological pH, it was necessary to 
introduce a cationic component to formulation in order to obtain required positive charge to 
complex the anionic siRNA, so the branched PEI 10K was chosen as the polycation to 
produce the polyplexes (as explained in Chapter 3). Like this we can enjoy from the benefits 
of both PEI and poloxamers regarding transfection efficiency, and PEGylated surface of 
PM.  
The morphological analysis has shown micelles with spherical shape and md close to 27 
nm (Figure 5.2), corroborating the results of DLS. The lower size of micelles composed by 
F127 is explained by its lower critical micelle concentration (CMC) and hydrophilic-lipophilic 
balance (HLB) values, resulting in more compact micelles (1).  
Due to their small size and the enhanced transfection efficiency capacity of both 
components, PM are quickly and efficiently internalized by cells (Figure 5.3) and efficiently 
promote the silencing of the gene of interest (Figure 5.8 and 5.9). Moreover, the cytotoxicity 
assay reveals that the presence of F127 reduce the PEI-related toxicity, probably due to the 
reduction of its surface cationic groups. Therefore, the system do not present significant 
toxicity both in vitro (Figure 5.5) as well as in vivo (Figure 5.7), which is related to the 
biocompatibility of poloxamers explaining their use on a variety of biomedical applications 
including drug delivery (7, 8).  
Another advantage about the presence of poloxamers in the formulation was evidenced by 
the serum stability assays. The results showed that there is no aggregation with serum 
components up to 12 hours of incubation, suggesting that this PM may be adequate for 
intravenous administration in vivo (Figure 5.6).  
Other research groups developed micellar systems for siRNA delivery proving the utility of 
this type of systems. For example, Liu L, et al. (2016) synthesized an amphiphilic and 
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biodegradable ternary copolymer conjugated with folate as ligand, polyethylenimine-graft-
polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol) for targeted siRNA 
delivery via folate-FR recognition (9). They obtained stable micelles with hydrodynamic 
diameters about 100 nm and a zeta potential of +8.6 mV. The presence of folate was 
responsible for the increased cellular uptake and in vitro gene knockdown observed in a 
folate receptor enriched cell line (SKOV-3 cells). Moreover, these PEI-PCL-PEG-Fol/siRNA 
micelles exhibited high stability in vivo and a long circulation half-life, which allowed 17% of 
the intravenously injected siRNA to reach the tumor mainly due to their effective folate 
targeting (10). Furthermore, the study of Salzano G, et al. (2015) brings the interesting 
possibility of micelles multifunctionalization (10). In their study they developed self-
assembly PM able to efficiently co-load an anti-survivin siRNA and a chemotherapeutic 
agent, such as PTX (survivin siRNA/PTX PM) and evaluated their applicability in vivo in an 
animal model of PTX-resistant ovarian cancer. They obtained a significant downregulation 
of survivin expression in tumor tissues together with a potent anticancer activity of survivin-
siRNA/PTX PM, while the tumors remained unaffected with the same quantity of free PTX. 
These results underline the importance of the combined therapy in the treatment of 
chemoresistant tumors (11). 
The versatility of the poloxamers used in our system opens the possibility of creating 
functionalized systems by conjugation of moieties to the PEG surface, and the co-
encapsulation of polyplexes and anticancer drugs, benefiting from the advantages of the 
combined therapy. In fact, poloxamers have shown to reduce the MDR capacity of cancer 
cells through a selective energy depletion and inhibition of the drug efflux systems, 
improving especially the therapeutic efficacy of the drugs in multidrug resistant tumors (12-
14). Exploring these characteristics of poloxamers, a formulation of PM encapsulating 
Doxorubicin (SP1049C) granted orphan designation by FDA to treat advanced carcinoma 
of the esophagus and advanced gastric cancers, proving its value in the development of 
systems for cancer treatment (15, 16). Additionally, poloxamers present cryoprotective 
properties, allowing the lyophilization of the system to obtain a powder with good 
redispersion profile, allowing the increase of the product stability and shelf-life, and reducing 
the costs associated to liquid formulations (1). 
Due to their unique phenotype, CSC are resistant to conventional therapies (17, 18). 
Therefore, it is of major importance to find an adequate target against CSC and an effective 
delivery system able to reach them, otherwise the reservoir of resistant CSC will cause 
recurrence of aggressive tumor and metastatic growth over the time (19, 20). We used a 
CSC model based on the tdTomato expression under the control of CSC specific ALDH1A1 
promoter, in order to study the efficacy of AKT2 silencing in CSC fraction. This CSC model 
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was previously extensively validated in vitro and in vivo (21). In Chapter 4, we have 
demonstrated that downregulating AKT2 using a siAKT2 have an important role in the EMT 
impairment and the consequent reduction metastatization and malignancy of cancer cells 
with special importance in CSC. After treatment with the PM-siAKT2, the transformation 
capacity of CSC fractions (MDA-MB-231 and MCF7) was significantly abolished (p≤0.001). 
Similarly, the invasion capacity of CSC significantly decreased (p≤0.001) after the 
transfection with the PM-siAKT2 (Figure 5.9). These results suggest that AKT2 silencing 
strategy may be successful as a target for future RNAi-based antitumor therapies 
particularly on the challenging fraction of highly aggressive CSC. 
The internalization studies demonstrated that micelles are able to be taken up by cells 
through endocytosis, being possible to observe their co-localization with the endosomal 
vesicles (Figure 5.4). This result is in agreement with the biological efficacy studies 
performed, since the internalization by endocytosis of polyplexes/micelles containing the 
siRNA is the first step to become available to perform is biological function inside the cell. 
It also revealed a significant preferential uptake of PM by CSC (p≤0.01) (Figure 5.3), 
resulting in a high biological therapeutic efficacy (Figure 5.9). The mechanism involved in 
the enhancement of transfection efficiency by poloxamers is the same underlying its effects 
as MDR chemosensitizers. By interfering with the cellular membrane, poloxamers inhibit 
the ATPase activity and the efflux function of P-gp, improving the efficacy of anticancer 
drugs (14, 22). Moreover, poloxamers interfere with mitochondrial function showing to 
enhance proapoptotic signaling and decrease tumorigenicity of cancer cells by altering the 
epigenetic regulation of cells mainly in MDR over non-MDR cells (12, 15, 23). Taking into 
account that CSC display some of the characteristics of MDR cells, like overexpression of 
efflux systems, poloxamers present the capacity to enhance the anticancer activity of drugs 
(e.g. Doxorubicin), increase the transfection efficiency of OGN, and to decrease the 
tumorigenicity and aggressiveness of tumor cells, especially in CSC sub-population (15).  
 
5.5. Conclusions 
 
In this study, an innovative nanocarrier system composed by Pluronic® F127 micelles 
associated with PEI-based polyplexes has been developed with the objective to overcome 
the major drawbacks usually associated to the genetic material delivery systems, namely 
siRNA degradation, insufficient transfection efficiency or excessive nanoparticles-related 
toxicity.  
The proposed system seems to gather the requirements for an efficient and safe transport 
of siRNA in terms of their physicochemical characteristics, internalization capacity, 
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biological efficacy and toxicity profile. Moreover we also observed a reduction of the 
invasion and transformation capacities of breast cancer cells, when transfected with PM 
entrapping the polyplexes with the siRNA against the gene of interest, with significant 
positive results observed mainly in the so feared CSC population. 
These results make us believe that this new formulation will serve as a technological 
platform for the development of systems to encapsulate different siRNAs, as well as other 
kind of genetic material, and bring new insights into the field of cancer gene therapy. 
The next step in the development and optimization of these PM would be the introduction 
of specific targeting moieties covalently linked to the polymers chains and assess to which 
extent the active targeting could even improve the biological and therapeutic efficacy of the 
system. It would be also priority to increase the loading capacity of the micelles to undergo 
in vivo assays. First it should be performed a biodistribution study to track how PM behave 
once in the blood circulation. Afterwards an in vivo efficacy study in a breast and/or colon 
cancer mouse model using the PM carrying the siAKT2 versus siC will be also performed. 
Another future objective of this work is the creation of a multifunctional system where can 
be combined the delivery of both conventional drugs and genes. The system developed 
presents adequate properties to deliver both hydrophobic and hydrophilic substances, 
added at different steps of the production method. Therefore, the design of a nanosystem 
combining an hydrophobic drug, such as the PTX or zileuton, and the hydrophilic polyplexes 
of a certain siRNA, chosen depending on the genetic pattern of the disease, could be a 
encouraging strategy in the future of the combined and personalized therapy.  
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Cancer is a higly prevalent disease having a major impact in the population health 
worldwide. Even though current treatments have improved the overall survival and life 
quality of patients, and despite the new generation of targeted anticancer drugs, cancer 
remains difficult to treat and control. Consequentely, the development of therapy-resistant 
metastasis that cause cancer relapse is still frequent. Despite the advancements observed 
in the fields of molecular biology and biotechnology allowing a better understanding of the 
mechanism of carcinogenesis and disease progression, as well as the development of 
improved therapies, advanced cancer is generally an incurable disease. As referred, the 
conventional treatments have improved the survival and cure rate of patients; however there 
are some associated drawbacks, mostly concerning high toxicity and serious side-effects, 
which may even cause death. More than half of the treated patients suffer from disease 
relapse, including the presence of distant metastasis in other organs. The rapid emergence 
of therapy resistance seen in the aggressive, metastatic forms of the disease is, by far, the 
biggest obstacle for the success of current cytotoxic and cytostatic therapies. Indeed, many 
of the newly developed cancer drugs elicit powerful initial responses, leading to dramatic 
effects on tumor reduction and disease control, but still modest results regarding of long-
term overall survival (1-3).  
Cancer maintenance, resistance to therapy and metastatic disease seem to be sustained 
by the presence of CSC within the tumors. These cells retain the capacity of repopulating 
the tumor, while being insensitive to conventional anticancer therapies, antimitotic agents 
or radiation. It is still not clear if the CSC are originated from epithelial stem cells (the ones 
essential to maintain proliferative homeostasis) or result from accumulation of mutations 
from differentiated cells. In this scenario, the new cancer therapies under development 
should fulfill two conditions: (i) reduce the toxicity displayed in current therapies and most 
importantly, (ii) effectively target and eliminate CSC to overcome drug resistance and tumor 
recurrence (4, 5).  
One major difference between conventional chemotherapies and targeted therapies with 
respect to the development of resistance is that resistance to targeted therapies follows a 
more predictable path, being therefore, easier to identify the resistance mechanism and to 
choose the more appropriate treatment. However, it remains a major challenge to predict 
which patients will develop metastatic disease. As a result, describing specific targets or 
signaling pathways is one of the pillars of current cancer research, although most tumors 
are still treated with conventional cytotoxic therapies. Thus, the development of more 
personalized and targeted anticancer therapies is essential. In that context the importance 
of gene therapy gained a new breath in the last decades. This is a result of the important 
advances observed in the field of molecular biology and particle engineering technology, 
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which allowed, respectively the characterization of new therapeutic targets and the 
development of new and improved formulations (4). 
Recent advances in genomics make possible now to consider the hypothesis that each 
tumor has an independent genetic identity and to enumerate all of the genetic lesions in 
specific cancers. These approaches will yield critical information regarding the biological 
alterations signature in different tumors and are increasingly being applied prospectively to 
patient samples in the clinic. At the same time, complementary approach to decipher the 
molecular basis of malignant transformation depends upon the application of genome scale 
tools to annotate the function of genes involved in cancer initiation and progression. Over 
the past several years, have been developed genome scale RNAi, CRISPR and open 
reading frame expression libraries that permit a systematic evaluation of genes involved in 
cancer initiation and maintenance. Using these libraries, it was possible to performed 
screens in a panel of human cancer cell lines to systematically identify cancer 
vulnerabilities. By combining these functional approaches with information derived from 
mapping the structural abnormalities present in cancer genomes, have been identified 
several new oncogenes that contribute to cancer development. The ability to systematically 
manipulate gene expression at genome scale now provides opportunities to investigate the 
function of genes involved in cancer initiation and maintenance, which will provide a 
framework for therapeutic strategies. For example, assays that apply massive parallel 
sequencing approaches to evaluate tumor tissue or blood from clinical samples for evidence 
of genomic harbingers of therapy response and resistance are becoming increasingly used. 
There are various types of approaches that can be used, including active monitoring of 
patients either during or at the end of their therapeutic regimen by comparison to a baseline 
sample. The sensitive and quantitative nature of these assays can pinpoint patients with 
therapy resistance, by virtue of unaltered prevalence of mutations relative to the baseline, 
or also identify patients with an incomplete response such as minimal residual disease 
(MRD). Before the treatment, the analysis of the disease genotype could be useful for the 
selection of the potential targeted therapy. Therapeutic response monitoring using 
biomarkers is also possible during the course of treatment and can indicate those non-
responding patients that might benefit from another therapy. Finally, post-mortem genomic 
analyses of therapy resistant disease can be obtained from banked metastatic lesions to 
inform about the genomic nature of therapy resistance. These studies can be incredibly 
informative towards future monitoring paradigms, therapeutic combinations or new drug 
design efforts to fight acquired resistance (6-8). Because of that, worldwide research groups 
have been actively focused in the development of molecular therapies that target specific 
oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, 
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HER2, FGFR, BRAF, MEK, PI3K, AKT, mTOR or IGF1-R) for patients displaying specific 
genetic lesions or pathways deregulations. One of the main objectives nowadays and area 
of intensive research is to identify new predictive biomarkers of response to diverse 
treatments as well as biomarkers of primary resistance (de novo) and secondary treatment 
(9, 10). 
Still in the context of advance biomarker and drug target discovery, there are also groups 
that are focused on the proteomic analysis of the cancer secretome and in the 
characterization of the mechanisms adopted by cancer cells to communicate amongst 
themselves as well as with their microenvironment during tumorigenesis. Most secreted 
proteins contain a signal peptide that directs their sorting to the extracellular space through 
the endoplasmic reticulum–Golgi secretory pathway. One of the most striking observations 
when secretome profiles are carefully analyzed is that they contain hundreds of theoretical 
intracellular proteins. Recent reports showing intracellular proteins with alternative 
extracellular functions, metastasis localizations could be relevant in tumorigenesis and 
could lead to novel therapies against cancer. Taking into consideration that metastasis 
depends on a gene program expressed by the tumor microenvironment, for example with 
the secretion of prosurvival factors by stromal cells during the colonization phase of 
metastasis, blockage of this crosstalk between tumor cells and their microenvironment 
through the use of chemical inhibitors could be very promising in prevent metastasis 
formation. This dependency can also be exploited to improve diagnosis and treatment of 
patients with advanced cancer (11, 12). 
In this work we focused in the characterization of the pathway related with the AKT2 
oncogene, since AKT2 is one of the three AKT isoforms that have shown to be amplified in 
solid tumors. This oncogene is increased in response to apoptosis and its activation is also 
associated with PI3-K related effects and TWIST-promoted metastatic process by 
enhancing cell migration and invasion (13, 14). We have shown that the silencing of AKT2 
signaling pathway both in bulk and in sub-populations of CSC is able to block their 
tumorigenic potential, and reverting them to a more epithelial and noninvasive phenotype, 
as demonstrated by the reduction in cell migration, proliferation, invasion and transformation 
capabilities after the treatment with the siAKT2. We also demonstrate that the silencing of 
AKT2 can act differently accordingly the cells phenotype. In cells that present TWIST (a 
major downstream effector of AKT2) we were able to detect the EMT reversion through the 
restoration of E-cadherin expression and the decrease of mesenchymal markers (Vimentin, 
N-cadherin and Fibronectin) expression. For cells that do not express TWIST, the silencing 
of AKT2 reduced the mTOR and increase the GSKβ expression, contributing for the 
reduction of cells tumorigenic potential. Also, in these cell lines the AKT2 silencing promotes 
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alteration in apoptosis markers like p53 and Bcl-2. The novelty of this study relies on the 
evidence that AKT2 silencing is also effective in the isolated subpopulation of CSC, both in 
breast and colon cancer, since we truly believe that the specific targeting of this cell sub-
population will improve the clinical outcomes by reducing the cancer resistance and 
recurrence.  
In this work we propose the silence of AKT2 as a target using an RNAi approach, with the 
final goal of developing a novel gene therapy-based system. However another strategy that 
could be worthy to explore in the future is the chemical inhibition of AKT2. CCT128930 is a 
novel, selective, and potent AKT2 inhibitor that blocks AKT2 activity exhibiting 28-fold 
greater selectivity for AKT2 than for the other isoforms. CCT128930 exhibited marked anti-
tumor responses and inhibited the phosphorylation of a range of downstream AKT2 
biomarkers in multiple tumor cell lines both in vitro and in vivo, arising as a new anticancer 
drug (15). Moreover, the combination of AKT2 silencing with a traditional chemotherapeutic 
agent, such as Doxorubicin or PTX, can represent an important future therapeutic approach 
forward the CSC eradication and improved anticancer therapy. 
The main goal of the present study is to develop a therapeutic system that reduce the cancer 
therapy-related secondary effects, and specifically target the subpopulation of CSC within 
the tumors to overcome resistance to therapy and recurrent metastatic and advanced 
disease. Both criteria could be accomplished using innovative targeted nanomedicines for 
drug and/or gene delivery, which is widely expected to create innovative therapeutics in 
cancer therapy thanks to the selective delivery of higher concentrations of encapsulated 
drugs, with reduced systemic toxicity, to tumor lesions trough the well-known EPR effect. 
Based on these characteristics, the first generation nanomedicines already in clinical 
practice or under clinical evaluation have been presenting improved therapeutic efficacy 
than the conventional drug formulations, and have changed the scenario of oncological 
diseases therapy (16). 
Of note, ubiquitously targeting cells within a tumor is not always feasible because some 
drugs cannot diffuse efficiently and the random nature of the passive targeting (EPR effect) 
makes difficult to control the process. This lack of control may also be responsible for 
inducing the problematic MDR. Thus, one strategy, to further enhance targeting of drugs to 
cancer cells including CSC, is the conjugation of nanocarriers with molecules that bind to 
overexpressed antigens or receptors on the target cells. These second generation vectors 
are especially useful in tumors that do not exhibit EPR effect or cases where the 
permeability of the vessels is not compromised (i.e. small metastasis). An additional 
advantage for using targeting moieties for drug delivery into cancer cells is that drugs will 
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benefit from entering inside tumor cells by receptor-mediated endocytosis, providing higher 
concentration levels of active drug compounds within the tumor cell (17). 
The nanodelivery system used in this work consisted in PEI-based polyplexes associated 
to PM composed by poloxamers prepared by thin FH technique to deliver siAKT2. PEI was 
used due to its well-recognized capacity to complex and transfect genetic material into cells. 
PM were chosen mainly due to its easy production, small size, versatility to encapsulate 
both hydrophobic and hydrophilic compounds, and the observed capacity of poloxamers to 
modify the biological response and decrease the MDR of many cancer cells. Moreover, the 
presence of PEG provides the formulation with stealth properties, allows the particles 
modification with several targeting ligands, and facilitates the lyophilization of the system. 
Regarding the last one, the inherent cryoprotectant properties of PEG reduce aggregation 
of particles during lyophilization without the need of additional cryoprotectants, which 
simplifies the formulation and could impact in their stability and safety profile. This question 
is important in technological terms since a future step of development of the presented 
system relies in the production of powders by lyophilization in order to increase its long-
term storage stability (18-20). 
After production and physicochemical characterization, biological assessment of 
formulations was performed in several cancer cell lines. No significant signs of cytotoxicity 
were observed as determined by MTT (in vitro) and MTD (in vivo), thus, no substantial 
toxicity is expected at therapeutic doses. The presence of F127 in the formulation not only 
serves to increase the particles functionality and their transfection and biological efficiency, 
but also proved to significantly reduce the PEI-associated toxicity. Furthermore, PM have 
shown to be preferentially taken up by the CSC sub-population, thus suffering a sort of 
passive targeting to CSC, which could be predictive indicator of its therapeutic efficacy. 
In conclusion, amphiphilic polymers-based formulations combined with PEI presented 
appropriate characteristics for delivery of siRNAs and achieve a strong gene silencing, 
including in CSC. These formulations serve as a platform for future development of 
improved gene delivery systems. 
The ultimate goal of this study is to develop a multifunctional targeted nanomedicine against 
breast and colorectal CSC by: i) using a specific targeting for CSC surface receptors (i.e. 
CD44 for breast and CD133 or CXCR4 for colon) and ii) combine classical chemotherapy 
with a specific siRNA against CSC. Thus, the next steps regarding the improvement of this 
system will be the addition of a chemotherapeutic agent to the formulation and the 
conjugation with targeting moieties (Figure 6.1). By efficiently targeting and killing CSC is 
expected to significantly circumvent CSC-related resistance, reduce the number of 
metastasis and tumor recurrence, and increase patient overall survival.  
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After perform in vitro and in vivo preclinical validation of our nanoconjugate targeting CSC, 
the final step would be to initiate scale-up and regulatory studies. 
Following the evolution that has been observed in this field during the last decades, is 
expected in the near future a further increase in the development of optimized formulations 
based on nanoparticles for gene delivery and/or to improve the properties of several 
chemotherapeutic drugs. Due to the well-known advantages presented by these systems 
would not be surprising to see an exponential increase of marketing authorization and 
commercialization of multifunctional nanotechnology products, which we hope will bring a 
new breath in the battle against cancer. 
 
 
 
Figure 6. 1. Schematic representation of an amphiphilic polymer based multifunctional 
nanoparticle for gene and drug delivery combination. 
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